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  virus	   	   	  
SIV	  	   	   	   	   Simian	  Immunodeficiency	  Virus	  
SNP	   	   	   	   Single	  nucleotide	  polymorphism	  
ssSGA	   	   	   	   Strain-­‐specific	  single	  genome	  amplification	  
STI	  	   	   	   	   Sexually	  transmitted	  infections	  
TCID	   	   	   	   Tissue	  culture	  infectious	  dose	  
T/F	   	   	   	   Transmitted/founder	  
TLR	   	   	   	   Toll-­‐like	  receptor	  
tMRCA	   	   	   	   Time	  since	  the	  most	  recent	  common	  ancestor	  
tOPV	   	   	   	   Trivalent	  oral	  polio	  vaccine	  
wpi	  	   	   	   	   Weeks	  post	  infection	  
ypi	   	   	   	   	   Years	  post	  infection
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Abstract	  
A	  better	  understanding	  of	  how	  neutralizing	  antibody	  responses	  develop	  during	  natural	  HIV-­‐
1	  infection,	  and	  the	  factors	  that	  augment	  them,	  would	  be	  invaluable	  in	  informing	  vaccine	  design	  
and	  testing.	  	  The	  use	  of	  polyvalent	  immunogens	  is	  a	  common	  strategy	  used	  in	  an	  attempt	  to	  
enhance	  the	  breadth	  of	  vaccine-­‐elicited	  immune	  responses	  and	  HIV	  dual	  infection	  (infection	  by	  
>1	  distinct	  HIV	  strain)	  provides	  a	  unique	  in	  vivo	  model	  to	  characterize	  how	  the	  immune	  system	  
responds	  to	  multiple	  HIV	  strains.	  	  
In	  the	  CAPRISA	  002	  cohort	  from	  KwaZulu	  Natal,	  South	  Africa	  eleven	  cases	  of	  dual	  infection	  
were	  detected,	  of	  whom	  eight	  were	  co-­‐infected	  at	  the	  first	  seropositive	  visit	  and	  three	  were	  
superinfected	  (infected	  with	  a	  second	  strain	  following	  seroconversion	  to	  an	  initial	  infection).	  	  	  
The	  incidence	  of	  superinfection	  was	  ~5.47%	  per	  person	  year	  (in	  a	  cohort	  with	  a	  primary	  
incidence	  of	  infection	  of	  7.2%	  per	  person	  year),	  although	  systematic	  screening	  to	  accurately	  
estimate	  the	  incidence	  of	  superinfection	  was	  beyond	  the	  scope	  of	  this	  project.	  	  To	  establish	  the	  
clinical	  consequences	  of	  dual	  infection,	  we	  compared	  the	  viral	  loads,	  and	  CD4+	  T	  cell	  counts	  of	  
dual	  infected	  participants	  to	  18	  singly	  infected	  participants	  from	  the	  same	  cohort.	  	  Neither	  dual	  
infection,	  nor	  envelope	  diversity	  in	  early	  infection	  was	  significantly	  associated	  with	  accelerated	  
disease	  progression.	  	  Further,	  a	  multivariate	  analysis	  suggested	  that	  infection	  with	  Neisseria	  
Gonorrhoeae	  was	  associated	  with	  multiple	  infection,	  suggesting	  N.	  Gonorrhoeae	  increased	  the	  
susceptibility	  to	  multiple	  infection,	  although	  this	  did	  not	  reach	  statistical	  significance	  
(p=0.0566).	  
Single	  genome	  amplification	  (SGA)	  derived	  sequences	  of	  the	  early	  superinfecting	  viral	  
quasispecies	  were	  generated.	  	  In	  all	  three	  superinfected	  participants	  identified,	  a	  single	  founder	  
variant	  likely	  established	  superinfection.	  	  Similar	  to	  transmitted/founder	  viruses	  from	  primary	  
HIV	  infection,	  these	  superinfecting	  viruses	  had	  significantly	  shorter,	  less	  glycosylated	  variable	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regions	  compared	  to	  viruses	  sampled	  at	  three	  years	  post	  infection	  from	  participants	  in	  the	  same	  
cohort.	  
Neutralization	  breadth	  data	  at	  three	  years	  post	  infection	  was	  available	  for	  all	  11	  of	  the	  dual	  
infected	  participants,	  as	  well	  as	  for	  16	  singly	  infected	  controls	  (1).	  	  	  Comparing	  the	  breadth	  
revealed	  that	  dual	  infection	  was	  not	  significantly	  associated	  with	  greater	  neutralizing	  antibody	  
breadth,	  even	  after	  controlling	  for	  viral	  loads	  and	  CD4+	  T	  cell	  counts.	  	  However,	  one	  
superinfected	  participant,	  CAP256,	  developed	  a	  broad,	  and	  extremely	  potent	  neutralizing	  
antibody	  response	  (2).	  	  Using	  computational	  methods,	  the	  epitope	  targeted	  by	  CAP256	  was	  
predicted	  to	  be	  highly	  dependent	  on	  residues	  166	  and	  169,	  overlapping	  epitopes	  recognized	  by	  
monoclonal	  antibodies	  PG9/PG16.	  	  This	  was	  later	  validated,	  and	  the	  epitope	  comprehensively	  
mapped	  (2).	  	  Longitudinal	  sequencing	  of	  envelope	  revealed	  that	  escape	  from	  this	  potent	  and	  
broad	  antibody	  response	  occurred	  via	  multiple	  pathways,	  and	  was	  accelerated	  by	  
recombination.	  	  Further,	  we	  show	  that	  the	  targeted	  epitope	  was	  not	  conserved	  in	  the	  primary	  
infecting	  virus,	  suggesting	  that	  superinfection	  did	  not	  focus	  the	  neutralizing	  antibody	  response	  
onto	  an	  epitope	  conserved	  in	  both	  infecting	  viruses.	  
Taken	  together,	  these	  results	  suggest	  that	  particular	  sexually	  transmitted	  infections	  might	  
enhance	  susceptibility	  to	  HIV	  infection.	  	  Further,	  they	  show	  that	  exposure	  to	  two	  divergent	  HIV	  
variants	  is	  not	  sufficient	  to	  broaden	  the	  neutralizing	  antibody	  response,	  and	  raise	  doubts	  in	  the	  
potential	  efficacy	  of	  polyvalent	  HIV	  immunogens.	  	  They	  also	  suggest	  the	  clinical	  consequences	  of	  
dual	  infection,	  if	  any,	  are	  not	  consistently	  severe.	  	  However,	  larger	  studies	  will	  be	  required	  to	  
definitively	  address	  the	  clinical	  and	  immunological	  consequences	  of	  HIV	  co-­‐	  and	  superinfection,	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CHAPTER	  1: Background	  
Disease	  burden	  and	  the	  need	  for	  an	  HIV	  vaccine	  
In	  2012	  alone,	  it	  is	  estimated	  that	  approximately	  2.3	  million	  people	  were	  newly	  infected	  
with	  the	  Human	  Immunodeficiency	  Virus	  (HIV),	  bringing	  the	  total	  number	  of	  HIV	  infected	  
individuals	  worldwide	  to	  an	  estimated	  35.3	  million	  (3).	  	  Although	  anti-­‐retroviral	  drugs	  (ARVs)	  
have	  dramatically	  improved	  the	  prognosis	  of	  HIV	  infection,	  they	  are	  costly,	  and	  unavailable	  to	  
many	  who	  need	  them.	  	  Estimates	  are	  that	  antiretroviral	  coverage	  in	  low-­‐	  and	  middle-­‐income	  
countries	  is	  less	  than	  35%	  of	  those	  who	  need	  them	  (according	  to	  the	  2013	  WHO	  guidelines).	  	  
Safe	  and	  effective	  prophylactic	  measures	  are	  therefore	  desperately	  needed	  to	  curb	  the	  
pandemic.	  	  While	  microbicides,	  and	  ARVs	  for	  pre-­‐	  and	  post-­‐exposure	  prophylaxis	  can	  be	  
effective	  in	  reducing	  the	  risk	  of	  HIV	  transmission	  (4–6),	  the	  efficacy	  of	  these	  approaches	  are	  
highly	  dependent	  on	  treatment	  adherence.	  	  The	  persistently	  high	  HIV	  transmission	  rates	  over	  
the	  duration	  of	  the	  pandemic	  despite	  the	  availability	  of	  highly	  protective,	  relatively	  inexpensive	  
prophylaxis	  in	  the	  form	  of	  condoms	  stresses	  the	  need	  for	  prophylactic	  measures	  that	  are	  not	  
dependent	  on	  continuous	  and	  active	  adherence	  as	  an	  intervention.	  	  	  
Vaccines	  remain	  the	  most	  effective	  tool	  available	  to	  control	  infectious	  diseases.	  	  Vaccines	  are	  
largely	  responsible	  for	  the	  eradication	  of	  smallpox,	  the	  near-­‐eradication	  of	  poliomyelitis,	  and	  for	  
significant	  reductions	  in	  the	  incidence	  of	  other	  infectious	  diseases	  such	  as	  tetanus	  and	  measles.	  	  
However,	  an	  effective	  HIV	  vaccine	  remains	  elusive.	  	  Except	  for	  the	  recent	  RV144	  vaccine	  trial	  in	  
Thailand	  which	  had	  a	  modest	  protective	  effect	  (~31%)	  (7),	  empirical	  efforts	  to	  date	  have	  not	  
been	  able	  elicit	  protective	  responses	  against	  HIV.	  	  Even	  in	  the	  RV144	  trial,	  although	  protection	  
appears	  to	  correlate	  with	  V2-­‐dependent	  antibodies	  (8),	  the	  mechanism	  of	  this	  protection	  is	  not	  
known.	  	  Therefore,	  basic	  research	  into	  features	  of	  the	  immune	  response	  to	  HIV	  and	  their	  
relevance	  to	  vaccine	  design	  is	  needed.	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HIV	  disease	  course	  
Sequencing	  of	  viral	  populations	  shortly	  after	  transmission	  has	  revealed	  that	  in	  ~80%	  of	  
mucosal	  transmissions,	  a	  single	  virus	  establishes	  a	  productive	  infection	  (9–11).	  	  Following	  
sexual	  transmission	  and	  crossing	  of	  the	  mucosal	  barrier,	  HIV	  replicates	  locally	  in	  the	  mucosa	  for	  
a	  few	  days,	  but	  viral	  RNA	  remains	  at	  undetectable	  levels	  in	  the	  plasma	  for	  ~5	  days	  (95%	  CI:	  3-­‐8	  
days)	  (12).	  	  	  During	  this	  so-­‐called	  “eclipse	  phase”,	  the	  virus	  is	  disseminated	  from	  the	  loci	  of	  
infection	  to	  draining	  lymph	  nodes,	  wherein	  numerous	  activated	  CD4+	  CCR5+	  T	  cells,	  susceptible	  
to	  HIV	  infection,	  are	  located.	  	  Thereafter,	  the	  virus	  spreads	  throughout	  the	  lymphoid	  tissues.	  	  
The	  gut-­‐associated	  lymphoid	  tissue	  (GALT)	  is	  a	  major	  site	  of	  HIV	  replication,	  with	  an	  abundance	  
of	  activated	  memory	  T	  cells	  (13,	  14).	  	  	  The	  high	  level	  of	  replication	  in	  the	  lymphoid	  tissues	  is	  
associated	  with	  an	  exponential	  rise	  in	  viral	  load,	  which	  peaks	  ~3-­‐4	  weeks	  following	  
transmission.	  	  The	  depletion	  of	  CD4+	  T	  cells	  in	  the	  GALT	  is	  substantial,	  and	  while	  the	  number	  of	  
CD4+	  T	  cells	  in	  the	  plasma	  can	  rebound	  following	  the	  spike	  in	  viremia,	  CD4+T	  cell	  numbers	  in	  
the	  GALT	  do	  not	  recover	  (13–15).	  	  Thereafter,	  viral	  load	  decreases	  and	  reaches	  a	  relatively	  
stable	  level	  (set	  point).	  	  Importantly,	  the	  viral	  load	  at	  set	  point	  is	  a	  strong	  predictor	  of	  the	  rate	  of	  
progression	  to	  Acquired	  Immunodeficiency	  Syndrome	  (AIDS)	  (16).	  	  In	  the	  absence	  of	  ARV	  
treatment,	  with	  continuous	  viral	  replication	  the	  numbers	  of	  CD4+	  T	  cells	  are	  gradually	  depleted,	  
until	  eventually	  the	  integrity	  of	  the	  immune	  response	  is	  compromised	  such	  that	  it	  cannot	  
adequately	  maintain	  effective	  immune	  responses	  and	  individuals	  are	  consequently	  susceptible	  
to	  opportunistic	  infections,	  characteristic	  of	  AIDS.	  	  While	  some	  HIV-­‐infected	  individuals	  develop	  
AIDS	  soon	  after	  infection,	  others	  are	  able	  to	  spontaneously	  control	  virus	  replication	  without	  
ARV	  treatment.	  
The	  role	  of	  cellular	  immune	  responses	  in	  the	  control	  of	  HIV	  replication	  
Early	  studies	  into	  the	  role	  of	  immune	  responses	  in	  HIV	  control	  investigated	  cases	  of	  HIV	  
infected	  individuals	  who	  were	  found	  to	  naturally	  control	  viral	  replication.	  	  Studies	  into	  these	  so-­‐
called	  “elite	  controllers”	  (individuals	  able	  to	  control	  viral	  loads	  to	  below	  50copies/ml	  in	  the	  
absence	  of	  ARV	  therapy)	  and	  “long	  term	  non-­‐progressors”	  (individuals	  able	  to	  control	  viral	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loads	  to	  between	  50	  and	  2000	  copies/ml	  in	  the	  absence	  of	  ARV	  therapy)	  are	  of	  great	  interest,	  as	  
correlates	  of	  these	  phenotypes	  may	  hold	  the	  key	  to	  understanding	  what	  kinds	  of	  immune	  
responses	  provide	  protection	  against	  HIV	  replication	  and	  disease	  progression.	  	  	  
Much	  of	  the	  evidence	  to	  date	  implicates	  a	  robust	  response	  by	  CD8+	  cytotoxic	  T	  cells	  (CTL	  
responses)	  in	  the	  control	  of	  HIV	  replication.	  	  Evidence	  for	  the	  role	  of	  CTL	  responses	  includes	  the	  
temporal	  correlation	  that	  exists	  between	  the	  onset	  of	  CTL	  responses	  in	  peripheral	  blood,	  and	  
the	  initial	  decline	  in	  peak	  viremia	  during	  primary	  infection	  (17,	  18).	  Mathematical	  modelling	  of	  
the	  early	  CTL	  responses	  to	  HIV	  estimates	  that	  a	  single	  CTL	  response	  could	  contribute	  as	  much	  
as	  15-­‐35%	  to	  the	  initial	  decline	  in	  viral	  load	  (17).	  	  Further	  evidence	  is	  provided	  by	  experiments	  
in	  non-­‐human	  primates,	  where	  the	  reduction	  in	  peak	  viremia	  was	  highly	  dependent	  on	  CD8+	  
cells	  [both	  CTLs	  and	  a	  population	  of	  natural	  killer	  (NK)	  cells	  are	  CD8+],	  as	  depletion	  of	  these	  
cells	  with	  anti-­‐CD8	  monoclonal	  antibodies	  (mAbs)	  resulted	  in	  a	  loss	  of	  control	  of	  Simian	  
Immunodeficiency	  Virus	  (SIV)	  replication	  and	  a	  lack	  of	  decline	  in	  viral	  load	  (19–21).	  	  	  However,	  
depletion	  of	  CD8+	  T	  cells	  was	  also	  associated	  with	  a	  rebound	  in	  cell	  proliferation,	  including	  
CD4+	  T	  cells,	  that	  may	  have	  contributed	  to	  the	  temporary	  increase	  in	  viral	  load.	  
The	  importance	  of	  CTL	  responses	  in	  the	  control	  of	  viral	  replication	  is	  supported	  by	  a	  strong	  
association	  between	  particular	  Human	  Leucocyte	  Antigen	  (HLA)	  class	  I	  alleles	  and	  disease	  
progression	  (reviewed	  in	  22).	  	  Genome-­‐wide	  association	  studies	  (GWAS)	  have	  convincingly	  
shown,	  with	  striking	  concordance	  in	  several	  populations,	  that	  the	  HLA	  class	  I	  locus	  is	  by	  far	  the	  
most	  significant	  host	  factor	  associated	  with	  the	  control	  of	  HIV	  viral	  loads	  (23–27).	  	  Specifically,	  a	  
single-­‐nucleotide	  polymorphism	  (SNP)	  in	  the	  HLA	  complex	  P5	  (HCP5)	  which	  is	  in	  high	  linkage	  
disequilibrium	  with	  HLA	  B*57:01,	  an	  intronic	  variant	  of	  the	  HLA-­‐B	  gene	  linked	  to	  HLA	  B*57:03	  
alleles,	  and	  variants	  ~35kb	  upstream	  of	  HLA-­‐C,	  were	  identified	  as	  the	  polymorphisms	  most	  
significantly	  associated	  with	  viral	  load.	  	  This	  is	  consistent	  with	  the	  previously	  identified	  
association	  of	  HLA	  B	  (28),	  and	  HLA	  B*57	  alleles	  in	  particular	  (29,	  30),	  with	  the	  control	  of	  HIV	  
replication.	  	  In	  a	  more	  recent	  GWAS	  of	  a	  large	  Caucasian	  cohort	  of	  2554	  HIV	  infected	  individuals,	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86	  other	  SNPs	  were	  significantly	  associated	  with	  lower	  set	  point	  viral	  loads	  after	  correcting	  for	  
multiple	  testing	  across	  the	  whole	  genome,	  and	  all	  were	  located	  within	  the	  MHC	  (23).	  	  There	  is	  
also	  evidence	  that	  NK	  cells,	  through	  interactions	  of	  the	  killer	  cell	  immunoglobulin-­‐like	  receptor	  
(KIR)	  in	  association	  with	  certain	  HLA	  alleles	  may,	  in	  part,	  be	  responsible	  for	  the	  association	  of	  
certain	  HLA	  alleles	  with	  improved	  control	  (31).	  	  	  
Epitopes	  targeted	  by	  CTL	  responses	  are	  under	  strong	  selective	  pressure	  during	  infection	  
(18,	  32).	  	  Mutations	  in,	  or	  flanking	  these	  epitopes	  can	  disrupt	  antigen	  processing	  or	  recognition	  
via	  a	  number	  of	  mechanisms,	  and	  consequently	  can	  prevent	  recognition	  by	  CTLs	  (CTL	  escape)	  
(17,	  32–37).	  	  In	  line	  with	  the	  role	  of	  CTL	  responses	  in	  controlling	  viral	  load,	  escape	  from	  CTL	  
responses	  has	  been	  temporally	  correlated	  with	  a	  temporary	  loss	  of	  immune	  control	  of	  HIV	  
replication	  (38).	  Furthermore,	  escape	  from	  CTL	  responses	  often	  comes	  at	  a	  fitness	  cost	  that	  is	  
particularly	  evident	  in	  the	  escape	  from	  responses	  restricted	  by	  HLA	  alleles	  associated	  with	  
better	  control	  (such	  as	  the	  B*57	  and	  B*81	  supertypes)	  (39–42).	  	  However,	  HIV	  is	  often	  able	  to	  
restore	  fitness	  with	  compensatory	  mutations	  (43,	  44).	  
Taken	  together,	  these	  data	  implicate	  CTL	  responses	  in	  the	  control	  of	  HIV,	  and	  further	  show	  
that	  certain	  CTL	  responses	  are	  more	  effective	  than	  others.	  	  The	  effectiveness	  of	  CTL	  responses	  is	  
attributable,	  in	  part,	  to	  the	  functional	  constraints	  of	  the	  epitopes	  targeted,	  and	  consequently	  the	  
fitness	  costs	  required	  to	  escape	  the	  response.	  	  
The	  role	  of	  neutralizing	  antibodies	  in	  the	  control	  of	  HIV	  replication	  
In	  contrast	  to	  CTL	  responses,	  which	  are	  first	  detected	  as	  early	  as	  several	  days	  before	  peak	  
viral	  load	  (17),	  neutralizing	  antibodies	  (i.e.	  antibodies	  that	  are	  able	  to	  prevent	  entry	  into	  cells)	  
are	  only	  detectable	  after	  viral	  load	  has	  stabilized	  following	  primary	  infection	  (usually	  ~12-­‐20	  
weeks	  post	  infection),	  suggesting	  they	  are	  not	  relevant	  for	  the	  initial	  control	  of	  viremia.	  	  While	  
the	  earliest	  B	  cell	  responses	  are	  evident	  within	  eight	  days	  following	  detectable	  plasma	  viremia	  
(initially	  in	  the	  form	  of	  immune	  complexes,	  and	  approximately	  five	  days	  later	  as	  free	  plasma	  
antibodies),	  they	  are	  non-­‐neutralizing,	  and	  mathematical	  modeling	  found	  little	  or	  no	  effect	  of	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these	  antibodies	  on	  the	  control	  of	  acute-­‐phase	  viremia	  (45).	  	  Further,	  results	  from	  experimental	  
depletion	  of	  B	  cells	  using	  anti-­‐CD20	  mAbs	  in	  non-­‐human	  primate	  models	  have	  been	  less	  clear	  
than	  those	  from	  T	  cell	  depletion.	  	  While	  B	  cell	  depletion	  in	  rhesus	  monkeys	  did	  not	  have	  an	  
effect	  on	  the	  initial	  decline	  in	  peak	  viremia,	  there	  was	  an	  inverse	  correlation	  between	  
neutralizing	  antibody	  titers	  and	  subsequent	  viral	  load,	  suggesting	  that	  neutralizing	  antibodies	  
do	  contribute	  to	  viral	  control	  (46).	  	  B	  cell	  depleted	  monkeys	  also	  had	  an	  accelerated	  progression	  
to	  AIDS	  (Acquired	  Immunodeficiency	  Syndrome)	  (47).	  	  In	  contrast,	  however,	  others	  found	  that	  
B	  cell	  depletion	  in	  rhesus	  macaques	  (48),	  and	  African	  green	  monkeys	  (49)	  did	  not	  significantly	  
affect	  acute	  or	  chronic	  SIV	  viral	  loads.	  	  A	  recent	  case	  study	  of	  an	  HIV	  infected	  individual	  that	  
underwent	  B	  cell	  depletion	  (as	  part	  of	  treatment	  for	  lymphoplasmacytoid	  lymphoma)	  showed	  a	  
temporal	  correlation	  between	  neutralizing	  titers	  and	  plasma	  viral	  load,	  suggesting	  that	  
neutralizing	  antibodies	  may	  indeed	  play	  a	  significant	  role	  in	  the	  control	  of	  HIV	  replication	  in	  
humans	  (50).	  	  However,	  as	  B	  cells	  have	  a	  multifaceted	  role	  in	  humoral	  and	  cellular	  responses,	  B	  
cell	  depletion	  may	  have	  affected	  immune	  functions	  other	  than	  neutralizing	  antibody	  titers.	  	  	  
Passive	  transfer	  of	  neutralizing	  antibodies	  provides	  a	  more	  direct	  means	  of	  evaluating	  the	  
role	  of	  neutralizing	  antibodies	  in	  controlling	  replication.	  	  Treatment	  of	  macaques	  with	  SIV-­‐
specific	  IgG	  seven	  days	  after	  infection	  resulted	  in	  lower	  viral	  load	  set	  point	  (51),	  and	  in	  humans,	  
passive	  transfer	  of	  neutralizing	  antibodies	  delayed	  the	  rebound	  of	  viremia	  following	  ART	  
interruption	  in	  some	  individuals	  (52).	  	  However,	  from	  this	  latter	  study,	  it	  has	  since	  been	  
revealed	  that	  titers	  10-­‐	  to	  100-­‐fold	  higher	  than	  the	  autologous	  titers	  present	  were	  required	  to	  
produce	  a	  clinical	  benefit	  (53).	  	  Passive	  immunotherapy	  of	  HIV-­‐1	  infected	  humanized	  mice	  with	  
multiple	  monoclonal	  antibodies	  that	  each	  target	  relatively	  conserved	  epitopes	  was	  also	  able	  to	  
suppress	  viral	  loads	  to	  below	  detection	  (54).	  
Neutralizing	  antibodies	  exert	  significant	  selective	  pressure	  on	  HIV	  during	  natural	  infection	  
(55–57).	  	  The	  HIV	  Envelope	  glycoproteins	  gp120	  and	  gp41,	  which	  form	  trimeric	  “spikes”	  of	  
gp120-­‐gp41	  heterodimers,	  are	  responsible	  for	  mediating	  viral	  entry	  into	  cells,	  and	  are	  the	  only	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known	  targets	  of	  HIV	  neutralizing	  antibodies.	  	  The	  neutralizing	  antibody	  response	  to	  HIV	  
develops	  several	  months	  after	  infection	  (55–59),	  and	  much	  of	  the	  extensive	  genetic	  variation	  in	  
Envelope	  that	  follows	  in	  early	  infection	  is	  thought	  to	  be	  due	  to	  escape	  from	  antibody	  pressure	  
(55,	  56).	  	  While	  the	  early	  neutralizing	  antibody	  response	  is	  often	  potent	  (55–58),	  Envelope	  is	  
able	  to	  tolerate	  a	  large	  amount	  of	  diversity.	  	  Together	  with	  an	  error-­‐prone	  reverse	  transcriptase,	  
HIV	  can	  readily	  mutate,	  allowing	  rapid	  escape	  from	  these	  neutralizing	  antibody	  responses.	  	  This	  
is	  evident	  in	  observations	  that	  most	  HIV	  variants	  in	  early	  infection	  are	  resistant	  to	  
neutralization	  by	  contemporaneous	  plasma	  (56,	  57,	  59,	  60).	  	  However,	  variants	  remain	  sensitive	  
to	  plasma	  from	  later	  timepoints,	  indicating	  that	  de	  novo	  responses	  are	  subsequently	  generated	  
against	  escape	  mutants,	  highlighting	  the	  dynamic	  nature	  of	  the	  neutralizing	  antibody	  response	  
to	  HIV	  (59,	  61).	  	  	  
Escape	  from	  antibody	  neutralization	  can	  occur	  via	  typical	  point	  mutations	  (59,	  62),	  or	  
insertions	  and	  deletions	  (63,	  64).	  	  Furthermore,	  the	  HIV	  Envelope	  is	  extensively	  glycosylated	  
(with	  approximately	  half	  of	  its	  mass	  attributable	  to	  glycans,	  (65)),	  such	  that	  much	  of	  the	  surface	  
of	  Envelope	  is	  decorated	  with	  relatively	  non-­‐immunogenic	  glycans	  (see	  Figure	  1.1;	  glycans	  are	  
shown	  in	  purple).	  	  	  	  These	  glycans	  are	  large	  and	  therefore	  provide	  a	  means	  to	  shield	  underlying	  
epitopes.	  	  It	  is	  not	  surprising,	  therefore,	  that	  HIV	  also	  appears	  to	  utilise	  an	  “evolving	  glycan	  
shield”	  to	  escape	  neutralizing	  antibody	  responses,	  whereby	  mutations	  result	  in	  shifting	  patterns	  
of	  glycosylation	  (56,	  63).	  	  	  
Escape	  from	  early	  neutralizing	  antibody	  responses	  appears	  to	  be	  primarily	  mediated	  by	  
mutations	  in	  V1V2,	  C3V4,	  and	  to	  a	  lesser	  extent,	  V5	  (reviewed	  in	  66).	  	  While	  mutations	  in	  V4	  
and	  V5	  can	  apparently	  mediate	  escape	  from	  neutralizing	  antibodies,	  they	  themselves	  do	  not	  
appear	  to	  be	  direct	  targets	  of	  early	  neutralizing	  antibodies	  (59,	  60).	  	  On	  the	  other	  hand,	  V1V2,	  
the	  membrane	  proximal	  external	  region	  (MPER)	  of	  gp41,	  and	  in	  the	  case	  of	  subtype	  C,	  C3	  
(particularly	  the	  alpha-­‐2	  helix),	  appear	  to	  be	  major	  targets	  of	  the	  early	  neutralizing	  antibody	  
response	  (58–60,	  67,	  68).	  	  While	  it	  is	  evident	  that	  V1V2	  is	  a	  direct	  target	  of	  the	  neutralizing	  
	  
	  
	   	   9	  
	  
antibody	  response,	  the	  ability	  of	  the	  V1V2	  loop	  to	  shield	  other	  neutralization	  determinants	  is	  
also	  well	  documented	  (64,	  69).	  	  Interestingly,	  while	  anti-­‐V3	  antibodies	  are	  generated	  in	  early	  
infection	  (45),	  they	  do	  not	  appear	  to	  contribute	  to	  autologous	  neutralization	  (59),	  potentially	  
due	  to	  the	  conformational	  shielding	  of	  V3	  in	  the	  context	  of	  the	  native	  trimer.	  	  	  	  
By	  characterising	  the	  specificities	  of	  the	  early	  neutralizing	  antibody	  response	  to	  HIV,	  it	  has	  
become	  apparent	  that	  this	  early	  response	  frequently	  comprises	  of	  only	  one	  or	  a	  few	  
specificities.	  	  Further,	  when	  more	  than	  one	  specificity	  were	  evident;	  they	  appeared	  sequentially	  
(59,	  60).	  	  An	  in	  depth	  analysis	  of	  the	  dynamics	  of	  the	  early	  neutralizing	  antibody	  response,	  
escape,	  and	  viral	  control	  in	  one	  individual	  showed	  that	  the	  onset	  of	  the	  neutralizing	  antibody	  
response	  was	  associated	  with	  a	  7-­‐fold	  drop	  in	  viral	  load	  (59).	  	  However,	  approximately	  seven	  
weeks	  and	  relatively	  low	  antibody	  titers	  (ID60	  titer	  >	  45)	  were	  required	  to	  drive	  selection	  of	  
escape	  variants.	  	  Escape	  from	  this	  response	  was	  temporally	  correlated	  with	  a	  four-­‐fold	  increase	  
in	  viral	  load,	  suggesting	  a	  temporary	  loss	  of	  immune	  control.	  
Taken	  together,	  these	  data	  suggest	  that	  while	  neutralizing	  antibodies	  may	  exert	  some	  
control	  over	  HIV	  replication,	  titers	  present	  during	  natural	  infection	  are	  likely	  too	  low	  to	  be	  
effective	  to	  prevent	  disease	  progression	  in	  the	  face	  of	  a	  rapidly	  escaping	  virus.	  	  Consistent	  with	  
this,	  reducing	  viral	  load	  and	  diversity	  with	  ARV	  pre-­‐treatment	  enabled	  passively	  transferred	  
neutralizing	  antibodies	  to	  control	  HIV	  replication	  in	  humanized	  mice	  (70).	  
Neutralizing	  antibodies	  can	  prevent	  infection	  
While	  even	  potent	  neutralizing	  antibody	  responses	  do	  not	  prevent	  disease	  progression	  in	  
HIV-­‐infected	  individuals	  (71–73),	  there	  is	  significant	  evidence	  that	  suggests	  that	  neutralizing	  
antibodies,	  if	  present	  at	  the	  time	  of	  challenge,	  could	  prevent	  infection.	  	  The	  most	  compelling	  of	  
which	  is	  that	  passive	  immunotherapy	  can	  protect	  non-­‐human	  primates	  against	  challenges	  with	  
SIV,	  and	  SIV-­‐HIV	  chimeric	  viruses	  (SHIV)	  (74–81).	  	  While	  initial	  studies	  utilized	  high	  antibody	  
titers	  targeted	  against	  the	  challenge	  strains,	  collectively,	  these	  results	  provided	  a	  proof	  of	  
concept	  that	  neutralizing	  antibodies	  can	  provide	  sterilizing	  immunity	  against	  primate	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immunodeficiency	  viruses.	  	  Interestingly,	  a	  monoclonal	  antibody,	  b12,	  provided	  macaques	  with	  
greater	  protection	  against	  SHIV	  challenge	  compared	  to	  a	  b12	  variant	  with	  similar	  neutralizing	  
activity	  but	  deficient	  in	  Fc	  mediated	  effector	  function	  (75).	  	  However,	  passive	  immunotherapy	  
with	  weakly-­‐	  and	  non-­‐neutralizing	  antibodies	  provided	  little	  or	  no	  protection	  from	  SHIV	  
challenge,	  emphasizing	  that	  vaccine	  research	  should	  still	  be	  focused	  on	  eliciting	  potent	  
neutralizing	  antibodies	  (82),	  the	  activities	  of	  which	  may	  be	  enhanced	  by	  Fc	  mediated	  functions.	  
Studies	  in	  non-­‐human	  primates	  have	  also,	  importantly,	  provided	  quantitative	  data	  on	  the	  
levels	  of	  neutralizing	  antibodies	  that	  would	  likely	  be	  required	  to	  provide	  protection.	  	  While	  
modest	  levels	  of	  neutralizing	  antibodies	  typical	  of	  those	  commonly	  found	  in	  HIV	  infected	  
individuals	  could	  provide	  partial	  protection	  and	  increase	  the	  number	  of	  challenges	  required	  to	  
infect	  macaques	  (75),	  high	  levels	  of	  neutralizing	  antibodies	  have	  been	  estimated	  to	  be	  required	  
to	  provide	  complete	  protection	  (74,	  83,	  84).	  	  In	  some	  (74),	  although	  not	  all	  (75)	  cases,	  titers	  
present	  at	  the	  time	  of	  challenge	  also	  correlated	  with	  the	  susceptibility	  to	  infection.	  	  	  While	  it	  is	  
difficult	  to	  extrapolate	  these	  data	  directly	  to	  humans,	  taken	  together,	  they	  do	  suggest	  that	  a	  
protective	  vaccine	  will	  likely	  need	  to	  elicit	  long-­‐lived,	  high	  titer	  neutralizing	  antibody	  responses.	  	  
Therefore,	  understanding	  factors	  that	  enhance	  B	  cell	  responses	  and	  the	  development	  of	  
neutralizing	  antibodies	  is	  an	  important	  objective.	  
Given	  the	  extraordinary	  diversity	  inherent	  in	  the	  circulating	  HIV	  variants,	  vaccines	  must	  not	  
only	  elicit	  relatively	  potent	  responses,	  but	  must	  also	  elicit	  antibodies	  able	  to	  neutralize	  a	  broad	  
range	  of	  variants	  (broadly	  neutralizing	  antibodies)	  at	  these	  titers.	  	  However,	  the	  early	  
neutralizing	  antibody	  response	  is	  invariably	  highly	  specific	  for	  an	  individual’s	  own	  virus	  
(autologous	  virus),	  and	  is	  unable	  to	  neutralize	  variants	  that	  the	  immune	  system	  has	  not	  been	  
exposed	  to	  (heterologous	  viruses).	  	  This	  is	  perhaps	  unsurprising	  given	  the	  highly	  variable	  
nature	  of	  the	  major	  targets	  of	  the	  early	  autologous	  neutralizing	  antibody	  response	  (described	  
above).	  	  Nevertheless,	  a	  number	  of	  studies	  that	  evaluated	  the	  breadth	  of	  the	  neutralizing	  
antibody	  response	  in	  HIV	  infected	  individuals	  have	  revealed	  that	  a	  subset	  of	  chronically	  infected	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individuals	  possess	  broadly	  neutralizing	  antibodies.	  	  While	  the	  definition	  of	  breadth	  was	  not	  
entirely	  consistent	  between	  studies,	  it	  is	  estimated	  that	  ~10-­‐30%	  of	  HIV	  infected	  individuals	  
develop	  moderate	  to	  broadly	  neutralizing	  activity	  during	  the	  course	  of	  natural	  HIV	  infection	  (1,	  
85–87),	  providing	  hope	  that	  a	  vaccine	  could	  elicit	  similar	  responses.	  	  While	  in	  some	  of	  these	  
cases,	  breadth	  was	  mediated	  by	  several	  different	  specificities,	  each	  responsible	  in	  part	  for	  the	  
breadth	  (88),	  there	  is	  also	  evidence	  that	  a	  single	  antibody	  specificity	  can	  mediate	  this	  breadth	  
(1,	  87,	  89,	  90).	  The	  identification	  of	  epitopes	  targeted	  by	  these	  broadly	  neutralizing	  antibodies	  
can	  identify	  vulnerable	  regions	  in	  the	  HIV	  Envelope	  that	  can	  be	  targeted	  in	  vaccine	  design.	  	  	  
Targets	  of	  broadly	  neutralizing	  antibodies	  
The	  HIV	  Envelope	  presents	  a	  formidable	  target	  for	  neutralizing	  antibodies.	  	  In	  addition	  to	  
the	  extensive	  glycosylation	  of	  the	  native	  Envelope	  trimer,	  immunogenic	  non-­‐native	  forms	  of	  
Envelope	  are	  also	  present	  on	  the	  surface	  of	  virions	  that	  elicit	  non-­‐neutralizing	  antibodies	  at	  the	  
expense	  of	  neutralizing	  responses	  (91).	  	  Native	  trimers	  are	  few	  and	  far	  between,	  with	  on	  
average	  only	  ~14	  spikes	  on	  the	  surface	  of	  each	  virion	  (92).	  	  This	  scarcity	  of	  Envelope	  spikes	  on	  
the	  surface	  of	  virions	  effectively	  prevents	  bivalent	  binding	  by	  antibodies,	  and	  consequently	  
minimises	  avidity,	  which	  antibodies	  use	  to	  achieve	  high	  affinity	  binding,	  and	  potent	  
neutralization	  (see	  93).	  	  HIV	  Envelope	  is	  also	  hypervariable,	  such	  that	  conserved	  epitopes	  that	  
could	  potentially	  be	  targets	  for	  broadly	  neutralizing	  antibodies	  are	  also	  relatively	  scarce.	  	  
Regions	  that	  are	  highly	  conserved	  are	  generally	  conformationally	  masked	  and	  consequently	  
difficult	  for	  antibodies	  to	  access.	  	  	  
Before	  2009,	  only	  a	  few	  broadly	  neutralizing	  monoclonal	  antibodies	  had	  been	  isolated	  from	  
HIV	  infected	  individuals	  (namely	  2F5,	  4E10,	  Z13,	  b12,	  and	  2G12).	  	  Renewed	  interest	  and	  the	  
advent	  of	  new	  high	  throughput	  techniques	  since	  have	  resulted	  in	  the	  identification	  of	  a	  number	  
of	  new	  broadly	  neutralizing	  monoclonal	  antibodies,	  some	  of	  which	  display	  exceptional	  breadth	  
and	  potency.	  	  The	  detailed	  characterisation	  of	  the	  epitopes	  targeted	  by	  these	  broadly	  
neutralizing	  antibodies	  has	  identified	  conserved,	  accessible	  epitopes	  in	  the	  HIV-­‐1	  Envelope	  that	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represent	  vulnerable	  regions	  that	  could	  be	  exploited	  by	  vaccines.	  	  These	  targets	  include	  (i)	  the	  
CD4bs,	  (ii)	  a	  quaternary	  (i.e.	  preferentially	  expressed	  in	  trimeric	  Envelope)	  epitope	  dependent	  
on	  residues	  in	  V2	  and	  V3	  (targeted	  by	  the	  so-­‐called	  “PG9/16-­‐like”	  antibodies),	  (iii)	  a	  cluster	  of	  
glycans	  on	  the	  outer	  domain	  of	  gp120	  (targeted	  by	  2G12),	  (iv)	  an	  epitope	  in	  V3	  including	  
glycans	  (targeted	  by	  several	  of	  the	  PGT	  monoclonal	  antibodies;	  “PGT128-­‐like”),	  and	  (v)	  the	  
membrane-­‐proximal	  external	  region	  (MPER)	  of	  gp41	  (see	  Figures	  1.1,	  1.2	  and	  Table	  1.1).	  	  
Studies	  that	  have	  mapped	  the	  specificities	  of	  broadly	  neutralizing	  sera	  have	  revealed	  that	  the	  
quaternary	  V2,	  PG9/16-­‐like	  epitope	  as	  well	  an	  epitope	  including	  the	  glycan	  at	  position	  332	  
(overlapping	  both	  the	  2G12	  and	  PGT128-­‐like	  epitope)	  are	  the	  most	  common	  targets	  of	  broadly	  
neutralizing	  antibodies	  (1,	  87).	  	  Importantly,	  in	  these	  studies,	  a	  fraction	  of	  broadly	  neutralizing	  
activity	  could	  not	  be	  mapped	  to	  known	  specificities,	  indicating	  that	  at	  least	  one	  additional	  
broadly	  neutralizing	  epitope	  awaits	  discovery.	  
Table	  1.1	  |	  Representatives	  of	  broadly	  neutralizing	  HIV	  monoclonal	  antibodies	  (mAbs)	  
mAb	   Year	  of	  
discovery	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Figure	  1.2	  |	  Bread-­‐potency	  curves	  for	  nine	  broadly	  neutralizing	  HIV	  antibodies.	  	  Curves	  were	  
generated	  from	  published	  data	  in	  HIV	  Antibody	  Database	  (197).	  	  The	  lower	  the	  concentration	  
required	  to	  neutralize,	  the	  more	  potent	  the	  antibody.	  	  
	  
and imprint immunological memory. However, for many reasons
these approaches have been unsuccessful for HIV vaccine
development (Burton et al., 2005; Kong and Sattentau, 2012;
Kwong et al., 2011; Overbaugh and Morris, 2012; Pantophlet
and Burton, 2006; Verkoczy et al., 2011; Wyatt and Sodroski,
1998). The challenges in this approach are largely related to
the properties of the HIV envelope (Env) spike, which is a heter-
odimer of the glycoproteins gp120 and gp41 that forms trimers
on the virion surface and mediates entry by binding to CD4 and
CCR5 or CXCR4 on the target cell surface. First, the variable
regions of the functional HIV Env trimer spike (Figure 1), the
trimer being the sole target of neutralizing antibodies, are typi-
cally immunodominant relative to conserved regions of the
spike and, thus, the neutralizing antibody response against
HIV is generally highly strain specific. Second, the extraordinary
variability in antigenic regions of the Env spike means that the
number of circulating HIV strains is extremely high and that
conventional concepts of viral serotypes are rendered irrele-
vant. Third, because of the instability of the HIV spike, most viral
particle-based vaccines tend to express immunodominant,
nonfunctional forms of Env on the virion surface (Poignard
et al., 2003), which favor the induction of nonneutralizing anti-
bodies (Crooks et al., 2007). Fourth, there is a relatively low
copy number of Env molecules on HIV particles, leading to
expectations of rather poor activation of B cells as compared
to viruses with dense Env coating, such as influenza. Fifth, other
complicating factors, such as the induction of antibodies
against cellular proteins, have contributed to difficulties with
viral particle-based immunogens (Chan et al., 1992; Crooks
et al., 2007; Hammonds et al., 2005). Although a number of
strategies to overcome these hurdles have been employed,
including pseudotyping HIV with heterologous envelopes (Kuate
Figure 1. Structure and Antibody
Recognition of the HIV Envelope Spike
The molecule is a heterotrimer of composition
(gp120)3 (gp41)3. Gp41 is a transmembrane pro-
tein, and gp120 is the receptor molecule for CD4
and CCR5 (or CXCR4). The model (Schief et al.,
2009) is adapted from a cryo-electron tomo-
graphic structure of the HIV trimer (Liu et al., 2008).
The crystal structure of the b12-bound monomeric
gp120 core (red) has been fitted into the density
map (Zhou et al., 2007). Glycans are shown in
purple. The CD4 binding site is shown in yellow.
The approximate locations of the epitopes tar-
geted by existing bnMAbs are indicated with
arrows, and the number of MAbs targeting each
epitope is shown in red boxes. A small selection of
bnMAbs targeting each epitope is included.
et al., 2006; Marsac et al., 2002) and
generating VLPs with cleavage-defective
or disulfide-shackled Env to prevent
gp120-gp41 dissociation (Crooks et al.,
2007), none of these approaches have
yet induced potent heterologous anti-
body responses in nonhuman primate
(NHP) models. Finally, it should be noted
that, because of the risk of mutation and
reversion to a pathogenic form, the use
of live attenuated HIV vaccines in humans raises formidable
safety and liability issues.
Subunit Vaccines: Recombinant Env
Using the same paradigm that formed the basis for successful
development of a vaccine against hepatitis B, initial attempts
to generate a protective vaccine against HIV focused on the elic-
itation of Env-specific humoral immune responses using gp120
subunit immunogens. Unfortunately, the results of clinical trials
indicated that the antibodies elicited by monomeric gp120 failed
to neutralize HIV primary isolates, prevent HIV infection, reduce
viral loads, or delay disease progression (Flynn et al., 2005;
Pitisuttithum et al., 2006). Therefore, over the ensuing years,
more attention has been focused on the generation of soluble,
recombinant trimers as immunogens to better simulate the
structure of the native HIV Env spike. Indeed, given that antibody
binding to the trimer is both necessary and sufficient for neu-
tralization (Pantophlet et al., 2009; Parren and Burton, 2001;
Roben et al., 1994; Sattentau and Moore, 1995; Wallace and
Stamatatos, 2009; Yang et al., 2006), a recombinant native trimer
represents an excellent starting point for the elicitation of bnAb
responses. However, the instability of the functional HIV spike
has presented challenges to the development of recombinant
trimers that mimic the structure of the native spike (Phogat and
Wyatt, 2007). Various strategies, including the introduction of
disulfide bonds to covalently link gp120 and gp41, the deletion
of the furin cleavage site in gp160 so that furin-mediated prote-
olysis to yield noncovalently linked gp120 and gp41 subunits
does not occur, and the incorporation of trimerization motifs
into the gp41 ectodomain, have been employed to stabilize
recombinant trimers (Phogat and Wyatt, 2007). However, none
of the recombinant trimers developed to date display antigenic
profiles that truly mimic the native HIV spike, and these
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Figure	  1.1	  |	  Targets	  for	  broadly	  neutralizing	  HIV	  antibodies.	  	  A	  model	  of	  the	  HIV-­‐1	  gp160,	  unliganded	  trimer	  
spike	  is	  shown,	  along	  with	  the	  targets	  of	  broadly	  neutralizing	  antibodies.	  Examples	  of	  mAbs	  targeting	  each	  site	  
are	  shown	  in	  parentheses.	  	  The	  gp120	  core,	  shown	  in	  red	  with	  the	  b12	  epitope	  overlapping	  the	  CD4	  binding	  
site	  (CD4bs)	  highlighted	  in	  yellow,	  is	  fitted	  in	  an	  cryo-­‐electron	  tomography	  density	  map	  (grey	  mesh).	  	  
Estimated	  N-­‐linked	  glycosylation	  is	  shown	  in	  purple	  (glycan	  shield).	  CD4bs,	  CD4-­‐binding	  site;	  MPER,	  membrane	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Development	  of	  broadly	  neutralizing	  antibodies	  
Understanding	  how	  broadly	  neutralizing	  activity	  develops	  during	  natural	  infection,	  and	  the	  
factors	  that	  augment	  this	  process,	  may	  provide	  clues	  as	  to	  how	  vaccines	  might	  be	  able	  to	  elicit	  
similar	  responses.	  	  While	  the	  initial	  neutralizing	  antibody	  response	  is	  highly	  specific	  for	  an	  
individual’s	  own	  virus	  and	  develops	  several	  months	  after	  infection,	  the	  ability	  to	  neutralize	  
heterologous	  viruses	  increases	  over	  time	  and	  is	  typically	  evident	  only	  years	  (mean	  ~2.5	  years)	  
after	  infection	  (1,	  105).	  	  Further,	  although	  broadly	  neutralizing	  antibodies	  (bnAbs)	  can	  be	  found	  
in	  individuals	  with	  low	  or	  undetectable	  viremia,	  albeit	  at	  a	  lower	  frequency	  (106),	  viral	  load	  has	  
been	  consistently	  associated	  with	  the	  development	  of	  enhanced	  neutralization	  breadth	  in	  a	  
number	  of	  cohorts	  (1,	  72,	  105,	  107).	  	  The	  dependency	  on	  time	  and	  high	  viral	  loads	  suggests	  that	  
chronic	  antigen	  exposure	  is	  required	  for	  the	  development	  of	  broadly	  cross-­‐reactive	  antibodies.	  	  
Cloning	  and	  sequencing	  of	  the	  immunoglobulin	  genes	  from	  B	  cells	  expressing	  broadly	  
neutralizing	  antibodies	  has	  also	  revealed	  that	  they	  are	  typically	  highly	  altered	  from	  their	  
genomic	  precursors	  by	  somatic	  hypermutation	  (89,	  90,	  108,	  109),	  suggesting	  a	  role	  for	  affinity	  
maturation	  in	  the	  development	  of	  cross-­‐reactivity.	  	  Further,	  the	  broadly	  neutralizing	  antibodies	  
characterized	  to	  date	  appear	  to	  each	  possess	  unusual	  physical	  features	  that	  are	  important	  
determinants	  of	  their	  neutralization	  capacity,	  such	  as	  a	  long	  heavy	  chain	  complementarity-­‐
determining	  region	  3	  (CDR	  H3),	  sulphated	  tyrosines	  (eg.	  PG9,	  PG16,	  CH01-­‐04,	  PGT141-­‐145),	  
heavy	  chain	  domain	  swaps	  [exchange	  of	  the	  heavy-­‐chain	  variable	  (VH)	  domains	  on	  the	  adjacent	  
antigen-­‐binding	  arms	  of	  the	  antibody	  (eg.	  2G12)],	  or	  apparent	  self-­‐	  or	  poly-­‐reactivity	  and	  
membrane	  binding	  (eg.	  2F5,	  4E10,	  b12,	  2G12)	  (reviewed	  in	  110).	  	  	  This	  suggests	  that	  these	  
broadly	  neutralizing	  antibodies	  may	  have	  been	  generated	  as	  a	  result	  of	  atypical	  pathways,	  and	  
may	  account	  in	  part	  for	  the	  fact	  that	  most	  infected	  individuals	  do	  not	  elicit	  broadly	  neutralizing	  
antibodies,	  as	  well	  as	  the	  appearance	  of	  these	  antibodies	  only	  after	  years	  of	  infection	  in	  those	  
that	  do.	  	  Whether	  extensive	  affinity	  maturation	  and	  unique	  physical	  features	  are	  necessary	  for	  
broad	  neutralization	  of	  HIV	  remains	  to	  be	  determined.	  	  However,	  if	  they	  are,	  eliciting	  broadly	  
neutralizing	  antibodies	  by	  typical	  vaccination	  strategies	  will	  prove	  difficult,	  and	  may	  require	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novel	  and	  extended	  vaccination	  regimens	  in	  addition	  to	  novel	  immunogens.	  	  Pre-­‐clinical	  testing	  
protocols	  may	  also	  need	  to	  allow	  for	  extended	  follow	  up	  following	  vaccination.	  
Polyvalent	  vaccines,	  and	  immunodominance	  
The	  use	  of	  polyvalent	  vaccines	  may	  be	  critical	  to	  an	  effective	  HIV	  vaccine,	  with	  the	  hope	  that	  
exposure	  of	  the	  immune	  system	  to	  multiple	  HIV	  antigens	  will	  result	  in	  immune	  responses	  that	  
are	  effective	  against	  a	  broader	  range	  of	  variants.	  	  This	  approach	  has	  been	  used	  successfully	  in	  
vaccines	  against	  Polio,	  Influenza,	  and	  Streptococcus	  pneumonia.	  	  	  
However,	  one	  potential	  shortcoming	  in	  the	  use	  of	  polyvalent	  immunogens	  in	  HIV	  vaccines	  is	  
the	  propensity	  of	  the	  human	  immune	  system	  to	  respond	  to	  only	  a	  fraction	  of	  potentially	  
immunogenic	  determinants,	  a	  phenomenon	  known	  as	  “immunodominance”.	  	  Some	  mechanisms	  
responsible	  for	  influencing	  the	  immunodominance	  of	  the	  CTL	  response	  have	  been	  identified	  and	  
include	  preferential	  antigen	  processing,	  HLA	  affinity	  and	  affinity	  for	  the	  cognate	  TCR,	  as	  well	  as	  
competition	  between	  CD8	  T	  cells	  for	  dendritic	  cells	  (111,	  112).	  	  While,	  immunodominance	  is	  
also	  a	  prominent	  feature	  of	  the	  neutralizing	  antibody	  response	  to	  HIV,	  the	  mechanisms	  are	  less	  
clear	  than	  those	  for	  CTL	  responses.	  	  In	  acute	  infection,	  HIV-­‐infected	  individuals	  develop	  a	  
limited	  number	  of	  oligoclonal	  B	  cell	  responses	  that	  are	  initially	  generated	  against	  one	  or	  a	  few	  
immunodominant	  epitopes	  within	  Envelope	  (59,	  60).	  	  These	  epitopes	  are	  generally	  regions	  that	  
can	  tolerate	  a	  large	  amount	  of	  genetic	  variability	  (and	  consequently	  can	  be	  highly	  variable	  
among	  circulating	  variants),	  and	  therefore	  while	  responses	  to	  these	  epitopes	  may	  be	  effective	  
against	  the	  variant	  that	  elicited	  them,	  they	  are	  not	  protective	  against	  heterologous	  variants	  
(type-­‐specific	  responses).	  	  It	  is	  unclear	  whether	  immunodominance	  will	  also	  extend	  to	  the	  
responses	  to	  multiple	  Envelopes	  and	  therefore	  would	  diminish	  the	  efficacy	  of	  polyvalent	  HIV	  
vaccines	  incorporating	  Envelope.	  	  
To	  date,	  vaccines	  have	  been	  unsuccessful	  in	  eliciting	  broad	  or	  potent	  neutralizing	  antibody	  
responses.	  	  The	  diversity	  inherent	  in	  hypervariable,	  immunodominant	  epitopes	  in	  Envelope	  is	  
overwhelming	  such	  that	  incorporating	  sufficient	  diversity	  in	  a	  polyvalent	  formulation	  to	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provide	  significantly	  broad	  protection	  may	  not	  be	  feasible.	  	  This	  is	  supported	  by	  the	  fact	  that	  
polyvalent	  vaccines	  have	  thus	  far	  not	  been	  able	  to	  elicit	  any	  significant	  neutralizing	  antibody	  
titers	  against	  tier	  2	  viruses	  (representative	  of	  primary	  variants,	  as	  opposed	  to	  easy	  to	  neutralize	  
laboratory-­‐adapted	  “	  tier	  1”	  strains)	  not	  incorporated	  in	  the	  vaccine,	  in	  animal	  models	  or	  in	  
humans,	  despite	  eliciting	  responses	  capable	  of	  neutralizing	  several	  variants	  that	  were	  
incorporated	  in	  the	  vaccine	  (113–119),	  although	  this	  may	  be	  confounded	  by	  inadequacies	  in	  
pre-­‐clinical	  testing.	  	  Furthermore,	  an	  eight-­‐valent	  formulation	  was	  previously	  shown	  to	  be	  less	  
immunogenic	  than	  a	  three-­‐valent	  one,	  providing	  evidence	  that	  higher	  valencies	  may	  not	  
necessarily	  be	  able	  to	  ceaselessly	  elicit	  greater	  specificities	  (120).	  	  Consequently,	  a	  key	  feature	  
of	  an	  effective	  neutralizing	  antibody-­‐based	  vaccine	  will	  likely	  rest	  on	  the	  ability	  to	  prevent	  the	  
generation	  of	  immunodominant,	  type-­‐specific	  responses	  typically	  seen	  during	  acute	  infection,	  
and	  to	  focus	  the	  immune	  response	  onto	  conserved,	  sub-­‐dominant	  epitopes	  such	  as	  those	  
targeted	  by	  broadly	  neutralizing	  antibodies.	  	  	  
While	  polyvalent	  vaccination	  is	  being	  evaluated	  for	  the	  potential	  to	  enhance	  the	  number	  of	  
specificities	  generated	  as	  a	  means	  to	  enhance	  breadth,	  the	  potential	  of	  polyvalent	  immunogens	  
to	  focus	  the	  immune	  response	  to	  conserved	  epitopes	  remains	  largely,	  although	  not	  completely,	  
unexplored	  (121,	  122).	  	  	  Boosting	  of	  an	  envelope	  DNA-­‐primed	  (rabbit)	  immune	  system	  with	  V3	  
fusion	  peptides	  resulted	  in	  >80%	  of	  the	  elicited	  neutralizing	  antibodies	  being	  specific	  for	  
epitopes	  in	  V3	  (122).	  	  	  	  	  Furthermore,	  sequential	  immunisation	  of	  rhesus	  macaques	  with	  a	  
quasispecies	  partially	  mimicked	  the	  response	  to	  that	  quasispecies	  seen	  in	  natural	  infection	  
(121).	  Taken	  together,	  these	  results	  suggest	  that	  it	  may	  be	  possible	  to	  focus	  the	  immune	  
response	  on	  a	  particular	  epitope	  within	  Envelope,	  or	  to	  direct	  the	  maturation	  of	  an	  antibody	  
specificity	  in	  a	  vaccine	  setting	  (121,	  122).	  	  However,	  it	  is	  unclear	  whether	  the	  immune	  response	  
to	  a	  heterologous	  boost	  will	  be	  preferentially	  targeted	  against	  epitopes	  present	  in	  the	  priming	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HIV	  vaccine	  research	  is	  further	  complicated	  by	  the	  fact	  that	  the	  correlates	  of	  protection	  in	  
humans	  are	  largely	  unknown.	  	  However,	  it	  seems	  likely	  that	  vaccines	  will	  need	  to	  elicit	  better	  
responses	  than	  those	  generated	  in	  natural	  infection.	  	  This	  is	  indicated	  by	  the	  fact	  that	  HIV	  
infected	  individuals	  can	  still	  be	  “superinfected”	  with	  a	  second	  variant	  after	  an	  established	  initial	  
infection.	  	  	  
Superinfection,	  as	  opposed	  to	  co-­‐infection	  where	  both	  variants	  are	  transmitted	  prior	  to	  
seroconversion,	  provides	  an	  opportunity	  to	  address	  the	  correlates	  of	  protection	  as	  a	  virus	  is	  
transmitted	  in	  the	  face	  of	  an	  on-­‐going	  anti-­‐HIV	  immune	  response.	  Several	  population-­‐based	  
studies	  found	  the	  incidence	  of	  superinfection	  to	  be	  similar	  to	  that	  of	  the	  incidence	  of	  primary	  
infection	  in	  the	  same,	  or	  comparatively	  similar	  cohorts	  (123–125),	  and	  suggested	  that	  immune	  
responses	  generated	  during	  natural	  infection	  likely	  provided	  limited	  or	  no	  protection	  against	  
subsequent	  superinfection.	  However,	  other	  studies	  have	  reported	  incidences	  of	  superinfection	  
to	  be	  less	  than	  that	  of	  primary	  infection	  (126–129).	  	  	  
Dual	  infection	  (infection	  with	  two	  or	  more	  distinct	  variants,	  regardless	  of	  timing	  i.e.	  
encompassing	  both	  co-­‐	  and	  superinfection)	  is	  also	  of	  clinical	  relevance,	  as	  it	  has	  previously	  been	  
associated	  with	  accelerated	  disease	  progression	  (130,	  131).	  	  As	  HIV	  is	  diploid	  (virions	  
encapsidate	  two	  genome	  copies),	  if	  two	  variants	  infect	  the	  same	  individual,	  and	  the	  same	  cell,	  
the	  genomes	  from	  each	  variant	  can	  subsequently	  be	  packaged	  into	  the	  same	  virion.	  	  Upon	  
infection	  of	  another	  cell,	  during	  the	  reverse	  transcription	  of	  the	  HIV	  genome,	  reverse	  
transcriptase	  can	  switch	  between	  templates	  thereby	  resulting	  in	  the	  generation	  of	  recombinant	  
viruses,	  whose	  genomes	  are	  a	  mosaic	  of	  the	  two	  different	  variants	  (Figure	  1.3).	  	  The	  potential	  
for	  HIV	  to	  recombine	  is	  highlighted	  by	  the	  high	  prevalence	  of	  circulating	  and	  unique	  
recombinant	  inter-­‐subtype	  recombinant	  forms.	  	  In	  addition	  to	  their	  value	  in	  addressing	  the	  
correlates	  of	  protection,	  and	  factors	  influencing	  the	  rate	  of	  progression	  to	  AIDS,	  dual	  infection	  
also	  provides	  a	  unique	  opportunity	  to	  evaluate	  how	  the	  immune	  system	  responds	  to	  multiple,	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highly	  diverse	  HIV	  antigens.	  	  	  However,	  no	  studies	  to	  date	  have	  comprehensively	  evaluated	  the	  
immune	  responses	  in	  HIV	  dual-­‐infected	  individuals.	  
A.	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Fig. 5. Co-infection is necessary for genetic recombination. The generation of viral
recombinants requires co-infection of a single cell with two genetically distinct viral
strains (strain 1; blue virus) (strain2; red virus). (A) Single infection of a cell does not
lead to the generation of viral recombinants. (B) Co-infection of a single cell with two
viral variants does not immediately lead to viral recombination. Genetically distinct
genomes are packaged into viral progeny according to Hardy–Weinberg principles.
50% of virions contain a single copy of each distinct viral genome (heterozygous),
25% contain two identical copies of strain 1 (homozygous), and 25% contain copies of
strain 2 (homozygous). Only the heterozygous virion can form viral recombinant in
subsequent cycles of viral replication. (For interpretation of the references to colour
in  this figure legend, the reader is referred to the web  version of the article.)
increased rates of recombination. However, the mechanism by
which they increase recombination is not related to pausing of
DNA synthesis (Balakrishnan et al., 2001; Kim et al., 1997; Moumen
et al., 2001). In vitro template switching assays using the HIV-1
5!UTR showed that the overall rate of recombination was corre-
lated to DIS facilitated dimerization of the templates through the
palindromic sequence present in the DIS stem loop (Andersen et al.,
2003; Balakrishnan et al., 2001, 2003). Indeed, the placement of the
DIS sequence within pol led to an increase in the overall level of tem-
plate switching in an in vitro assay (Balakrishnan et al., 2001). These
data indicate that template dimerization might play an important
role in promoting recombination by bringing the two  sequences
into close proximity. Si ilar interactions between the TAR loop of
the cDNA inter ediate and the acceptor RNA have been proposed
to facilitate minus strand transfer (Berkhout et al., 2001).
As mentioned previously, template switching between two  co-
packaged genomes can lead to the production of cDNA that is a
recombinant of the two templates. If these templates are identi-
cal then template switching will be genetically neutral and no viral
recombination will be observed. Conversely, if these two genomes
are non-identical, template switching can lead to viral recombi-
nation and the generation of progeny that is genetically distinct
from the parental strains (Fig. 5). In order for template switch-
ing to generate new genetic diversity two key prerequisites must
be fulfilled: firstly, a single cell must be infected with two or
more genetically distinct viruses; secondly, these genetically dis-
tinct viral genomes must be co-expressed and co-packaged into
the same virion. Although HIV-1 and MLV  RTs have similar tem-
plate switching frequencies, the rate of genetic recombination is
nearly an order of magnitude higher in HIV-1 than in MLV  (Onafuwa
et al., 2003). The difference in genetic recombination rates lies in
the fact that MLV  does not co-package RNA genomes randomly,
and instead preferentially co-packages genomes from the same
provirus (Flynn et al., 2004; Zhuang et al., 2006). In contrast, HIV-
1 efficiently co-packages genomic RNA at ratios expected from a
random distribution (Chen et al., 2009). Therefore, when a single
cell contains two  different proviruses, both homozygous virions
(containing two  identical genomes) and heterozygous virions (con-
taining two non-identical genomes) will be produced according to
the Hardy–Weinberg principle (50% heterozygous, 25% homozy-
gous, 25% homozygous). This implies that for HIV-1, co-packaging
does not limit the overall rate of genetic recombination. An excep-
tion to this occurs during co-infection of a single cell with virions
from different subtypes. For example, the genetic recombination
rate between subtype B and subtype C viruses is much lower than
the rate of recombination within either subtype B or subtype C
(Chin et al., 2005). The most important region responsible for this
effect was mapped to the DIS and demonstrated that matching
(complementary) DIS stem–loop sequences are required for effi-
cient heterozygote formation (Chin et al., 2005). It was later shown
that even when the DIS stem–loop sequences from subtype C and
CRF01 A/E are artificially matched, the inter-subtype recombina-
tion rate is still lower than the rate within the same subtype (Chin
et al., 2007). Interestingly, one study identified a long range recom-
bination gradient between HIV-1 subtypes B and C variants caused
by non-complementary DIS sequences (Chin et al., 2008). These
data imply that although the DIS stem–loop is a critical component
of genetic recombination, other regions of the genome may affect
packaging and recombination.
One of the major requirements in all models of recombina-
tion is a region of homology between the nascent donor DNA
and the acceptor RNA onto which DNA synthesis will continue
once template switching takes place. Although recombination can
occur in the absence of any homology, it is extremely inefficient.
Measurements of non-homologous recombination in Rous sar-
coma virus (RSV) estimated the rate to be less than 1% the rate
of homologous recombination and that even this involved regions
of micro-homology (Zhang and Temin, 1993). The role of homology
to recombination has been investigated in detail for the special case
of ‘first strand transfer’ that occurs between the repeat (R) regions
at the ends of the RNA genome. Reduction in the length of the HIV-
1 R region from 97 nt in wild-type to 30 nt had minimal effects
on replication, demonstrating that surprisingly short regions of
homology can still efficiently direct first strand transfer (Berkhout
et al., 1995). For murine leukaemia virus (MLV), reduction of the
repeat region fro  69 nt of homology to 12 nt was tolerated, but
a reduction of the repeat to 6 nt significantly reduced first strand
transfer (Dang and Hu, 2001). Nevertheless, it is important to note
that first strand transfer differs from the template switches that
occur internally within a genome. During first strand transfer, DNA
synthesis is halted at the 5! end of the RNA genome, theoretically
allowing unlimited time for invasion and branch migration to com-
plete transfer. During template switches within the HIV-1 genome,
DNA polymerization is continuous or only temporarily stalled mak-
ing it likely that much larger regions of homology are required for
branch migration to catch up to the primer terminus. Investigation
into an internal template switch caused by an in vitro reverse tran-
scription pause site showed that increasing the length of homology
before a pause site from 19 nt to 52 nt enhanced strand transfer
by threefold (Gao et al., 2007). Another study, this time within
the 5!UTR, showed that invasion occurred 60–80 nt upstream of
the site of transfer (Balakrishnan et al., 2003). Therefore, template
switches occurring within a genome probably occur over a more
extended region than is necessary for first strand transfer; the
amount of homology required during first strand transfer proba-
bly reflects the minimum necessary to efficiently direct transfer of
RT from one te plate to another. Furthermore, the overall level of
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increased rates of recombination. However, the mechanism by
which they increase recombination is not related to pausing of
DNA synthesis (Balakrishnan et al., 2001; Kim et al., 1997; Moumen
et al., 2001). In vitro template switching assays using the HIV-1
5!UTR showed that the overall rate of recombination was corre-
lated to DIS facilitated dimerization of the templates through the
palindromic sequence present in the DIS stem loop (Andersen et al.,
2003; Balakrishnan et al., 2001, 2003). Indeed, the placement of the
DIS sequence within pol led to an increase in the overall level of tem-
plate switching in an in vitro assay (Balakrishnan et al., 2001). These
data indicate that template dimerization might play an important
role in promoting recombination by bringing the two  sequences
into close proximity. Similar interactions between the TAR loop of
the cDNA intermediate and the acceptor RNA have been proposed
to facilitate minus strand transfer (Berkhout et al., 2001).
As mentioned previously, template switching between two  co-
packaged genomes can lead to the production of cDNA that is a
recombinant of the two templates. If these templates are identi-
cal then template switching will be genetically neutral and no viral
recombination will be observed. Conversely, if these two genomes
are non-identical, template switching can lead to viral recombi-
nation and the generation of progeny that is genetically distinct
from the parental strains (Fig. 5). In order for template switch-
ing to generate new genetic diversity two key prerequisites must
be fulfilled: firstly, a single cell must be infected with two or
more genetically distinct viruses; secondly, these genetically dis-
tinct viral genomes must be co-expressed and co-packaged into
the same virion. Although HIV-1 and MLV  RTs have similar tem-
plate switching frequencies, the rate of genetic recombination is
nearly an order of magnitude higher in HIV-1 than in MLV  (Onafuwa
et al., 2003). The difference in genetic recombination rates lies in
the fact that MLV  does not co-package RNA genomes randomly,
and instead preferentially co-packages genomes from the same
provirus (Flynn et al., 2004; Zhuang et al., 2006). In contrast, HIV-
1 efficiently co-packages genomic RNA at ratios expected from a
random distribution (Chen et al., 2009). Therefore, when a single
cell contains two  different proviruses, both homozygous virions
(containing two  identical genomes) and heterozygous virions (con-
taining two non-identical genomes) will be produced according to
the Hardy–Weinberg principle (50% heterozygous, 25% homozy-
gous, 25% homozygous). This implies that for HIV-1, co-packaging
does not limit the overall rate of genetic recombination. An excep-
tion to this occurs during co-infection of a single cell with virions
from different subtypes. For example, the genetic recombination
rate between subtype B and subtype C viruses is much lower than
the rate of recombination within either subtype B or subtype C
(Chin et al., 2005). The most important region responsible for this
effect was mapped to the DIS and demonstrated that matching
(complementary) DIS stem–loop sequences are required for effi-
cient heterozygote formation (Chin et al., 2005). It was later shown
that even when the DIS stem–loop sequences from subtype C and
CRF01 A/E are artificially matched, the inter-subtype recombina-
tion rate is still lower than the rate within the same subtype (Chin
et al., 2007). Interestingly, one study identified a long range recom-
bination gradient between HIV-1 subtypes B and C variants caused
by non-complementary DIS sequences (Chin et al., 2008). These
data imply that although the DIS stem–loop is a critical component
of genetic recombination, other regions of the genome may affect
packaging and recombination.
One of the major requirements in all models of recombina-
tion is a region of homology between the nascent donor DNA
and the acceptor RNA onto which DNA synthesis will continue
once template switching takes place. Although recombination can
occur in the absence of any homology, it is extremely inefficient.
Measurements of non-homologous recombination in Rous sar-
coma virus (RSV) estimated the rate to be less than 1% the rate
of homologous recombination and that even this involved regions
of micro-homology (Zhang and Temin, 1993). The role of homology
to recombination has been investigated in detail for the special case
of ‘first strand transfer’ that occurs between the repeat (R) regions
at the ends of the RNA genome. Reduction in the length of the HIV-
1 R region from 97 nt in wild-type to 30 nt had minimal effects
on replication, demonstrating that surprisingly short regions of
homology can still efficiently direct first strand transfer (Berkhout
et al., 1995). For murine leukaemia virus (MLV), reduction of the
repeat region from 69 nt of homology to 12 nt was tolerated, but
a reduction of the repeat to 6 nt significantly reduced first strand
transfer (Dang and Hu, 2001). Nevertheless, it is important to note
that first strand transfer differs from the template switches that
occur internally within a genome. During first strand transfer, DNA
synthesis is halted at the 5! end of the RNA genome, theoretically
allowing unlimited time for invasion and branch migration to com-
plete transfer. During template switches within the HIV-1 genome,
DNA polymerization is continuous or only temporarily stalled mak-
ing it likely that much larger regions of homology are required for
branch migration to catch up to the primer terminus. Investigation
into an internal template switch caused by an in vitro reverse tran-
scription pause site showed that increasing the length of homology
before a pause site from 19 nt to 52 nt enhanced strand transfer
by threefold (Gao et al., 2007). Another study, this time within
the 5!UTR, showed that invasion occurred 60–80 nt upstream of
the site of transfer (Balakrishnan et al., 2003). Therefore, template
switches occurring within a genome probably occur over a more
extended region than is necessary for first strand transfer; the
amount of homology required during first strand transfer proba-
bly reflects the minimum necessary to efficiently direct transfer of
RT from one template to another. Furthermore, the overall level of
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increased rates of recombination. However, the mechanism by
which they increase recombination is not related to pausing of
DNA synthesis (Balakrishnan et al., 2001; Kim et al., 1997; Moumen
et al., 2001). In vitro template switching assays using the HIV-1
5!UTR showed that the overall rate of recombination was corre-
lated to DIS facilitated dimerization of the templates through the
palindromic sequence present in the DIS stem loop (Andersen et al.,
2003; Balakrishnan et al., 2001, 2003). Indeed, the placement of the
DIS sequence within pol led to an increase in the overall level of tem-
plate switching in an in vitro assay (Balakrishnan et al., 2001). These
data indicate that template dimerization might play an important
role in promoting recombination by bringing the two  sequences
into close proximity. Similar interactions between the TAR loop of
the cDNA intermediate and the acceptor RNA have been proposed
to facilitate minus strand transfer (Berkhout et al., 2001).
As mentioned previously, template switching between two  co-
packaged genomes can lead to the production of cDNA that is a
recombinant of the two templates. If these templates are identi-
cal then template switching will be genetically neutral and no viral
recombination will be observed. Conversely, if these two genomes
are non-identical, template switching can lead to viral recombi-
nation and the generation of progeny that is genetically distinct
from the parental strains (Fig. 5). In order for template switch-
ing to generate new genetic diversity two key prerequisites must
be fulfilled: firstly, a single cell must be infected with two or
more genetically distinct viruses; secondly, these genetically dis-
tinct viral genomes must be co-expressed and co-packaged into
the same virion. Although HIV-1 and MLV  RTs have similar tem-
plate switching frequencies, the rate of genetic recombination is
nearly an order of magnitude higher in HIV-1 than in MLV  (Onafuwa
et al., 2003). The difference in genetic recombination rates lies in
the fact that MLV  does not co-package RNA genomes randomly,
and instead preferentially co-packages genomes from the same
provirus (Flynn et al., 2004; Zhuang et al., 2006). In contrast, HIV-
1 efficiently co-packages genomic RNA at ratios expected from a
random distribution (Chen et al., 2009). Therefore, when a single
cell contains two  different proviruses, both homozygous virions
(containing two  identical genomes) and heterozygous virions (con-
taining two non-identical genomes) will be produced according to
the Hardy–Weinberg principle (50% heterozygous, 25% homozy-
gous, 25% homozygous). This implies that for HIV-1, co-packaging
does not limit the overall rate of genetic recombination. An excep-
tion to this occurs during co-infection of a single cell with virions
from different subtypes. For example, the genetic recombination
rate between subtype B and subtype C viruses is much lower than
the rate of recombination within either subtype B or subtype C
(Chin et al., 2005). The most important region responsible for this
effect was mapped to the DIS and demonstrated that matching
(complementary) DIS stem–loop sequences are required for effi-
cient heterozygote formation (Chin et al., 2005). It was later shown
that even when the DIS stem–loop sequences from subtype C and
CRF01 A/E are artificially matched, the inter-subtype recombina-
tion rate is still lower than the rate within the same subtype (Chin
et al., 2007). Interestingly, one study identified a long range recom-
bination gradient between HIV-1 subtypes B and C variants caused
by non-complementary DIS sequences (Chin et al., 2008). These
data imply that although the DIS stem–loop is a critical component
of genetic recombination, other regions of the genome may affect
packaging and recombination.
One of the major requirements in all models of recombina-
tion is a region of homology between the nascent donor DNA
and the acceptor RNA onto which DNA synthesis will continue
once template switching takes place. Although recombination can
occur in the absence of any homology, it is extremely inefficient.
Measurements of non-homologous recombination in Rous sar-
coma virus (RSV) estimated the rate to be less than 1% the rate
of homologous recombination and that even this involved regions
of micro-homology (Zhang and Temin, 1993). The role of homology
to recombination has been investigated in detail for the special case
of ‘first strand transfer’ that occurs between the repeat (R) regions
at the ends of the RNA genome. Reduction in the length of the HIV-
1 R region from 97 nt in wild-type to 30 nt had minimal effects
on replication, demonstrating that surprisingly short regions of
homology can still efficiently direct first strand transfer (Berkhout
et al., 1995). For murine leukaemia virus (MLV), reduction of the
repeat region from 69 nt of homology to 12 nt was tolerated, but
a reduction of the repeat to 6 nt significantly reduced first strand
transfer (Dang and Hu, 2001). Nevertheless, it is important to note
that first strand transfer differs from the template switches that
occur internally within a genome. During first strand transfer, DNA
synthesis is halted at the 5! end of the RNA genome, theoretically
allowing unlimited time for invasion and branch migration to com-
plete transfer. During template switches within the HIV-1 genome,
DNA polymerization is continuous or only temporarily stalled mak-
ing it likely that much larger regions of homology are required for
branch migration to catch up to the primer terminus. Investigation
into an internal template switch caused by an in vitro reverse tran-
scription pause site showed that increasing the length of homology
before a pause site from 19 nt to 52 nt enhanced strand transfer
by threefold (Gao et al., 2007). Another study, this time within
the 5!UTR, showed that invasion occurred 60–80 nt upstream of
the site of transfer (Balakrishnan et al., 2003). Therefore, template
switches occurring within a genome probably occur over a more
extended region than is necessary for first strand transfer; the
amount of homology required during first strand transfer proba-
bly reflects the minimum necessary to efficiently direct transfer of
RT from one template to another. Furthermore, the overall level of
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increased rates of recombination. However, the mechanism by
which they increase recombination is not related to pausing of
DNA synthesis (Balakrishnan et al., 2001; Kim et al., 1997; Moumen
et al., 2001). In vitro template switching assays using the HIV-1
5!UTR showed that the overall rate of recombination was corre-
lated to DIS facilitated dimerization of the templates through the
palindromic sequence present in the DIS stem loop (Andersen et al.,
2003; Balakrishnan et al., 2001, 2003). Indeed, the placement of the
DIS sequence within pol led to an increase in the overall level of tem-
plate switching in an in vitro assay (Balakrishnan et al., 2001). These
data indicate that template dimerization might play an important
role in promoting recombination by bringing the two  sequences
into close proximity. Similar interactions between the TAR loop of
the cDNA intermediate and the acceptor RNA have been proposed
to facilitate minus strand transfer (Berkhout et al., 2001).
As mentioned previously, template switching between two  co-
packaged genomes can lead to the production of cDNA that is a
recombinant of the two templates. If these templates are identi-
cal then template switching will be genetically neutral and no viral
recombination will be observed. Conversely, if these two genomes
are non-identical, template switching can lead to viral recombi-
nation and the generation of progeny that is genetically distinct
from the parental strains (Fig. 5). In order for template switch-
ing to generate new genetic diversity two key prerequisites must
be fulfilled: firstly, a single cell must be infected with two or
more genetically distinct viruses; secondly, these genetically dis-
tinct viral genomes must be co-expressed and co-packaged into
the same virion. Although HIV-1 and MLV  RTs have similar tem-
plate switching frequencies, the rate of genetic recombination is
nearly an order of magnitude higher in HIV-1 than in MLV  (Onafuwa
et al., 2003). The difference in genetic recombination rates lies in
the fact that MLV  does not co-package RNA genomes randomly,
and instead preferentially co-packages genomes from the same
provirus (Flynn et al., 2004; Zhuang et al., 2006). In contrast, HIV-
1 efficiently co-packages genomic RNA at ratios expected from a
random distribution (Chen et al., 2009). Therefore, when a single
cell contains two  different proviruses, both homozygous virions
(containing two  identical genomes) and heterozygous virions (con-
taining two non-identical genomes) will be produced according to
the Hardy–Weinberg principle (50% heterozygous, 25% homozy-
gous, 25% homozygous). This implies that for HIV-1, co-packaging
does not limit the overall rate of genetic recombination. An excep-
tion to this occurs during co-infection of a single cell with virions
from different subtypes. For example, the genetic recombination
rate between subtype B and subtype C viruses is much lower than
the rate of recombination within either subtype B or subtype C
(Chin et al., 2005). The most important region responsible for this
effect was mapped to the DIS and demonstrated that matching
(complementary) DIS stem–loop sequences are required for effi-
cient heterozygote formation (Chin et al., 2005). It was later shown
that even when the DIS stem–loop sequences from subtype C and
CRF01 A/E are artificially matched, the inter-subtype recombina-
tion rate is still lower than the rate within the same subtype (Chin
et al., 2007). Interestingly, one study identified a long range recom-
bination gradient between HIV-1 subtypes B and C variants caused
by non-complementary DIS sequences (Chin et al., 2008). These
data imply that although the DIS stem–loop is a critical component
of genetic recombination, other regions of the genome may affect
packaging and recombination.
One of the major requirements in all models of recombina-
tion is a region of homology between the nascent donor DNA
and the acceptor RNA onto which DNA synthesis will continue
once template switching takes place. Although recombination can
occur in the absence of any homology, it is extremely inefficient.
Measurements of non-homologous recombination in Rous sar-
coma virus (RSV) estimated the rate to be less than 1% the rate
of homologous recombination and that even this involved regions
of micro-homology (Zhang and Temin, 1993). The role of homology
to recombination has been investigated in detail for the special case
of ‘first strand transfer’ that occurs between the repeat (R) regions
at the ends of the RNA genome. Reduction in the length of the HIV-
1 R region from 97 nt in wild-type to 30 nt had minimal effects
on replication, demonstrating that surprisingly short regions of
homology can still efficiently direct first strand transfer (Berkhout
et al., 1995). For murine leukaemia virus (MLV), reduction of the
repeat region from 69 nt of homology to 12 nt was tolerated, but
a reduction of the repeat to 6 nt significantly reduced first strand
transfer (Dang and Hu, 2001). Nevertheless, it is important to note
that first strand transfer differs from the template switches that
occur internally within a genome. During first strand transfer, DNA
synthesis is halted at the 5! end of the RNA genome, theoretically
allowing unlimited time for invasion and branch migration to com-
plete transfer. During template switches within the HIV-1 genome,
DNA polymerization is continuous or only temporarily stalled mak-
ing it likely that much larger regions of homology are required for
branch migration to catch up to the primer terminus. Investigation
into an internal template switch caused by an in vitro reverse tran-
scription pause site showed that increasing the length of homology
before a pause site from 19 nt to 52 nt enhanced strand transfer
by threefold (Gao et al., 2007). Another study, this time within
the 5!UTR, showed that invasion occurred 60–80 nt upstream of
the site of transfer (Balakrishnan et al., 2003). Therefore, template
switches occurring within a genome probably occur over a more
extended region than is necessary for first strand transfer; the
amount of homology required during first strand transfer proba-
bly reflects the minimum necessary to efficiently direct transfer of
RT from one template to another. Furthermore, the overall level of
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increased rates of recombination. However, the mechanism by
which they increase recombination is not related to pausing of
DNA synthesis (Balakrishnan et al., 2001; Kim et al., 1997; Moumen
et al., 2001). In vitro template switching assays using the HIV-1
5!UTR showed that the overall rate of recombination was corre-
lated to DIS facilitated dimerization of the templates through the
palindromic sequence present in the DIS stem loop (Andersen et al.,
2003; Balakrishnan et al., 2001, 2003). Indeed, the placement of the
DIS sequence within pol led to an increase in the overall level of tem-
plate switching in an in vitro assay (Balakrishnan et al., 2001). These
data indicate that template dimerization might play an important
role in promoting recombination by bringing the two  sequences
into close proximity. Similar interactions between the TAR loop of
the cDNA intermediate and the acceptor RNA have been proposed
to facilitate minus strand transfer (Berkhout et al., 2001).
As mentioned previously, template switching between two  co-
packaged genomes can lead to the production of cDNA that is a
recombinant of the two templates. If these templates are identi-
cal then template switching will be genetically neutral and no viral
recombination will be observed. Conversely, if these two genomes
are non-identical, template switching can lead to viral recombi-
nation and the generation of progeny that is genetically distinct
from the parental strains (Fig. 5). In order for template switch-
ing to generate new genetic diversity two key prerequisites must
be fulfilled: firstly, a single cell must be infected with two or
more genetically distinct viruses; secondly, these genetically dis-
tinct viral genomes must be co-expressed and co-packaged into
the same virion. Although HIV-1 and MLV  RTs have similar tem-
plate switching frequencies, the rate of genetic recombination is
nearly an order of magnitude higher in HIV-1 than in MLV  (Onafuwa
et al., 2003). The difference in genetic recombination rates lies in
the fact that MLV  does not co-package RNA genomes randomly,
and instead preferentially co-packages genomes from the same
provirus (Flynn et al., 2004; Zhuang et al., 2006). In contrast, HIV-
1 efficiently co-packages genomic RNA at ratios expected from a
random distribution (Chen et al., 2009). Therefore, when a single
cell contains two  different proviruses, both homozygous virions
(containing two  identical genomes) and heterozygous virions (con-
taining two non-identical genomes) will be produced according to
the Hardy–Weinberg principle (50% heterozygous, 25% homozy-
gous, 25% homozygous). This implies that for HIV-1, co-packaging
does not limit the overall rate of genetic recombination. An excep-
tion to this occurs during co-infection of a single cell with virions
from different subtypes. For example, the genetic recombination
rate between subtype B and subtype C viruses is much lower than
the rate of recombination within either subtype B or subtype C
(Chin et al., 2005). The most important region responsible for this
effect was mapped to the DIS and demonstrated that matching
(complementary) DIS stem–loop sequences are required for effi-
cient heterozygote formation (Chin et al., 2005). It was later shown
that even when the DIS stem–loop sequences from subtype C and
CRF01 A/E are artificially matched, the inter-subtype recombina-
tion rate is still lower than the rate within the same subtype (Chin
et al., 2007). Interestingly, one study identified a long range recom-
bination gradient between HIV-1 subtypes B and C variants caused
by non-complementary DIS sequences (Chin et al., 2008). These
data imply that although the DIS stem–loop is a critical component
of genetic recombination, other regions of the genome may affect
packaging and recombination.
One of the major requirements in all models of recombina-
tion is a region of homology between the nascent donor DNA
and the acceptor RNA onto which DNA synthesis will continue
once template switching takes place. Although recombination can
occur in the absence of any homology, it is extremely inefficient.
Measurements of non-homologous recombination in Rous sar-
coma virus (RSV) estimated the rate to be less than 1% the rate
of homologous recombination and that even this involved regions
of micro-homology (Zhang and Temin, 1993). The role of homology
to recombination has been investigated in detail for the special case
of ‘first strand transfer’ that occurs between the repeat (R) regions
at the ends of the RNA genome. Reduction in the length of the HIV-
1 R region from 97 nt in wild-type to 30 nt had minimal effects
on replication, demonstrating that surprisingly short regions of
homology can still efficiently direct first strand transfer (Berkhout
et al., 1995). For murine leukaemia virus (MLV), reduction of the
repeat region from 69 nt of homology to 12 nt was tolerated, but
a reduction of the repeat to 6 nt significantly reduced first strand
transfer (Dang and Hu, 2001). Nevertheless, it is important to note
that first strand transfer differs from the template switches that
occur internally within a genome. During first strand transfer, DNA
synthesis is halted at the 5! end of the RNA genome, theoretically
allowing unlimited time for invasion and branch migration to com-
plete transfer. During template switches within the HIV-1 genome,
DNA polymerization is continuous or only temporarily stalled mak-
ing it likely that much larger regions of homology are required for
branch migration to catch up to the primer terminus. Investigation
into an internal template switch caused by an in vitro reverse tran-
scription pause site showed that increasing the length of homology
before a pause site from 19 nt to 52 nt enhanced strand transfer
by threefold (Gao et al., 2007). Another study, this time within
the 5!UTR, showed that invasion occurred 60–80 nt upstream of
the site of transfer (Balakrishnan et al., 2003). Therefore, template
switches occurring within a genome probably occur over a more
extended region than is necessary for first strand transfer; the
amount of homology required during first strand transfer proba-
bly reflects the minimum necessary to efficiently direct transfer of
RT from one template to another. Furthermore, the overall level of
















Fig. 5. Co-infection is necessary for genetic recombination. The generation of viral
recombinants requires co-infection of a single cell with two genetically distinct viral
strains (strain 1; blue virus) (strain2; red virus). (A) Single infection of a cell does not
lead to the generation of viral recombinants. (B) Co-infection of a single cell with two
viral variants does not immediately lead to viral recombination. Genetically distinct
genomes are packaged into viral progeny according to Hardy–Weinberg principles.
50% of virions contain a single copy of each distinct viral genome (heterozygous),
25% contain two identical copies of strain 1 (homozygous), and 25% contain copies of
strain 2 (homozygous). Only the heterozygous virion can form viral recombinant in
subsequent cycles of viral replication. (For interpretation of the references to colour
in  this figure legend, the reader is referred to the web  version of the article.)
increased rates of recombination. However, the mechanism by
which they increase recombination is not related to pausing of
DNA synthesis (Balakrishnan et al., 2001; Kim et al., 1997; Moumen
et al., 2001). In vitro template switching assays using the HIV-1
5!UTR showed that the overall rate of recombination was corre-
lated to DIS facilitated dimerization of the templates through the
palindromic sequence present in the DIS stem loop (Andersen et al.,
2003; Balakrishnan et al., 2001, 2003). Indeed, the placement of the
DIS sequence within pol led to an increase in the overall level of tem-
plate switching in an in vitro assay (Balakrishnan et al., 2001). These
data indicate that template dimerization might play an important
role in promoting recombination by bringing the two  sequences
into close proximity. Similar interactions between the TAR loop of
the cDNA intermediate and the acceptor RNA have been proposed
to facilitate minus strand transfer (Berkhout et al., 2001).
As mentioned previously, template switching between two  co-
packaged genomes can lead to the production of cDNA that is a
recombinant of the two templates. If these templates are identi-
cal then template switching will be genetically neutral and no viral
recombination will be observed. Conversely, if these two genomes
are non-identical, template switching can lead to viral recombi-
nation and the generation of progeny that is genetically distinct
from the parental strains (Fig. 5). In order for template switch-
ing to generate new genetic diversity two key prerequisites must
be fulfilled: firstly, a single cell must be infected with two or
more genetically distinct viruses; secondly, these genetically dis-
tinct viral genomes must be co-expressed and co-packaged into
the same virion. Although HIV-1 and MLV  RTs have similar tem-
plate switching frequencies, the rate of genetic recombination is
nearly an order of magnitude higher in HIV-1 than in MLV  (Onafuwa
et al., 2003). The difference in genetic recombination rates lies in
the fact that MLV  does not co-package RNA genomes randomly,
and instead preferentially co-packages genomes from the same
provirus (Flynn et al., 2004; Zhuang et al., 2006). In contrast, HIV-
1 efficiently co-packages genomic RNA at ratios expected from a
random distribution (Chen et al., 2009). Therefore, when a single
cell contains two  different proviruses, both homozygous virions
(containing two  identical genomes) and heterozygous virions (con-
taining two non-identical genomes) will be produced according to
the Hardy–Weinberg principle (50% heterozygous, 25% homozy-
gous, 25% homozygous). This implies that for HIV-1, co-packaging
does not limit the overall rate of genetic recombination. An excep-
tion to this occurs during co-infection of a single cell with virions
from different subtypes. For example, the genetic recombination
rate between subtype B and subtype C viruses is much lower than
the rate of recombination within either subtype B or subtype C
(Chin et al., 2005). The most important region responsible for this
effect was mapped to the DIS and demonstrated that matching
(complementary) DIS stem–loop sequences are required for effi-
cient heterozygote formation (Chin et al., 2005). It was later shown
that even when the DIS stem–loop sequences from subtype C and
CRF01 A/E are artificially matched, the inter-subtype recombina-
tion rate is still lower than the rate within the same subtype (Chin
et al., 2007). Interestingly, one study identified a long range recom-
bination gradient between HIV-1 subtypes B and C variants caused
by non-complementary DIS sequences (Chin et al., 2008). These
data imply that although the DIS stem–loop is a critical component
of genetic recombination, other regions of the genome may affect
packaging and recombination.
One of the major requirements in all models of recombina-
tion is a region of homology between the nascent donor DNA
and the acceptor RNA onto which DNA synthesis will continue
once template switching takes place. Although recombination can
occur in the absence of any homology, it is extremely inefficient.
Measurements of non-homologous recombination in Rous sar-
coma virus (RSV) estimated the rate to be less than 1% the rate
of homologous recombination and that even this involved regions
of micro-homology (Zhang and Temin, 1993). The role of homology
to recombination has been investigated in detail for the special case
of ‘first strand transfer’ that occurs between the repeat (R) regions
at the ends of the RNA genome. Reduction in the length of the HIV-
1 R region from 97 nt in wild-type to 30 nt had minimal effects
on replication, demonstrating that surprisingly short regions of
homology can still efficiently direct first strand transfer (Berkhout
et al., 1995). For murine leukaemia virus (MLV), reduction of the
repeat region from 69 nt of homology to 12 nt was tolerated, but
a reduction of the repeat to 6 nt significantly reduced first strand
transfer (Dang and Hu, 2001). Nevertheless, it is important to note
that first strand transfer differs from the template switches that
occur internally within a genome. During first strand transfer, DNA
synthesis is halted at the 5! end of the RNA genome, theoretically
allowing unlimited time for invasion and branch migration to com-
plete transfer. During template switches within the HIV-1 genome,
DNA polymerization is continuous or only temporarily stalled mak-
ing it likely that much larger regions of homology are required for
branch migration to catch up to the primer terminus. Investigation
into an internal template switch caused by an in vitro reverse tran-
scription pause site showed that increasing the length of homology
before a pause site from 19 nt to 52 nt enhanced strand transfer
by threefold (Gao et al., 2007). Another study, this time within
the 5!UTR, showed that invasion occurred 60–80 nt upstream of
the site of transfer (Balakrishnan et al., 2003). Therefore, template
switches occurring within a genome probably occur over a more
extended region than is necessary for first strand transfer; the
amount of homology required during first strand transfer proba-
bly reflects the minimum necessary to efficiently direct transfer of
RT from one template to another. Furthermore, the overall level of
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Fig. 3. Copy choice model of template switching. Copy choice template switching
occurs during minus strand synthesis when concomitant with DNA synthesis the
RNase-H activity of RT degrades the RNA component of the RNA/DNA hybrid. This
exposes single stranded regions of the nascent DNA that can base pair with the
complementary RNA genome. A process of branch migration followed by strand
transfer completes the template switch.
particle. This led to the proposal that strand transfer is driven by
breaks in the RNA (Coffin, 1979). These forced template switches
are analogous to the obligatory first strand and second strand tem-
plate switches that occur when DNA synthesis is stalled at the end
of the genome. Whilst it is not clear whether the genome is bro-
ken within the virion, this seems a likely hypothesis due to the
liable nature of RNA. Attempts have been made to test this model
directly by measuring rates of recombination after gamma  irradi-
ation of SNV with inconclusive results as treatment did not appear
to cause breaks in the RNA (Hu and Temin, 1992). Although this
model is appealing as a genetic repair mechanism to enable the
virus to complete reverse transcription in the presence of damaged
genomic RNA, it is now well established that breaks in the RNA are
not necessary for template switching.
Template switching in the absence of breaks in the RNA genome
is proposed to occur via a mechanism of ‘copy choice’. In this
model, concomitant with minus strand DNA synthesis, the RNase-
H activity of RT cleaves the RNA portion of the RNA/DNA hybrid.
This cleavage exposes single stranded regions of the donor DNA
that then base pair to the complementary region of the accep-
tor genomic RNA template (Temin, 1993). Translocation of DNA
synthesis occurs via a process of branch migration followed by
template switching.
This copy choice model has been extended and termed ‘dynamic
copy choice’. The ‘dynamic copy choice’ model proposes that
there is a steady state between the rate of DNA polymerization
and genomic RNA degradation by the polymerase and RNase-H
activities of RT, respectively. This steady state determines the level
of template switching (Svarovskaia et al., 2000). The model predicts
that exposure of single stranded DNA increases when the RNase-H
activity of RT is enhanced compared to the DNA polymerase activ-
ity. This leads to an increase in the rate of template switching by
facilitating base pairing between the donor and acceptor genomic
template. Conversely, a low RNase-H to DNA polymerase activity
reduces availability of single stranded regions of DNA for binding
to the complementary RNA genome, leading to a decrease in the
rate of template switching. The ‘dynamic copy choice’ model can
be used to explain the experimental observations that led to the
development of the ‘forced copy choice’ and ‘copy choice’ mod-
els. The predictions of this model have been rigorously tested,
and are generally accepted to be the most complete explanation
of minus strand template switching (Delviks-Frankenberry et al.,
2007; Nikolenko et al., 2004; Operario et al., 2006; Svarovskaia et al.,
2000).
4.2. Genetic consequences of recombination
In contrast to the slow and steady change caused by mutation,
recombination is a much more powerful evolutionary force (Fig. 4).
First, recombination facilitates the repair of viral genomes. This
can be physical repair at genome breaks (Fig. 4A) via a mecha-
nism of forced copy choice or genetic repair of genomes that have
accumulated deleterious mutations (Fig. 4B). In the absence of
recombination, organisms tend to accumulate deleterious muta-
tions at each replication cycle via a process termed Muller’s ratchet
(Muller, 1964). The central tenants of Muller’s ratchet are that
(1) new mutations are more likely than reversions and (2) new
mutations are more likely to be deleterious than beneficial. Conse-
quently, with each replication cycle, the accumulation of mutations
decreases the replication capacity of the organism until extinction
occurs. Recombination can bypass Muller’s ratchet by recreating
mutation free individuals from a population of mutants (Kim et al.,
2005).
Second, recombination can both create and maintain genetic
diversity in a population (Fig. 4C and D). As the ability of a popu-
lation to respond to natural selection is proportional to the genetic
variance in that population, recombination can speed adaptation
in the face of rapid evolutionary change (Fisher, 1958). During
infection HIV is exposed to huge selective pressures by the host
immune system. In order to survive, the virus must continually
adapt to evade a rapidly changing immune response that contin-
ually generates new selective pressures through the generation
of novel antibody and cytotoxic T-cell responses. This evolution-
ary arms race between host and parasite, is known as the ‘Red
Queen hypothesis’ after the Red Queen in ‘Through the Looking
Glass’ who  stated that ‘it takes all the running you can do to
stay in the same place’ (Van Valen, 1973). This need for continual
evolution through natural selection for adaptation and counter-
adaptation is thought to be the driving force behind the evolution
of recombination. Recombination creates new diversity by shuffling
pre-existing mutations within a population, generating complex
combinations of mutations that would otherwise have to arise
sequentially in an asexual organism (Fig. 4C). Recombination also
maintains genetic diversity by breaking linkages between muta-
tions (Fig. 4D). For example, if a viral genome containing a drug
resistance mutation is targeted by a new CTL response, in the
absence of recombination the CTL response will clear the bene-
ficial mutation as it is physically linked to the genetic sequence
under immune selection. Recombination ensures that the drug
resistance mutation can be maintained within the population as
long as it can recombine onto a genome containing an appropriate
CTL escape mutation. Thus recombination ensures that differ-
ent areas of the viral genome can evolve independently of one
another.
RT	  
Figure	  1.3	  |	  Schematic	  of	  HIV	  recombination.	  	  A.	  As	  HIV	  is	  diploid,	  co-­‐infection	  of	  cells	  with	  two	  distinct	  
virions	  can	  produce	  a	  proportion	  of	  heterozygous	  viruses	  (50%,	  assuming	  equal	  numbers	  and	  random	  
pairing	  of	  each	  genome).	  	  Subsequent	  infection	  of	  cells	  by	  heterozygous	  virions	  can	  produce	  recombinant	  
viruses.	  	  B.	  Copy-­‐choice	  model	  of	  HIV	  recombination.	  	  During	  reverse	  transcription,	  RNAse	  H	  activity	  of	  
Reverse	  Transcriptase	  (RT)	  degrades	  the	  RNA	  strand	  in	  a	  DNA-­‐RNA	  hybrid.	  	  The	  resulting	  ssRNA	  can	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Aims:	  
The	  use	  of	  polyvalent	  immunogens	  is	  a	  common	  strategy	  used	  in	  an	  attempt	  to	  enhance	  the	  
breadth	  of	  vaccine-­‐elicited	  immune	  responses	  and	  HIV	  dual	  infection	  provides	  a	  unique	  in	  vivo	  
model	   to	   characterize	  how	   the	   immune	  system	  responds	   to	  multiple	  HIV	   strains.	   	   	  This	   study	  
takes	   advantage	   of	   multiply	   HIV-­‐infected	   participants	   to	   characterise	   the	   properties	   of	   the	  
infecting	   viruses;	   the	   clinical	   consequences	   of	   dual	   infection;	   and	   evaluate	   the	   impact	   that	  
exposure	   to	   two	   or	   more	   divergent	   HIV	   variants	   will	   have	   on	   the	   neutralizing	   antibody	  
response.	   	  Taken	  together,	   these	  data	  will	  potentially	  shed	   light	  on	  the	  potential	  of	  polyvalent	  
and	  prime-­‐boost	  based	  vaccinations	  to	   influence	  the	  specificity	  of	  vaccine-­‐elicited	  neutralizing	  
antibody	  responses.	  	  	  
Objectives:	  
I. Identify	  cases	  of	  multivariant	  or	  dual	  HIV	  infection	  
a. Identify	  and	  confirm	  cases	  of	  multivariant	  or	  dual	  HIV	  infection	  in	  the	  	  
CAPRISA	  002	  cohort	  
b. Characterise	  the	  infecting	  variants,	  and	  the	  relative	  timing	  of	  transmission	  
events	  
c. Estimate	  the	  incidence	  of	  superinfection	  based	  on	  available	  follow	  up	  and	  
compare	  to	  the	  incidence	  of	  primary	  infection	  in	  the	  cohort.	  	  	  
d. Model	  the	  statistical	  power	  to	  detect	  correlates	  of	  protection	  against	  
superinfection	  
e. Identify	  whether	  higher	  CD4+	  T	  cell	  counts,	  or	  sexually	  transmitted	  infections	  
predisposed	  participants	  to	  infection	  with	  multiple	  viruses	  
II. Characterise	  the	  impact	  of	  dual	  infection	  on	  viral	  diversification,	  and	  disease	  
progression	  
III. Determine	  whether	  HIV	  superinfection	  promoted	  cross-­‐neutralizing	  antibody	  responses	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CHAPTER	  2: Identification	  and	  genetic	  characterization	  of	  HIV-­‐1	  
dual	  infection	  
2.1	  Introduction:	  
A	  significant	  challenge	  facing	  the	  development	  of	  an	  HIV	  vaccine	  is	  that	  correlates	  of	  
protection	  against	  HIV	  are	  not	  clear.	  	  Studies	  in	  non-­‐human	  primates	  provide	  strong	  evidence	  
that	  high	  titers	  of	  antibodies	  capable	  of	  neutralizing	  the	  challenge	  virus	  can	  provide	  protection.	  	  
However,	  eliciting	  neutralizing	  antibodies	  against	  HIV	  by	  vaccination	  has	  proven	  to	  be	  a	  
daunting	  challenge.	  	  Further,	  it	  is	  not	  clear	  whether	  results	  from	  these	  animal	  models	  will	  
translate	  into	  humans.	  	  Results	  from	  the	  analysis	  of	  the	  RV144	  vaccine	  trial	  have	  also	  suggested	  
that	  non-­‐neutralizing	  antibodies	  against	  V2	  may	  have	  provided	  partial	  protection	  (8).	  	  However,	  
large	  vaccine	  efficacy	  trials	  are	  time	  consuming	  and	  expensive,	  and	  models	  that	  increase	  our	  
understanding	  of	  correlates	  of	  protection	  can	  potentially	  accelerate	  vaccine	  development.	  	  By	  
definition,	  in	  HIV	  superinfection	  the	  secondary	  transmission	  occurs	  in	  the	  face	  of	  an	  ongoing	  
anti-­‐HIV	  immune	  response,	  and	  therefore	  provides	  a	  unique	  opportunity	  to	  address	  whether	  
the	  immune	  responses	  typically	  elicited	  during	  natural	  HIV	  infection	  provide	  any	  protection	  
against	  subsequent	  HIV	  infection.	  	  
Several	  studies	  have	  compared	  immunological	  markers	  (such	  as	  autologous	  and	  
heterologous	  neutralizing	  antibodies,	  and	  non-­‐neutralizing	  V1V2	  antibodies)	  in	  superinfected	  
participants	  to	  those	  who	  were	  presumably	  exposed,	  but	  not	  superinfected.	  	  In	  one	  study,	  three	  
men	  who	  had	  sex	  with	  men	  (MSM),	  who	  subsequently	  became	  superinfected,	  were	  unable	  to	  
neutralize	  two	  heterologous	  viruses	  (tier	  1,	  easy	  to	  neutralize),	  compared	  to	  detectable	  
neutralization	  of	  the	  same	  viruses	  in	  9/11	  (81.82%)	  matched,	  non-­‐superinfected	  controls	  (132).	  	  
Superinfected	  participants	  also	  displayed	  weaker	  autologous	  nAb	  responses	  compared	  to	  non-­‐
superinfected	  controls	  (although	  this	  was	  not	  statistically	  significant).	  	  Similarly,	  in	  a	  
heterosexual	  cohort	  from	  Zambia	  (133),	  three	  superinfected	  participants	  had	  significantly	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lower,	  more	  delayed	  neutralizing	  antibody	  titers	  to	  their	  primary	  virus	  than	  ten	  non-­‐
superinfected	  controls	  did.	  	  Together,	  these	  data	  suggest	  that	  stronger	  humoral	  responses	  to	  
primary	  infection	  may	  be	  correlated	  with	  a	  reduced	  susceptibility	  to	  superinfection.	  	  In	  contrast,	  
in	  a	  cohort	  of	  female	  sex	  workers	  from	  Mombasa,	  Kenya,	  no	  difference	  was	  evident	  in	  the	  
breadth	  or	  potency	  of	  neutralizing	  antibody	  responses	  at	  the	  time	  of	  superinfection	  in	  six	  
superinfected	  women	  compared	  to	  18	  matched,	  monoinfected	  controls	  (134).	  	  	  
In	  an	  attempt	  to	  establish	  whether	  the	  natural	  immune	  response	  to	  HIV	  affords	  any	  
protection	  from	  superinfection,	  without	  the	  need	  to	  explicitly	  test	  a	  specific	  correlate,	  several	  
studies	  have	  compared	  the	  experimentally	  determined	  incidence	  of	  superinfection	  to	  the	  
incidence	  of	  primary	  infection	  in	  the	  same	  or	  similar	  cohorts.	  	  In	  a	  high-­‐risk	  cohort	  of	  Kenyan	  
women,	  superinfection	  was	  detected	  at	  a	  rate	  approximately	  half	  that	  of	  initial	  infection:	  ~4%	  
per	  person	  year	  (/py),	  (123,	  135)	  compared	  to	  a	  primary	  infection	  incidence	  of	  8%/py	  (136).	  	  In	  
a	  cohort	  of	  Californian	  MSM	  (124),	  the	  incidence	  of	  superinfection	  was	  estimated	  at	  5%/py;	  
comparable	  to	  the	  primary	  incidence	  in	  a	  comparable	  cohort	  (5%/py;(137,	  138)).	  	  In	  a	  
heterosexual	  cohort	  of	  149	  individuals	  from	  the	  Rakai	  district	  in	  Uganda	  screened	  with	  deep	  
sequencing,	  the	  incidence	  of	  superinfection	  (1.44%/py)	  was	  comparable	  to	  the	  primary	  HIV	  
incidence	  (1.15%/py)	  in	  the	  general	  population	  of	  Rakai	  (125).	  	  In	  contrast,	  two	  studies	  were	  
not	  able	  to	  find	  any	  evidence	  of	  superinfection	  despite	  extensive	  follow	  up	  (127,	  128).	  More	  
recently,	  screening	  of	  high-­‐risk	  women	  from	  Mombasa,	  Kenya	  with	  next	  generation	  sequencing	  
(NGS)	  estimated	  the	  incidence	  of	  superinfection	  at	  less	  than	  half	  the	  primary	  incidence	  in	  the	  
same	  cohort	  (126).	  	  This	  apparent	  contrast	  may	  be	  due,	  in	  part,	  to	  differences	  in	  study	  cohorts,	  
methodology	  used,	  and	  the	  difficulties	  in	  identifying	  cases	  of	  superinfection.	  	  Superinfecting	  
viral	  populations	  can	  potentially	  comprise	  the	  minor	  population	  and	  consequently	  can	  evade	  
detection	  if	  the	  depth	  of	  sequencing	  is	  inadequate.	  	  Furthermore,	  recombination	  between	  
variants	  can	  obscure	  the	  identification	  of	  superinfection	  if	  only	  small	  regions	  of	  the	  genome	  are	  
sequenced,	  although	  how	  soon	  after	  superinfection	  recombination	  occurs	  is	  unclear.	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Alternatively,	  immune	  responses	  elicited	  by	  primary	  HIV	  infection	  may	  afford	  protection	  
against	  superinfection,	  albeit	  incomplete.	  
The	  utility	  of	  superinfection	  as	  a	  challenge	  model	  also	  depends	  on	  superinfection	  
resembling	  primary	  transmission,	  though	  this	  has	  not	  been	  established.	  	  	  Primary	  HIV	  
transmission	  results	  in	  a	  severe	  genetic	  bottleneck	  associated	  with	  the	  transmission	  of	  HIV.	  	  It	  is	  
estimated	  that	  in	  the	  sexual	  transmission	  of	  HIV,	  ~80%	  of	  infections	  can	  be	  traced	  to	  a	  single	  
founder	  variant	  (10,	  11).	  	  These	  transmitted/founder	  (T/F)	  viruses	  are	  consistently	  CCR5-­‐tropic	  
(9,	  10),	  and	  have	  previously	  been	  shown	  to	  have	  shorter,	  less	  glycosylated	  Envelopes	  compared	  
to	  viruses	  from	  chronic	  infection	  (139,	  140).	  	  However,	  the	  genetic	  bottleneck	  associated	  with	  
superinfection,	  and	  whether	  the	  superinfecting	  viruses	  have	  phenotypes	  typical	  of	  primary	  
viruses	  has	  not	  been	  addressed.	  
In	  this	  chapter,	  we	  characterize	  the	  multiplicity	  of	  infection	  in	  women	  from	  the	  CAPRISA002	  
cohort.	  	  We	  confirm	  three	  cases	  of	  intra-­‐subtype	  superinfection,	  and	  isolate	  the	  envelope	  genes	  
of	  the	  superinfecting	  T/F.	  	  Through	  the	  characterization	  of	  the	  properties	  of	  viruses	  responsible	  
for	  superinfection,	  this	  chapter	  aims	  to	  contribute	  to	  our	  understanding	  of	  dual	  infection,	  and	  
the	  utility	  of	  this	  model	  for	  understanding	  correlates	  of	  protection.	  	  Furthermore,	  it	  touches	  on	  
the	  kinetics	  and	  extent	  of	  recombination	  following	  dual	  infection,	  and	  its	  potential	  to	  mislead	  









Samples	  were	  provided	  from	  participants	  from	  the	  CAPRISA	  002	  Acute	  Infection	  Study	  
established	  in	  2004	  (141).	  	  High	  risk,	  HIV	  negative	  women	  from	  Durban,	  KwaZulu-­‐Natal,	  South	  
Africa	  were	  monitored	  monthly	  and	  enrolled	  upon	  detection	  of	  HIV	  infection.	  	  The	  
demographics,	  self-­‐reported	  sexual	  history	  and	  risk	  behavior	  are	  described	  elsewhere	  (141).	  	  
HIV	  serostatus	  was	  determined	  using	  two	  rapid	  HIV-­‐1	  antibody	  tests	  (Determine,	  Abbott	  89	  
Laboratories;	  Tokyo	  and	  Capillus,	  Trinity	  Biotech,	  Jamestown,	  NY).	  	  All	  antibody	  negative	  
samples	  were	  tested	  for	  HIV-­‐1	  RNA	  by	  pooled	  PCR	  (Ampliscreen	  v1.5,	  Roche	  Diagnostics,	  
Rotkreuz,	  Switzerland)	  and	  if	  positive	  were	  confirmed	  by	  an	  HIV	  enzyme	  immunoassay	  (EIA,	  
BEP2000,	  Dade	  Behring,	  Marburg,	  Germany)	  and	  quantitating	  viral	  RNA	  (Cobas	  Amplicor	  HIV-­‐1	  
monitor	  test	  version	  1.5;	  Roche	  Diagnostics,	  Rotkreuz,	  Switzerland).	  	  Women	  were	  also	  enrolled	  
from	  other	  seroincidence	  cohorts	  from	  Vulindlela,	  Kwa-­‐Zulu-­‐Natal,	  if	  they	  had	  a	  reactive	  
antibody	  test	  within	  five	  months	  of	  a	  negative	  result,	  or	  if	  HIV-­‐1	  RNA	  was	  detectable	  by	  PCR	  in	  
the	  absence	  of	  detectable	  HIV	  antibodies.	  	  The	  timing	  of	  infection	  was	  estimated	  as	  either	  the	  
midpoint	  between	  the	  last	  antibody	  negative	  and	  first	  antibody	  positive	  visits,	  or	  14	  days	  prior	  
to	  an	  RNA-­‐positive,	  antibody	  negative	  sample.	  	  	  
Enrolled	  HIV	  positive	  participants	  were	  followed	  longitudinally,	  and	  plasma	  samples	  were	  
taken	  weekly	  for	  three	  weeks,	  fortnightly	  until	  approximately	  three	  months	  post	  infection,	  
monthly	  until	  approximately	  1	  year	  post	  infection,	  and	  quarterly	  thereafter.	  	  Plasma	  was	  stored	  
in	  either	  EDTA,	  or	  ACD	  (acid	  citrate	  dextrose)	  to	  prevent	  coagulation,	  and	  stored	  at	  -­‐80°C	  until	  
use.	  Participants	  were	  initiated	  on	  ARV	  therapy	  once	  CD4	  T	  cell	  counts	  fell	  below	  200	  cells/µl,	  
and	  later	  350	  cells/µl,	  consistent	  with	  the	  prevailing	  South	  African	  ARV	  treatment	  guidelines.	  	  
Ethical	  approval	  for	  this	  study	  was	  received	  from	  the	  ethics	  committees	  of	  the	  University	  of	  
Cape	  Town,	  the	  University	  of	  KwaZulu-­‐Natal,	  and	  the	  University	  of	  the	  Witwatersrand,	  and	  all	  
participants	  provided	  written,	  informed	  consent.	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2.2.2	   PCR	  and	  Sequencing	  of	  envelope	  
Plasma	  viral	  RNA	  was	  extracted	  from	  200	  µl	  or	  400	  µl	  of	  plasma	  using	  either	  the	  Roche	  
MagNApure	  (Roche	  Applied	  Science,	  Mannheim,	  Germany)	  or	  QIAgen	  viral	  RNA	  extraction	  kits	  
(Qiagen,	  Valencia,	  CA,	  Valencia,	  CA).	  	  RNA	  was	  reversed-­‐transcribed	  to	  cDNA	  on	  the	  same	  day	  as	  
the	  RNA	  extraction,	  using	  Superscript	  III	  (Invitrogen,	  Life	  Technologies,	  Carlsbad,	  CA).	  	  Briefly,	  
50ul	  of	  extracted	  RNA	  was	  reverse	  transcribed	  in	  1X	  Superscript	  RT	  buffer,	  with	  0.2	  mM	  of	  each	  
dNTP,	  1	  μM	  of	  oligo-­‐dT(20)	  (Integrated	  DNA	  Technologies,	  Germany),	  5	  mM	  Dithithreitol	  
(Invitrogen,	  Life	  Technologies,	  Carlsbad,	  CA),	  80	  units	  of	  an	  RNAse	  inhibitor	  (RNAseOUT,	  
Invitrogen,	  Life	  Technologies,	  Carlsbad,	  CA),	  	  and	  400	  units	  of	  reverse	  transcriptase	  
(SuperScript	  III,	  Invitrogen,	  Life	  Technologies,	  Carlsbad,	  CA).	  	  The	  mixture	  of	  RNA,	  
deoxynucleotide	  triphosphates	  (dNTPs)	  and	  oligo-­‐dT	  was	  first	  heated	  to	  65°C	  for	  5	  minutes	  to	  
denature	  RNA	  secondary	  structures,	  then	  cooled	  to	  4°C.	  	  	  The	  full	  reaction	  was	  then	  incubated	  at	  
45°C	  for	  120	  minutes	  for	  reverse	  transcription,	  and	  then	  heat	  inactivated	  at	  75°C	  for	  15	  
minutes.	  	  Reactions	  were	  then	  treated	  with	  2	  units	  of	  RNAse	  H	  (Invitrogen,	  Life	  Technologies,	  
Carlsbad,	  CA),	  and	  digested	  at	  37°C	  for	  20	  minutes	  to	  degrade	  RNA	  annealed	  to	  newly	  
synthesized	  cDNA.	  	  The	  synthesized	  cDNA	  was	  either	  used	  immediately	  or	  stored	  at	  -­‐60°C	  until	  
use.	  
Envelope	  cassettes	  were	  amplified	  from	  the	  full-­‐length	  cDNA	  in	  a	  nested	  PCR	  by	  Single	  
Genome	  Amplification	  (SGA)	  using	  0.025	  units	  of	  Platinum	  Taq	  High	  Fidelity	  (Invitrogen,	  Life	  
Technologies,	  Carlsbad,	  CA)	  per	  20	  μl	  reaction,	  as	  previously	  described	  (10,	  11).	  	  Reactions	  were	  
performed	  in	  1X	  High	  Fidelity	  Platinum	  PCR	  buffer,	  with	  2	  mM	  MgSO4,	  0.2	  mM	  of	  each	  dNTP,	  
and	  0.2	  μM	  of	  each	  primer.	  	  cDNA	  was	  serially	  diluted	  until	  <30%	  of	  the	  reactions	  were	  PCR	  
positive,	  such	  that	  >80%	  	  of	  the	  amplicons	  likely	  would	  have	  been	  amplified	  from	  a	  single	  
template	  (according	  to	  a	  Poisson	  distribution)	  (9).	  	  This	  approach	  prevents	  template	  
resampling,	  and	  PCR-­‐induced	  recombination	  that	  can	  occur	  if	  multiple	  templates	  are	  amplified	  
in	  a	  reaction	  (9).	  	  Primers	  used	  in	  the	  outer	  reaction	  were	  Vif1	  (5’-­‐	  
GGGTTTATTACAGGGACAGCAGAG	  -­‐3’;	  HXB2	  nt	  4900	  -­‐	  4923)	  and	  OFM19	  (5’-­‐
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GCACTCAAGGCAAGCTTTATTGAGGCTTA	  -­‐3’;	  HXB2	  nt	  9604	  -­‐	  9632).	  	  Inner	  primers	  used	  were	  
*ENV1A-­‐Rx	  (5’-­‐	  CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-­‐3’;	  HXB2	  nt	  5954	  -­‐	  5982)	  and	  
EnvN	  (5’-­‐	  TTGCCAATCAAGGAAGTAGCCTTGTGT	  -­‐3’;	  HXB2	  nt	  9145-­‐9171).	  *Env1A-­‐Rx	  possesses	  
a	  5’	  CACC	  overhang	  that	  facilitates	  directional	  cloning	  into	  the	  pcDNA3.1	  Directional	  cloning	  
vector	  (Invitrogen,	  Life	  Technologies,	  Carlsbad,	  CA).	  	  Further,	  it	  introduces	  an	  M	  to	  I	  mutation	  
that	  removes	  the	  Rev	  start	  codon,	  in	  order	  to	  enhance	  the	  expression	  of	  envelope	  downstream,	  
and	  restore	  functionality	  in	  Env-­‐pseudotyped	  assays	  of	  viruses	  that	  encode	  a	  Rev-­‐Vpu	  fusion	  
protein	  (142).	  	  	  Outer	  reaction	  thermal	  cycling	  conditions	  were	  as	  follows:	  initial	  denaturation	  
at	  94oC	  for	  2	  minutes,	  followed	  by	  35	  cycles	  of	  [at	  94°C	  for	  15	  seconds,	  55°C	  for	  30	  seconds,	  
68°C	  for	  4	  minutes],	  followed	  by	  a	  final	  extension	  for	  1	  cycle	  at	  68°C	  for	  20	  minutes.	  	  Inner	  
reaction	  thermal	  cycling	  conditions	  were	  the	  same	  as	  above,	  for	  45	  cycles.	  	  	  The	  products	  were	  
analyzed	  by	  1%	  agarose	  gel	  electrophoresis,	  visualized	  with	  a	  UVIpro	  Silver	  transilluminator	  
(UVItech,	  Cambridge,	  UK)	  using	  GelRed	  (Biotium,	  Hayward,	  CA)	  incorporated	  into	  the	  loading	  
dye.	  	  	  
Amplicons	  identified	  as	  	  ~	  3kb	  in	  size	  by	  agarose	  gel	  electrophoresis,	  were	  directly	  
sequenced	  using	  an	  ABI3000	  genetic	  analyser	  and	  BigDye	  terminator	  reagents	  (Applied	  
Biosystems,	  Foster	  City,	  CA)	  by	  the	  Central	  Analytic	  Facility	  at	  the	  University	  of	  Stellenbosch,	  
South	  Africa.	  	  The	  12	  primers	  used	  for	  envelope	  sequencing	  are	  tabulated	  in	  supplementary	  
Table	  S2.1.	  	  Contigs	  were	  assembled	  using	  Sequencher	  4.10.1	  (Gene	  Codes,	  Ann	  Arbor,	  MI).	  	  All	  
sequences	  were	  screened	  for	  contamination	  against	  a	  database	  of	  all	  sequences	  generated	  in	  the	  
laboratory	  including	  all	  constructs	  used,	  with	  a	  pairwise	  DNA	  distance	  of	  less	  than	  5%	  flagged	  
as	  potential	  contamination.	  
2.2.3	   Strain	  specific	  single	  genome	  amplification	  (ssSGA)	  
	  
For	  strain-­‐specific	  single	  genome	  amplification	  (ssSGA)	  of	  the	  CAP256	  superinfecting	  virus,	  
reverse	  transcription	  was	  performed	  using	  a	  primer	  specific	  for	  the	  superinfecting	  variant	  
(256spR	  5’-­‐CTCCCTCTGCTGTTGGCTGCGCTCGCGC-­‐3’;	  HXB2	  nt	  8856	  -­‐	  8884).	  Single	  genome	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amplification	  was	  then	  performed	  as	  described	  above	  (2.2.2),	  using	  the	  strain-­‐specific	  primer	  as	  
the	  anti-­‐sense	  primer	  in	  both	  rounds	  of	  amplification.	  	  
	  
2.2.4	   Sequence	  alignment	  and	  analysis	  
Sequences	  were	  aligned	  relative	  to	  a	  curated	  HIV	  alignment	  via	  a	  Hidden	  Markov	  Model	  
(HMM-­‐align)	  using	  HIValign	  
(http://www.hiv.lanl.gov/content/sequence/HIValign/HIValign.html),	  and	  phylogenetic	  trees	  
were	  constructed	  using	  FastTree	  2	  (143),	  with	  a	  GTR+CAT	  model.	  	  Where	  necessary,	  trees	  were	  
pruned	  for	  ease	  of	  visualization,	  using	  iTOL	  (144).	  	  Diversification	  was	  visualized	  using	  the	  
Highlighter	  tool	  
(http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/HIGHLIGHT_POSTSCRIPT/highlighte
r.html),	  with	  the	  “matches”	  setting	  used	  to	  visualize	  intra-­‐participant	  recombination.	  
Recombination	  with	  an	  unknown,	  divergent	  variant	  was	  evaluated	  with	  RIP	  
(http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html),	  using	  a	  background	  alignment	  of	  
26	  pseudo-­‐randomly	  selected,	  subtype-­‐matched	  sequences,	  weighted	  heavily	  for	  sequences	  
from	  the	  CAPRISA	  cohort.	  	  Pairwise	  DNA	  distances	  were	  computed	  using	  Mega	  5	  (30).	  	  
2.2.5	   Estimating	  the	  time	  to	  the	  most	  recent	  common	  ancestor	  (tMRCA)	  
In	  order	  to	  improve	  the	  estimates	  of	  the	  timing	  of	  superinfection,	  and	  to	  differentiate	  the	  
transmission	  of	  one	  or	  multiple	  viruses,	  we	  estimated	  the	  time	  to	  the	  most	  recent	  common	  
ancestor	  (tMRCA)	  of	  multiple	  closely	  related	  sequences	  shortly	  following	  the	  estimated	  time	  of	  
infection/superinfection.	  	  The	  tMRCA	  was	  estimated	  with	  Poisson	  Fitter	  
(http://www.hiv.lanl.gov/content/sequence/poisson_fitter/poisson_fitter/html)	  with	  default	  
settings	  (mutation	  rate	  of	  2.16x10-­‐05	  and	  a	  generation	  time	  of	  two	  days).	  	  Sequences	  were	  
determined	  to	  have	  originated	  from	  a	  single	  transmitted/founder	  virus	  if	  the	  number	  of	  
mutations	  conformed	  to	  a	  Poisson	  distribution,	  displayed	  a	  star	  phylogeny,	  and	  with	  an	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estimated	  MRCA	  dating	  within	  the	  clinically	  defined	  window	  of	  infection	  (described	  in	  detail	  in	  
10).	  
2.2.6	   Comparison	  of	  variable	  region	  length	  and	  glycosylation	  
For	  analysis,	  consensus	  sequences	  were	  derived	  for	  each	  participant	  at	  each	  timepoint	  
according	  to	  “majority	  rules”.	  	  Variable	  region	  lengths	  and	  the	  number	  of	  N-­‐linked	  glycosylation	  
sites	  were	  calculated	  from	  the	  alignment	  using	  an	  in-­‐house	  script	  in	  Wolfram	  Mathematica	  8	  
(Wolfram	  Research,	  Champaign,	  IL,	  USA).	  	  V1,	  V2,	  V3,	  and	  V4	  loops	  were	  measured	  from	  
Cysteine	  to	  Cysteine.	  	  However,	  for	  V2,	  the	  first	  cysteine	  was	  designated	  as	  the	  end	  of	  V1.	  	  V5	  
was	  measured	  from	  HXB2	  position	  460	  to	  471.	  	  Potential	  N-­‐linked	  glycosylation	  sites	  were	  
identified	  by	  the	  presence	  of	  sequons	  (N	  X	  S/T,	  where	  X	  is	  any	  amino	  acid	  except	  for	  Proline).	  	  
Overlapping	  sequons	  (i.e.	  NNST,	  NNSS,	  NNTT,	  NNTS)	  were	  counted	  as	  a	  single	  N-­‐linked	  
glycosylation	  site	  as	  it	  is	  highly	  unlikely	  that	  both	  can	  be	  glycosylated.	  	  The	  length	  and	  
glycosylation	  of	  the	  variable	  regions	  in	  acute	  and	  superinfecting	  viruses	  were	  compared	  to	  
those	  of	  the	  three	  year	  sequences	  using	  a	  two-­‐tailed	  T-­‐test,	  implemented	  in	  Prism	  5	  (GraphPad	  
Software,	  San	  Diego,	  CA).	  
2.2.7	   Power	  calculations	  
Statistical	  power	  was	  calculated	  by	  simulating	  data	  in	  Wolfram	  Mathematica	  8	  (Wolfram	  
Research,	  Champaign,	  IL,	  USA).	  
We	  modeled	  the	  risk	  of	  superinfection	  as:	  
	  
where	  
b	  =	  the	  baseline	  risk	  of	  infection	  over	  the	  sample	  period	  
p	  =	  the	  risk	  of	  superinfection	  in	  the	  maximally	  protected	  participants	  over	  the	  sample	  period	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k	  =	  slope	  parameter	  
x	  =	  correlate	  sampled	  from	  a	  normal	  distribution	  with	  mean	  =	  μ,	  and	  standard	  deviation	  =	  1.	  
The	  model	  was	  developed	  in	  collaboration	  with	  Ben	  Murrell	  (UCSD,	  San	  Diego,	  USA).	  	  Statistical	  
power	  for	  a	  Mann-­‐Whitney	  U	  test	  to	  detect	  correlates	  of	  risk	  of	  superinfection	  was	  estimated	  
from	  data	  simulated	  under	  these	  models,	  with	  500	  iterations.	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2.3	  Results:	  
Dual	  infection	  with	  two	  HIV-­‐1	  strains	  can	  be	  a	  consequence	  of	  either	  co-­‐infection	  or	  
superinfection	  (Table	  2.1).	  	  Superinfection	  was	  defined	  as	  infection	  following	  seroconversion	  
with	  a	  second	  variant	  that	  is	  separated	  on	  a	  phylogeny	  by	  epidemiologically	  unlinked	  viruses	  
(phylogenetically	  unlinked).	  	  Co-­‐infection	  was	  defined	  by	  the	  identification	  of	  two	  (or	  more)	  
phylogenetically	  unlinked	  variants,	  or	  by	  evidence	  of	  a	  recombinant	  region	  of	  at	  least	  150	  bp	  
inherited	  from	  a	  phylogenetically	  unlinked	  variant,	  at	  or	  before	  the	  first	  seropositive	  visit.	  	  	  
Sequences	  from	  individuals	  with	  no	  evidence	  of	  dual	  infection	  (i.e.	  monoinfected)	  were	  further	  
classified	  as	  infected	  with	  a	  single	  variant	  (single	  infection)	  or	  multiple	  closely	  related	  variants	  
or	  quasispecies	  (multivariant	  infection)	  based	  on	  statistical	  modeling	  of	  early	  virus	  evolution	  as	  
described	  by	  Keele	  et	  al.	  (10).	  	  	  Multivariant	  infection	  was	  defined	  by	  the	  sequences	  (obtained	  
shortly	  following	  transmission)	  not	  following	  a	  star	  phylogeny,	  with	  the	  number	  of	  observed	  
mutations	  not	  conforming	  to	  a	  Poisson	  distribution,	  and	  the	  estimated	  tMRCA	  of	  these	  
sequences	  pre-­‐dating	  the	  clinically	  defined	  date	  of	  infection.	  	  	  
This	  chapter	  expands	  on	  previous	  data	  which	  identified	  four	  cases	  of	  dual	  infection	  out	  of	  39	  
participants	  from	  the	  CAPRISA002	  cohort	  screened	  using	  an	  envelope	  C2C3	  heteroduplex	  
mobility	  assay	  (HMA)	  (145),	  and	  two	  putative	  cases	  of	  superinfection	  (CAP256	  and	  CAP281)	  (	  
114,	  F.	  Treurnicht,	  UCT,	  unpublished	  data).	  	  These	  were	  combined	  with	  sequences	  from	  
published	  and	  ongoing	  studies	  from	  UCT	  and	  the	  National	  Institute	  for	  Communicable	  Diseases	  
(R.	  Thebus	  unpublished	  data,	  B.	  Lambson	  unpublished	  data,	  Wibmer	  et	  al.,	  in	  press,	  2,	  68,	  118,	  
119).	  	  	  	  As	  part	  of	  these	  studies,	  gag,	  nef	  and/or	  envelope	  sequences	  were	  generated	  for	  58	  
participants	  over	  time,	  of	  which	  18	  participants	  were	  followed	  up	  for	  approximately	  three	  
years.	  	  These	  sequences	  were	  used	  to	  identify	  cases	  of	  potential	  dual	  infection	  (i.e.	  individuals	  
who	  harboured	  viruses	  with	  high	  diversity	  inconsistent	  with	  the	  known	  duration	  of	  clinical	  
infection,	  or	  evidence	  of	  recombination	  with	  divergent	  variants).	  	  For	  all	  individuals	  with	  
putative	  dual	  infection,	  additional	  full-­‐length	  envelope	  sequences	  were	  generated	  at	  the	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enrollment	  visit	  and	  at	  approximately	  3-­‐,	  6-­‐,	  and	  12-­‐months	  post	  infection	  (mpi).	  Where	  dual	  
infection	  was	  evident	  in	  one	  sample	  but	  not	  in	  the	  preceding	  sample,	  intervening	  timepoints	  
were	  sequenced	  in	  order	  to	  identify	  the	  likely	  timing	  of	  the	  secondary/super-­‐	  infection	  (Figure	  
2.7).	  	  In	  one	  case	  (CAP256),	  strain-­‐specific	  primers	  were	  also	  designed	  to	  estimate	  the	  timing	  of	  
the	  superinfection	  event,	  and	  to	  generate	  amplicons	  from	  the	  superinfecting	  virus.	  	  For	  this	  
thesis,	  a	  total	  of	  361	  full-­‐length	  envelope	  sequences	  were	  generated	  from	  11	  participants	  over	  







*Participants	  for	  whom	  insufficient	  sequence	  data	  was	  available	  are	  classified	  as	  “indeterminate	  multiplicity”.	  
	  
2.3.1	  At	  least	  eleven	  participants	  from	  the	  CAPRISA	  002	  cohort	  were	  dual	  infected	  
Multivariant	  and	  co-­‐infections	  
To	  determine	  the	  multiplicity	  of	  infection,	  we	  analyzed	  envelope	  SGA	  sequences	  at	  (or	  
before)	  the	  first	  HIV	  seropositive	  visit	  for	  forty-­‐four	  participants.	  	  An	  analysis	  of	  the	  phylogenies	  
of	  these	  early	  sequences,	  and	  the	  distribution	  of	  the	  number	  of	  mutations,	  identified	  29	  
participants	  as	  harbouring	  homogeneous	  viruses	  consistent	  with	  single	  infection,	  and	  15	  
participants	  likely	  infected	  with	  multiple	  viruses	  by	  seroconversion	  (Table	  2.1).	  	  The	  maximum	  
*	  
Figure	  2.1	  |	  Schematic	  illustrating	  the	  classification	  of	  multiplicity	  of	  infection.	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DNA	  distances	  observed	  in	  sequences	  from	  participants	  likely	  infected	  with	  more	  than	  one	  virus	  
(red	  dots),	  was	  consistently	  higher	  at	  comparable	  time	  post-­‐infection	  than	  those	  from	  
participants	  where	  a	  single	  virus	  likely	  established	  infection	  (black	  dots)	  (Figure	  2.2).	  	  
	  
	  
Table	  2.1	  |	  Early	  envelope	  diversity	  at	  the	  first	  HIV	  positive	  visits	  providing	  evidence	  of	  multivariant	  or	  co-­‐
























CAP8	   2	   No	   No	   0.47%	   Multivariant	  (2)	   No	  
CAP177	   4	   No	   No	   3.54%	   Multivariant	  (2)	   No	  
CAP228	   7	   Yes	   No	   0.35%	   Multivariant	  (2)	   No	  
CAP69	   2	   No	   No	   3.52%	   Multivariant	  (5)*	   No	  
CAP136	   2	   No	   No	   1.31%	   Multivariant	  (2)*	   No	  
CAP222	   2	   No	   No	   3.0%	   Multivariant	  (3)*	   No	  
CAP224	   3	   No	   No	   2.05%	   Multivariant	  (2)*	   No	  
CAP260	   2	   No	   No	   2.53%	   Multivariant	  (2)*	   No	  
CAP37	   2	   No	   No	   9.04%	   Coinfection	  	  (3)*	   Yes	  
CAP84	   4	   Yes	   No	   2.29%	   Coinfection	  	  (2)	   Yes	  
CAP137	   7	   No	   No	   14.49%	   Coinfection	  	  (2)	   Yes	  
CAP225	   3	   Yes	   No	   4.43%	   Coinfection	  	  (2)	   Yes	  
CAP258	   7	   No	   No	   5.57%	   Coinfection	  	  (3)	   Yes	  
CAP266	   7	   No	   No	   6.24%	   Coinfection	  	  (2)	   Yes	  
CAP267	   6	   No	   No	   6.49%	   Coinfection	  	  (3)	   Yes	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Figure	  2.2	  |	  DNA	  distance	  in	  envelope	  at	  the	  first	  available	  HIV	  positive	  visit	  (RNA	  positive/antibody	  negative	  
or	  seropositive),	  plotted	  according	  to	  the	  estimated	  time	  post	  infection.	  	  Participants	  where	  the	  viral	  
evolution	  is	  consistent	  with	  a	  single	  virus	  founding	  infection	  are	  shown	  in	  black,	  whereas	  those	  who	  were	  
likely	  infected	  by	  more	  than	  one	  virus	  are	  highlighted	  in	  red.	  	  A	  linear	  regression	  line	  is	  fitted	  to	  distances	  
observed	  in	  participants	  where	  infection	  was	  likely	  established	  by	  a	  single	  founder	  virus.	  
	  
Reconstructing	  the	  phylogeny	  from	  envelope	  sequences	  for	  the	  15	  participants	  initially	  
infected	  with	  multiple	  viruses	  together	  with	  a	  panel	  of	  100	  randomly	  selected	  subtype	  C	  
reference	  sequences	  from	  South	  Africa	  revealed	  that	  only	  sequences	  from	  CAP37	  and	  CAP137	  
clustered	  separately	  from	  each	  other	  on	  the	  tree,	  separated	  by	  epidemiologically	  unlinked	  
sequences.	  	  Sequences	  from	  the	  remaining	  13	  participants	  were	  monophyletic,	  although	  long	  
branch	  lengths	  were	  suggestive	  of	  highly	  diverse	  infecting	  viruses	  in	  some	  cases.	  	  We	  therefore	  
looked	  for	  evidence	  of	  recombination	  with	  a	  divergent	  virus	  in	  these	  13	  participants.	  	  Using	  
sliding	  window	  distance	  measures	  to	  a	  panel	  of	  25	  viruses,	  we	  found	  no	  evidence	  of	  
recombination	  with	  a	  divergent	  virus	  in	  six	  participants.	  	  However,	  for	  seven	  of	  these	  13	  
participants,	  there	  was	  evidence	  of	  recombination	  with	  an	  unknown	  divergent	  virus	  over	  a	  sub-­‐
genomic	  window	  (illustrated	  in	  Figure	  2.5).	  	  Partitioning	  each	  alignment	  according	  to	  predicted	  
breakpoints	  confirmed	  that	  these	  subgenomic	  regions	  were	  separated	  by	  epidemiologically	  
unlinked	  sequences	  on	  the	  phylogeny	  in	  five	  out	  of	  six	  cases,	  providing	  evidence	  of	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recombination	  with	  an	  unlinked	  virus.	  In	  five	  of	  these	  cases,	  several	  discontiguous	  recombinant	  
regions	  were	  detected.	  	  In	  the	  sixth	  case,	  CAP84,	  a	  single	  recombinant	  region	  was	  detected	  in	  
only	  one	  of	  seven	  sequences	  at	  the	  first	  seropositive	  visit.	  	  However,	  multiple	  unique	  
recombinant	  regions	  arose	  over	  the	  course	  of	  infection	  (Figure	  2.6),	  suggesting	  the	  presence,	  
below	  detection,	  of	  a	  second	  strain.	  	  This,	  together	  with	  previous	  data	  demonstrating	  
heteroduplex	  banding	  with	  a	  C2C3	  HMA	  (145)	  is	  highly	  suggestive	  of	  co-­‐infection	  in	  this	  
participant.	  	  In	  the	  last	  case,	  CAP177,	  several	  subgenomic	  regions	  of	  a	  virus	  detected	  in	  the	  CVL	  
(B.	  Lambson,	  NICD,	  JHB,	  RSA,	  unpublished	  data)	  were	  genotypically	  divergent	  from	  the	  initial	  
virus	  detected	  in	  the	  plasma.	  	  However,	  these	  viruses	  were	  still	  monophyletic	  based	  on	  these	  
partitions	  (Figure	  2.5).	  	  CAP177	  was	  therefore	  classified	  as	  a	  “multivariant”	  infection.	  	  	  	  
In	  total,	  we	  classified	  eight	  participants	  as	  infected	  with	  more	  than	  one	  closely	  related	  virus	  
(multivariant),	  of	  whom	  five	  were	  previously	  identified	  (11).	  	  Seven	  participants	  were	  classified	  
as	  infected	  with	  more	  than	  one	  divergent	  virus	  by	  the	  first	  available	  seropositive	  visit	  
(coinfection).	  	  In	  two	  cases	  of	  coinfection	  (CAP37,	  CAP137),	  viruses	  were	  phylogenetically	  
unlinked	  based	  on	  full	  envelope	  sequences.	  	  In	  a	  further	  five	  cases,	  although	  viruses	  were	  
monophyletic	  based	  on	  full	  envelope	  there	  was	  significant	  evidence	  of	  sub-­‐genomic	  regions	  
inherited	  from	  a	  phylogenetically	  unlinked	  virus,	  highly	  suggestive	  of	  recombination	  with	  a	  
divergent	  virus.	  	  However,	  it	  is	  not	  clear	  whether	  recombination	  occurred	  post	  infection,	  or	  
prior	  to	  transmission	  in	  a	  dual	  infected	  donor.	  	  All	  infections	  and	  dual	  infections	  occurred	  with	  


























































































































































































































































































































































































































































































































































Figure	  2.3	  |	  Maximum	  likelihood	  phylogenetic	  tree	  illustrating	  representative	  envelope	  
sequences	  from	  15	  participants	  initially	  infected	  with	  more	  than	  one	  virus	  in	  a	  background	  
of	  100	  reference	  subtype	  C	  sequences	  from	  South	  Africa	  and	  rooted	  on	  the	  subtype	  B	  HXB2	  
reference	  sequence.	  	  For	  the	  15	  participants,	  only	  the	  sequence	  pairs	  with	  the	  greatest	  DNA	  
distance	  are	  shown.	  	  	  
Figure	  2.4	  |	  No	  significant	  evidence	  of	  recombination	  with	  unlinked	  viruses	  in	  seven	  participants	  
infected	  with	  more	  than	  one	  variant.	  	  DNA	  similarity	  to	  a	  panel	  of	  25	  subtype	  C	  viruses	  as	  well	  as	  
the	  most	  distant	  within	  patient	  sequence	  was	  calculated	  using	  a	  sliding	  window	  (100bp	  in	  size)	  
across	  envelope	  using	  RIP.	  	  	  
	  
	  





















































































































































































































































































































































Figure	  2.5	  |	  Evidence	  of	  
divergent	  subgenomic	  regions	  
in	  seven	  participants.	  	  Distances	  
were	  calculated	  with	  RIP	  using	  a	  
sliding	  window	  of	  100bp.	  	  
Aligments	  were	  partitioned	  
according	  to	  the	  inferred	  
breakpoints	  and	  the	  phylogeny	  
was	  inferred	  from	  the	  partition.	  
The	  two	  most	  divergent	  within	  
participant	  sequences	  at	  the	  
first	  seropositive	  visit	  are	  
highlighted	  in	  red	  and	  blue	  in	  
each	  tree,	  which	  was	  inferred	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Superinfections	  
For	  three	  participants	  (namely	  CAP237,	  CAP256,	  and	  CAP281),	  a	  second	  phylogenetically	  
unlinked	  variant	  was	  detectable	  (Figure	  2.8),	  only	  following	  seroconversion	  (Figure	  2.7),	  
indicating	  likely	  cases	  of	  superinfection.	  	  
CAP256.	  CAP256	  was	  previously	  identified	  as	  potentially	  superinfected	  prior	  to	  30	  weeks	  
post	  infection	  (wpi),	  based	  on	  longitudinal,	  near	  full-­‐length	  genome	  sequences	  (F.	  Treurnicht,	  
NICD,	  JHB,	  RSA,	  unpublished	  results).	  To	  identify	  the	  superinfecting	  virus	  in	  CAP256,	  a	  strain-­‐
specific	  primer	  was	  designed	  based	  on	  the	  sequences	  of	  later	  recombinant	  viruses	  from	  30	  wpi.	  
Strain-­‐specific	  single	  genome	  amplification	  (ssSGA)	  was	  performed	  using	  plasma	  from	  6,	  11,	  13,	  
and	  15	  weeks	  post	  infection,	  corresponding	  to	  the	  earliest	  available	  sample	  and	  those	  prior	  to	  
and	  at	  the	  peak	  of	  the	  viral	  load	  spike	  at	  15	  weeks	  post	  infection	  (Figure	  2.7).	  While	  no	  
amplification	  was	  evident	  in	  the	  samples	  from	  6,	  11,	  and	  13	  wpi,	  a	  phylogenetically	  unlinked	  
envelope	  was	  successfully	  amplified	  at	  15	  wpi.	  The	  six	  amplicons	  sequenced	  from	  15	  wpi	  were	  
Figure	  2.6	  |	  Multiple	  unique	  recombination	  breakpoints	  detected	  in	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highly	  homogenous	  (three	  were	  identical,	  with	  the	  other	  three	  differing	  by	  no	  more	  than	  two	  
nucleotide	  changes	  (Figure	  2.9B)	  and	  no	  mutation	  common	  to	  more	  than	  one	  virus),	  suggesting	  
that	  they	  had	  been	  recently	  transmitted	  (estimated	  time	  since	  MRCA	  of	  8	  days)	  (95%	  CI:	  0	  –	  26	  
days).	  	  Furthermore,	  there	  was	  no	  significant	  evidence	  of	  recombination	  with	  the	  initial	  virus	  at	  
this	  time	  point	  (Figure	  2.10B).	  	  We	  therefore	  estimate	  that	  CAP256	  was	  superinfected	  at	  ~14	  
wpi	  (95%	  CI:	  11-­‐15wpi).	  	  	  
CAP237.	  	  A	  comparison	  of	  envelope	  SGA	  sequences	  from	  three	  years	  post	  infection	  in	  CAP237	  
to	  those	  at	  the	  first	  HIV	  positive	  visit	  (R.	  Thebus,	  unpublished	  sequences)	  was	  highly	  suggestive	  
of	  superinfection.	  In	  order	  to	  confirm	  superinfection,	  and	  to	  identify	  the	  superinfecting	  envelope	  
sequence	  in	  CAP237,	  single	  genome	  PCR	  amplification	  was	  performed	  on	  longitudinal	  plasma	  
samples,	  taken	  at	  4,	  11,	  24	  and	  54	  wpi.	  	  A	  phylogenetically	  unlinked	  virus	  was	  detected	  at	  11	  
wpi,	  but	  not	  at	  4	  wpi,	  consistent	  with	  superinfection.	  	  Viruses	  from	  CAP237	  were	  separated	  on	  
the	  phylogeny	  by	  a	  virus	  (C.ZA.2004.04ZASK13681)	  sampled	  in	  2004,	  three	  years	  before	  
CAP237	  was	  initially	  infected	  (inconsistent	  with	  a	  transmission	  chain).	  The	  superinfecting	  
envelope	  sequences	  were	  highly	  homogenous	  (Figure	  2.9A),	  with	  no	  significant	  evidence	  of	  
recombinant	  regions	  inherited	  from	  the	  initial	  virus	  (Figure	  2.10A).	  	  The	  time	  since	  a	  MRCA	  was	  
estimated	  at	  8	  days	  (95%	  CI:	  0-­‐24	  days),	  suggesting	  superinfection	  likely	  occurred	  at	  ~	  10	  wpi	  
(95%	  CI:	  7-­‐11	  wpi).	  	  Similarly,	  a	  strain-­‐specific	  PCR	  of	  gag,	  estimated	  that	  superinfection	  likely	  
occurred	  between	  7	  and	  11	  wpi	  (146).	  	  	  
CAP281.	  	  In	  the	  case	  of	  CAP281,	  gag	  sequences	  of	  the	  dominant	  population	  at	  46	  wpi	  were	  
highly	  divergent	  from	  those	  at	  26	  wpi,	  suggestive	  of	  superinfection	  (146).	  	  In	  order	  to	  identify	  
the	  superinfecting	  envelope,	  longitudinal	  SGAs	  were	  generated	  from	  the	  earliest	  available	  
sample	  (10	  wpi),	  and	  from	  13,	  30,	  42,	  46	  wpi	  plasma	  samples.	  	  The	  superinfecting	  virus	  was	  
detectable	  at	  46	  wpi,	  but	  not	  42	  wpi	  or	  earlier.	  	  Sequences	  at	  46	  wpi	  were	  highly	  homogenous	  
(Figure	  2.9C),	  with	  an	  estimated	  time	  since	  MRCA	  of	  28	  days	  (95%	  CI:	  0-­‐43	  days),	  suggesting	  
that	  superinfection	  likely	  occurred	  at	  ~42	  wpi	  (95%	  CI:	  40	  –	  46	  wpi).	  	  There	  was	  also	  no	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significant	  evidence	  of	  recombinant	  regions	  in	  the	  46	  wpi	  sequences	  inherited	  from	  the	  initial	  
variant	  (Figure	  2.10C).	  	  
In	  summary,	  in	  three	  participants	  two	  phylogenetically	  unlinked	  viruses	  were	  detectable,	  
only	  following	  seroconversion,	  suggestive	  of	  superinfection	  (Figure	  2.9).	  	  In	  all	  three	  cases,	  the	  
estimated	  tMRCA	  indicated	  the	  secondary	  infection	  dated	  post-­‐seroconversion,	  and	  was	  
consistent	  with	  the	  sequencing	  data,	  and/or	  strain-­‐specific	  SGAs	  (Figure	  2.7).	  	  In	  each	  case,	  a	  
spike	  in	  viral	  load	  (increase	  >10-­‐fold)	  was	  also	  evident	  at	  or	  shortly	  after	  the	  estimated	  time	  of	  
superinfection.	  	  While	  it	  is	  not	  possible	  to	  exclude	  the	  possibility	  of	  co-­‐infection,	  these	  data	  
strongly	  suggest	  that	  these	  three	  participants	  were	  superinfected,	  all	  within	  the	  first	  year	  of	  
infection.	  The	  three	  superinfecting	  viruses	  from	  CAP256,	  CAP237	  and	  CAP281	  were	  all	  
classified	  as	  subtype	  C,	  and	  differed	  from	  the	  primary	  infecting	  variants	  across	  envelope	  by	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Figure	  2.7	  |	  Viral	  loads	  (red)	  and	  CD4	  counts	  (blue)	  over	  time	  in	  participants	  CAP256	  (A),	  CAP237	  
(B),	  and	  CAP281	  (C),	  along	  with	  the	  estimated	  timing	  of	  superinfection.	  	  The	  timepoints	  for	  which	  
single	  genome	  PCR	  amplification	  (SGA)	  was	  performed,	  along	  with	  the	  presence	  (+)	  or	  absence	  (-­‐)	  
of	  the	  superinfecting	  strain	  is	  shown.	  	  The	  estimated	  timing	  of	  superinfection	  based	  on	  dating	  of	  
the	  most	  recent	  common	  ancestor	  of	  the	  superinfecting	  sequences	  (tMRCA),	  is	  also	  depicted,	  along	  
with	  the	  95%	  confidence	  interval	  for	  this	  estimate.	  	  For	  CAP256,	  PCR	  specific	  for	  the	  
superinfecting	  variant	  (ssPCR)	  were	  additionally	  performed	  and	  the	  detection	  of	  the	  
superinfecting	  variant	  is	  shown.	  ARVs,	  start	  of	  anti-­‐retroviral	  treatment.	  
	  
	  
















Figure	  2.9	  |	  Nucleotide	  highlighter	  plots	  of	  envelope	  SGA	  sequences	  sampled	  recently	  post	  superinfection	  
depicting	  the	  high	  homogeneity	  in	  CAP237	  (A),	  CAP256	  (B),	  and	  CAP281	  (C).	  	  Identity	  to	  the	  consensus	  
sequence	  is	  depicted	  by	  a	  horizontal	  gray	  line	  and	  the	  absence	  of	  a	  coloured	  tick.	  	  Synonymous	  mutations	  are	  
shown	  in	  red	  and	  non-­‐synonymous	  mutations	  are	  shown	  in	  green.	  	  In	  all	  three	  cases,	  the	  superinfecting	  
population	  was	  highly	  homogenous,	  with	  no	  two	  sequences	  harbouring	  the	  same	  mutations	  away	  from	  the	  
consensus.	  
	  Figure	  2.8	  |	  Maximum	  likelihood	  phylogeny	  depicting	  the	  presence	  of	  two	  strains	  separated	  on	  the	  
phylogeny	  by	  epidemiologically	  unlinked	  viruses	  in	  participants	  CAP237	  (blue	  circles),	  CAP256	  (red	  
squares),	  and	  CAP281	  (green	  diamonds).	  	  The	  phylogeny	  was	  reconstructed	  using	  envelope	  sequences	  
from	  CAP237,	  CAP256,	  CAP281	  along	  with	  58	  subtype	  C	  sequences	  from	  30	  individuals	  including	  24	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2.3.3	  Superinfecting	  viruses	  have	  phenotypes	  typical	  of	  recently	  transmitted	  viruses	  
While	  a	  single	  founder	  variant	  establishes	  infection	  in	  ~80%	  of	  primary	  HIV	  transmissions	  
(9–11),	  the	  multiplicity	  of	  superinfection	  is	  not	  known.	  	  Here	  we	  were	  able	  to	  accurately	  time	  
superinfection	  to	  within	  a	  short	  window	  in	  three	  participants.	  	  Sequencing	  of	  the	  early	  
superinfecting	  viral	  population	  revealed	  that,	  in	  all	  three	  cases,	  sequences	  exhibited	  a	  star-­‐like	  
phylogeny	  with	  the	  number	  of	  mutations	  arising	  consistent	  with	  a	  Poisson	  distribution.	  	  The	  
inferred	  common	  ancestors	  also	  dated	  near	  to	  the	  time	  of	  superinfection.	  	  This	  is	  consistent	  
with	  superinfection	  established	  by	  a	  single	  transmitted/founder	  (T/F)	  variant.	  	  	  Importantly,	  in	  
all	  three	  cases	  of	  superinfection,	  the	  earliest	  envelope	  sequences	  representative	  of	  the	  
	  
A.	   B.	  
C.	  
Figure	  2.10	  |	  No	  evidence	  of	  recombinant	  regions	  inherited	  from	  the	  primary	  virus	  within	  
envelope	  of	  the	  superinfecting	  viruses.	  The	  similarity	  of	  the	  (A)	  CAP237,	  (B)	  CAP256	  and	  (C)	  
CAP281	  superinfecting	  envelope	  sequences	  to	  a	  panel	  of	  24	  subtype-­‐matched	  viruses,	  
including	  the	  primary	  infecting	  viruses	  was	  evaluated.	  Only	  the	  plots	  from	  the	  most	  similar	  
subset	  of	  viruses	  are	  displayed	  for	  ease	  of	  visualization.	  	  Similarity	  was	  calculated	  with	  a	  100	  
bp	  sliding	  window	  using	  RIP.	  	  No	  windows	  within	  envelope	  of	  the	  superinfecting	  viruses	  were	  
significantly	  more	  similar	  to	  the	  primary	  virus	  than	  they	  were	  to	  the	  panel	  viruses,	  suggesting	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superinfecting	  viral	  population	  were	  highly	  homogenous	  (Figure	  2.9),	  and	  showed	  no	  evidence	  
of	  recombinant	  regions	  inherited	  from	  the	  initial	  virus	  (Figure	  2.10).	  	  Therefore,	  sequences	  
identical	  to	  the	  consensus	  were	  considered	  as	  an	  accurate	  representation	  of	  the	  superinfecting	  
transmitted/founder	  (T/F)	  virus.	  	  	  
Recently	  transmitted	  viruses	  appear	  to	  possess	  shorter,	  less	  glycosylated	  variable	  regions	  
than	  viruses	  from	  chronic	  infection	  (139,	  140).	  	  In	  order	  to	  establish	  whether	  superinfecting	  
founder	  viruses	  had	  similar	  characteristics,	  we	  compared	  the	  length	  and	  potential	  N-­‐linked	  
glycosylation	  of	  the	  variable	  regions	  to	  a	  panel	  of	  matched	  acute	  and	  chronic	  subtype	  C	  
sequences	  from	  the	  same	  cohort,	  sampled	  over	  a	  similar	  period.	  	  Acute	  envelope	  SGAs	  were	  
available	  from	  21	  participants	  in	  the	  CAPRISA002	  cohort,	  for	  whom	  matched	  SGAs	  were	  
available	  at	  either	  one	  year	  (n=5),	  or	  three	  years	  (n=16)	  post	  infection.	  Consistent	  with	  previous	  
observations,	  viruses	  sampled	  at	  three	  years	  post	  infection	  had	  longer,	  potentially	  more	  
glycosylated	  variable	  regions	  compared	  to	  those	  sampled	  shortly	  following	  transmission.	  	  
Superinfecting	  viruses	  had	  characteristics	  typical	  of	  recently	  transmitted	  viruses,	  with	  length	  
and	  glycosylation	  significantly	  lower	  than	  in	  viruses	  from	  three	  years	  post	  infection	  (p	  =	  0.0074,	  
























































Figure	  2.11	  |	  Superinfecting	  T/F	  viruses	  have	  Envelopes	  with	  shorter,	  less	  glycosylated	  variable	  
regions	  compared	  to	  viruses	  sampled	  at	  three	  years	  post	  infection.	  Each	  point	  represents	  the	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2.3.2	  Recombination	  occurred	  early,	  and	  frequently	  played	  a	  major	  role	  in	  generating	  
envelope	  diversity.	  	  
Recombination	  is	  intrinsic	  to	  HIV	  replication,	  and	  is	  an	  important	  evolutionary	  mechanism	  
employed	  by	  HIV	  to	  generate	  sequence	  diversity.	  	  Recombination	  is	  not	  an	  unconstrained	  
process,	  and	  the	  extent	  and	  timing	  of	  recombination	  following	  dual	  infection	  is	  not	  clear.	  	  To	  
assess	  the	  extent	  of	  recombination	  following	  dual	  infection,	  we	  used	  single	  genome	  
amplification	  to	  sequence	  envelope	  over	  the	  first	  year	  of	  infection	  in	  seven	  dual	  infected	  
participants	  (CAP37,	  CAP84,	  CAP137,	  CAP267,	  CAP237,	  CAP256,	  CAP281).	  	  Importantly,	  single	  
genome	  amplification	  prevents	  artificial	  recombination	  due	  to	  PCR	  amplification.	  	  
Recombination	  following	  superinfection	  was	  evident	  (within	  envelope)	  in	  all	  three	  
superinfected	  participants	  (Figure	  2.12).	  	  As	  sampling	  in	  the	  CAPRISA002	  cohort	  was	  more	  
frequent	  during	  acute	  infection	  (weekly	  vs	  monthly/quarterly),	  co-­‐infected	  participants	  offer	  
the	  best	  cases	  to	  evaluate	  the	  early	  kinetics	  of	  recombination.	  	  Of	  the	  co-­‐infected	  participants,	  
CAP137	  was	  the	  only	  case	  in	  which	  there	  was	  no	  evidence	  of	  recombinant	  regions	  shared	  
between	  the	  two	  infecting	  variants.	  	  	  The	  absence	  of	  homology	  between	  the	  infecting	  viruses	  in	  
CAP137	  sampled	  pre-­‐seroconversion	  	  (ie	  HIV	  RNA	  positive,	  antibody	  negative;	  an	  estimated	  two	  
weeks	  post	  infection)	  is	  consistent	  with	  infection	  by	  two	  separate	  donors,	  and	  provides	  an	  
opportunity	  to	  evaluate	  how	  soon	  recombination	  can	  become	  evident	  after	  dual	  infection.	  	  
Analyzing	  envelope	  sequences	  (N=5)	  sampled	  five	  weeks	  later	  (~7	  wpi),	  we	  find	  evidence	  of	  at	  
least	  two	  unique	  recombinant	  viruses	  (Figure	  2.13).	  	  Viral	  loads	  at	  this	  time	  point	  reached	  
360,000	  copies/ml.	  	  While	  we	  cannot	  exclude	  the	  possibility	  that	  these	  recombinant	  variants	  
were	  co-­‐transmitted,	  the	  small	  number	  of	  mutations	  away	  from	  the	  putative	  parental	  virus	  
sequences	  supports	  the	  hypothesis	  that	  recombination	  occurred	  (rapidly)	  following	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A.	  CAP237	   	   	   	   	  	  	  B.	  CAP256	  	  	  	  	  	  	  	  	  	   	   	   C.	  CAP281	  
	  
	  
Figure	  2.12	  |	  Highlighter	  plot	  depicting	  recombination	  in	  envelope	  over	  time	  in	  3	  superinfected	  participants:	  CAP237	  (A),	  
CAP256	  (B),	  and	  CAP281(C).	  	  Residues	  identical	  to	  the	  superinfecting	  or	  primary	  infecting	  viruses	  are	  show	  with	  red	  or	  
blue	  ticks	  respectively.	  	  The	  presence	  of	  mutations	  not	  present	  in	  neither	  of	  the	  infecting	  strains	  are	  shown	  with	  black	  
ticks,	  while	  sites	  conserved	  in	  both	  strains	  are	  shown	  in	  white.	  	  	  
Figure	  2.13	  |	  Highlighter	  plot	  depicting	  recombination	  over	  time	  in	  a	  co-­‐infected	  
participant,	  CAP137.	  	  Residues	  identical	  to	  each	  of	  the	  infecting	  strains	  are	  shown	  
with	  red	  or	  blue	  ticks.	  	  The	  presence	  of	  mutations	  not	  present	  in	  neither	  of	  the	  
infecting	  strains	  are	  shown	  with	  black	  ticks,	  while	  sites	  conserved	  in	  both	  strains	  are	  
shown	  in	  white.	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2.3.4	  Small	  sample	  sizes	  have	  little	  power	  to	  detect	  correlates	  of	  protection	  from	  
superinfection	  
In	  total,	  18	  participants	  were	  followed	  up	  for	  three	  years,	  with	  no	  evidence	  of	  superinfection	  
and	  were	  therefore	  classified	  as	  “singly	  infected”	  (Table	  2.2).	  	  For	  16	  of	  these	  participants,	  
sequence	  data	  was	  available	  from	  three	  genes	  (gag,	  nef	  and	  env)	  (146).	  For	  two	  participants,	  
sequences	  were	  only	  available	  for	  two	  genes	  (gag/nef	  and	  env).	  
	  
Table	  2.2	  |	  Defining	  the	  multiplicity	  of	  infection	  
	   Mono	  infection	   Dual	  infection**	  
	   Single	  variant	   Multivariant	   Co-­‐infection	   Superinfection	  
Multiplicity	   1	   >1	  variant	   >1	   >1	  


















N	   18	   7	  (3)#	   7	   3	  
*Indeterminate	  multiplicity:	  N=33	  
**	  CAP200	  was	  identified	  as	  dual	  infected,	  but	  it	  is	  unclear	  whether	  this	  was	  as	  a	  result	  of	  co-­‐	  or	  
superinfection	  
#	  While	  seven	  participants	  were	  infected	  with	  more	  than	  one	  closely	  related	  virus,	  only	  three	  of	  these	  
participants	  had	  at	  least	  two	  years	  of	  follow	  up	  to	  exclude	  superinfection.	  
	  
In	  summary,	  a	  total	  32	  individuals	  had	  envelope	  SGA	  sequencing	  upon	  enrolment	  with	  
follow	  up	  over	  at	  least	  18	  months,	  of	  whom	  21	  were	  “monoinfected”	  and	  11	  were	  dual	  infected.	  	  
Of	  the	  21	  with	  monoinfection,	  three	  were	  classified	  as	  multivariant	  infection	  and	  18	  as	  single	  
variant	  infection.	  	  Of	  the	  11	  cases	  of	  dual-­‐infection	  identified,	  five	  were	  first	  identified	  as	  part	  of	  
this	  thesis.	  	  Of	  these	  11,	  seven	  were	  classified	  as	  co-­‐infected,	  three	  were	  superinfected,	  and	  in	  
one	  case	  the	  timing	  could	  not	  be	  resolved	  (Table	  2.2).	  	  To	  estimate	  the	  incidence	  of	  
superinfection,	  we	  considered	  only	  SGA	  follow	  up	  as	  population	  sequencing	  potentially	  offers	  
little	  power	  to	  detect	  superinfection	  and	  its	  inclusion	  could	  therefore	  have	  resulted	  in	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underestimating	  the	  incidence	  of	  superinfection.	  	  A	  total	  of	  54.89	  person	  years	  of	  follow	  up	  
were	  available	  with	  SGA	  sequencing.	  We	  therefore	  conservatively	  estimate	  the	  incidence	  of	  
superinfection	  as	  5.47/100	  person	  years.	  	  This	  is	  not	  markedly	  different	  from	  the	  primary	  
incidence	  in	  this	  cohort	  (7.2/100	  person	  years)	  (141).	  	  
To	  establish	  whether	  we	  had	  any	  power	  to	  detect	  correlates	  of	  protection	  against	  
superinfection	  with	  three	  cases	  of	  superinfection	  and	  18	  singly	  infected	  controls,	  we	  modeled	  a	  
hypothetical	  protective	  effect	  in	  silico.	  	  While	  we	  cannot	  know,	  a	  priori,	  the	  relationship	  between	  
this	  hypothetical	  correlate	  and	  risk	  of	  infection,	  we	  can	  estimate	  the	  power	  under	  the	  most,	  and	  
less	  favourable	  combination(s)	  of	  variables.	  	  	  The	  most	  favourable	  scenario	  (from	  the	  
standpoint	  of	  power	  of	  detection)	  would	  result	  from	  complete	  protection	  above	  a	  particular	  
threshold,	  but	  no	  protection	  for	  individuals	  with	  values	  below	  this	  threshold	  (i.e.	  Titers	  above	  
“X”	  provide	  complete	  protection	  against	  superinfection,	  but	  any	  titers	  below	  “X”	  offer	  no	  
protection)	  (see	  Figure	  14A).	  	  Under	  a	  less	  favourable,	  but	  perhaps	  more	  biologically	  relevant,	  
scenario,	  protection	  would	  scale	  with	  the	  correlate,	  providing	  100%	  protection	  only	  to	  those	  
with	  the	  highest	  values	  (Figure	  2.14B).	  	  
	  






Figure	  2.14	  |	  Modelling	  a	  hypothetical	  correlate	  of	  risk	  of	  superinfection.	  A.	  	  The	  most	  statistically	  favourable	  
scenario	  can	  be	  modeled	  with	  complete	  protection	  above	  a	  critical	  threshold.	  This	  relationship	  was	  modeled	  
with	  k→∞ ,	  p	  =	  0,	  and	  μ 	  =-­‐0.7.	  	  B.	  A	  statistically	  less	  favourable,	  but	  perhaps	  more	  biologically	  relevant,	  
scenario	  can	  be	  modeled	  with	  k	  =	  1,	  p	  =	  0	  and	  μ 	  =	  -­‐1.5.	  	  Under	  this	  model,	  protection	  against	  superinfection	  
scales	  proportionally	  to	  the	  correlate,	  providing	  complete	  protection	  to	  only	  those	  individuals	  with	  the	  
highest	  response.	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Even	  under	  a	  favourable	  scenario	  (as	  in	  Figure	  2.14A),	  a	  protective	  effect	  which	  produces	  a	  
mean	  incidence	  of	  superinfection	  of	  5.47%/py	  in	  a	  cohort	  with	  a	  baseline	  risk	  of	  7.2%/py,	  
screened	  over	  three	  years,	  would	  have	  ~6%	  power	  to	  detect	  this	  association.	  	  With	  a	  shallower	  
slope	  culminating	  in	  complete	  protection	  for	  those	  participants	  with	  the	  highest	  values	  (as	  in	  
Figure	  2.14B),	  there	  is	  essentially	  no	  power	  to	  detect	  this	  association	  (i.e.	  equivalent	  to	  the	  false	  
positive	  rate	  of	  5%).	  	  Even	  assuming	  a	  true	  incidence	  of	  superinfection	  half	  that	  of	  primary	  
infection	  (i.e.	  3.6%/py	  in	  this	  cohort),	  under	  our	  model,	  a	  sample	  ~3-­‐15	  times	  larger	  (i.e.	  9-­‐45	  
superinfections	  and	  54-­‐270	  monoinfected	  controls)	  would	  be	  needed	  to	  have	  ~80%	  power	  to	  
detect	  this	  hypothetical	  correlate	  of	  protection.	  	  This	  also	  assumes	  that	  a	  single	  variable	  would	  
be	  tested.	  	  Testing	  a	  number	  of	  candidate	  immunological	  variables	  will	  require	  correcting	  for	  
multiple	  testing,	  further	  reducing	  power.	  	  	  
	  
	  
	   	   48	  
	  
2.4	  Discussion	  
Since	  the	  first	  case	  was	  reported	  in	  2002	  (147),	  cases	  of	  HIV	  superinfection	  are	  increasingly	  
being	  identified.	  	  A	  case	  of	  HIV	  triple	  infection	  has	  also	  been	  described	  (148).	  	  The	  implication	  is	  
that	  the	  natural	  immune	  response	  to	  HIV	  infection	  is	  frequently	  not	  sufficient	  to	  provide	  
protection	  from	  infection	  with	  another	  HIV	  variant,	  raising	  concerns	  for	  vaccine	  design.	  	  Even	  if	  
the	  immune	  responses	  generated	  during	  natural	  infection	  provide	  no	  protection	  from	  HIV	  
infection,	  quantifying	  these	  responses	  at	  the	  time	  of	  superinfection	  will	  still	  address	  an	  
important	  question,	  namely:	  What	  is	  not	  sufficient	  to	  provide	  protection?	  	  However,	  the	  utility	  
of	  superinfection	  as	  a	  model	  of	  vaccine	  protection	  depends	  on	  the	  superinfection	  event	  
accurately	  reflecting	  primary	  infection,	  though	  this	  has	  not	  previously	  been	  demonstrated.	  Here,	  
we	  were	  able	  to	  show	  that	  all	  three	  cases	  of	  superinfection	  identified	  were	  likely	  established	  by	  
a	  single	  virus.	  	  This	  is	  consistent	  with	  primary	  HIV	  infection,	  where	  infection	  is	  established	  by	  a	  
single	  virus	  in	  ~80%	  of	  individuals	  (10,	  11).	  	  	  We	  also	  show	  here	  that	  the	  superinfecting	  viruses	  
had	  shorter,	  less	  glycosylated	  variable	  regions	  than	  variants	  from	  chronic	  infection;	  a	  
characteristic	  of	  recently	  transmitted	  viruses.	  	  These	  data	  indicate	  that	  superinfecting	  viruses	  
are	  genotypically	  similar	  to	  primary	  infecting	  viruses,	  providing	  further	  support	  for	  
superinfection	  as	  a	  model	  to	  address	  correlates	  of	  protection	  against	  HIV.	  
While	  the	  natural	  immune	  response	  is	  frequently	  inadequate	  to	  prevent	  superinfection,	  
identifying	  correlates	  of	  even	  partial	  protection	  would	  be	  invaluable	  for	  vaccine	  design.	  	  To	  
address	  whether	  the	  immune	  response	  elicited	  in	  response	  to	  HIV	  infection	  provides	  any	  
protection	  from	  superinfection,	  several	  studies	  have	  systematically	  screened	  for	  superinfection,	  
and	  compared	  the	  incidence	  to	  that	  of	  primary	  infection	  in	  the	  same	  or	  similar	  cohort(s).	  	  
Though	  systematic	  screening	  of	  CAPRISA	  002	  to	  accurately	  quantify	  the	  incidence	  of	  
superinfection	  was	  beyond	  the	  scope	  of	  this	  project,	  within	  54.89	  person	  years	  of	  follow	  up	  with	  
full	  envelope	  SGAs	  from	  25	  participants,	  we	  identified	  three	  cases	  of	  superinfection.	  	  This	  
corresponds	  to	  an	  incidence	  of	  superinfection	  of	  5.47%/py	  of	  follow	  up,	  which	  is	  not	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significantly	  different	  from	  a	  primary	  incidence	  of	  infection	  of	  7.2%/py	  (141).	  	  This	  is	  consistent	  
with	  the	  idea	  that,	  at	  best,	  only	  a	  minority	  of	  HIV	  infected	  individuals	  are	  likely	  protected	  from	  
superinfection.	  	  	  Similar	  observations	  were	  made	  from	  cohorts	  from	  Rakai,	  Uganda	  
(heterosexual),	  and	  California,	  USA	  (MSM),	  where	  the	  incidence	  of	  superinfection	  was	  
comparable	  to	  that	  of	  primary	  infection	  (124,	  125).	  	  However,	  in	  a	  high-­‐risk	  heterosexual	  cohort	  
from	  Kenya,	  superinfection	  was	  detected	  at	  a	  rate	  approximately	  half	  that	  of	  primary	  infection	  
(126,	  135),	  and	  two	  other	  studies	  were	  not	  able	  to	  find	  any	  evidence	  of	  superinfection	  despite	  
extensive	  follow	  up	  (127,	  128).	  	  	  Moreover,	  behavioural	  changes	  following	  initial	  diagnosis	  can	  
result	  in	  lower	  risk	  behavior	  following	  infection	  (127,	  135).	  	  The	  reported	  incidences	  of	  
superinfection	  in	  these	  (and	  other)	  studies	  are	  also	  likely	  underestimates	  as	  fluctuating	  viral	  
populations	  can	  result	  in	  minority	  variants	  evading	  detection	  and	  recombination	  can	  result	  in	  
divergent	  viruses	  appearing	  as	  monophyletic.	  	  	  
Through	  in-­‐depth	  sequencing	  of	  dual	  infected	  participants,	  we	  have	  shown	  here	  that	  
recombination	  following	  dual	  infection	  can	  be	  extensive.	  While	  six	  participants	  could	  be	  
separated	  phylogenetically	  based	  on	  partial	  envelope	  sequences,	  in	  some	  cases	  DNA	  distances	  
were	  not	  significantly	  higher	  than	  those	  observed	  for	  multivariant	  infection.	  	  These	  data	  
highlight	  the	  fact	  that	  DNA	  distance	  measures	  and	  phylogenetic	  approaches	  that	  ignore	  
recombination	  lack	  sensitivity	  to	  detect	  cases	  of	  dual	  infection.	  	  Further,	  we	  show	  that	  
recombination	  can	  obscure	  the	  ability	  to	  detect	  superinfection	  as	  rapidly	  as	  seven	  weeks	  
following	  dual	  infection.	  	  With	  this	  in	  mind,	  we	  re-­‐analyzed	  sequences	  from	  a	  previous	  study	  
that	  found	  no	  evidence	  of	  superinfection	  in	  1072	  person	  years	  of	  follow	  up	  (128).	  	  Gag	  
sequences	  were	  publicly	  available	  from	  ten	  of	  the	  37	  participants	  with	  high	  diversity	  in	  
Protease	  and	  Reverse	  Transcriptase	  (greater	  than	  4.5%	  and	  3%	  respectively).	  	  In	  two	  out	  of	  
these	  ten	  pairs	  of	  gag	  sequences,	  we	  find	  significant	  evidence	  of	  recombination	  with	  an	  
unknown	  divergent	  variant	  (Supplementary	  Figure	  S2.1),	  suggestive	  of	  superinfection.	  	  Though	  
we	  cannot	  exclude	  a	  transmission	  chain	  (i.e.	  the	  sequences	  that	  phylogenetically	  separate	  the	  
two	  viruses	  are	  not	  epidemiologically	  unlinked),	  these	  results	  highlight	  that	  if	  recombination	  is	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not	  taken	  into	  account,	  it	  can	  obscure	  the	  identification	  of	  superinfection.	  	  Furthermore,	  while	  
we	  identified	  extensive	  recombination	  in	  envelope	  here,	  breakpoints	  within	  envelope	  (apart	  
from	  near	  the	  borders)	  occurs	  less	  frequently	  than	  elsewhere	  in	  the	  HIV-­‐1	  genome	  (149)	  
suggesting	  that	  recombination	  in	  other	  genes	  is	  likely	  to	  be	  even	  more	  pervasive.	  	  
As	  cases	  of	  superinfection	  are	  comparatively	  rare,	  simply	  comparing	  the	  incidence	  of	  
superinfection	  to	  the	  incidence	  of	  primary	  infection	  offers	  little	  statistical	  power	  to	  identify	  
protective	  effects.	  	  To	  illustrate	  this,	  we	  assumed	  the	  lower	  incidence	  of	  superinfection	  
compared	  to	  primary	  infection	  (5.4%/py	  vs	  7.2%/py)	  in	  the	  CAPRISA002	  cohort	  was	  solely	  due	  
to	  a	  hypothetical	  correlate	  of	  protection,	  and	  calculated	  the	  power	  an	  analysis	  based	  on	  21	  
participants	  screened	  here	  (three	  superinfections;	  18	  single	  infections)	  would	  have.	  	  While	  we	  
cannot	  know,	  a	  priori,	  the	  relationship	  between	  any	  potential	  correlate	  and	  the	  susceptibility	  to	  
superinfection,	  we	  calculated	  the	  statistical	  power	  under	  the	  most,	  and	  less	  favourable	  models.	  	  
A	  scenario	  in	  which	  a	  fraction	  of	  individuals	  are	  completely	  protected,	  and	  the	  rest	  have	  no	  
protection	  against	  superinfection	  would	  be	  the	  most	  favourable	  for	  statistical	  power	  of	  
detection	  (though	  it	  may	  represent	  a	  biologically	  unlikely	  scenario).	  	  Even	  under	  this	  model,	  if	  
we	  were	  able	  to	  accurately	  predict,	  and	  precisely	  measure	  the	  hypothetical	  correlate	  of	  
protection,	  we	  would	  have	  only	  ~	  6%	  power	  to	  detect	  this	  effect.	  	  In	  a	  perhaps	  more	  biologically	  
plausible	  (though	  still	  optimistic)	  model	  where	  protection	  correlates	  proportionally,	  the	  power	  
was	  essentially	  zero.	  	  Even	  assuming	  an	  incidence	  of	  superinfection	  half	  that	  of	  primary	  
infection	  (3.6%/py	  vs	  7.2%/py)	  due	  to	  a	  protective	  correlate,	  the	  entire	  CAPRISA	  002	  cohort	  
(n=62)	  meticulously	  screened	  over	  5	  years,	  would	  have	  only	  ~50%	  power	  to	  detect	  this	  effect.	  	  
These	  calculations	  bring	  to	  light	  the	  magnitude	  of	  the	  cohort	  that	  will	  likely	  be	  required	  to	  
detect	  a	  correlate	  of	  protection	  under	  the	  observation	  that	  (at	  best)	  only	  a	  fraction	  of	  infected	  
individuals	  are	  protected	  from	  superinfection.	  	  The	  only	  situation	  we	  can	  envisage	  in	  which	  an	  
association	  would	  be	  readily	  evident	  in	  these	  sample	  sizes	  is	  if	  the	  immune	  responses	  to	  HIV	  
infection	  did	  in	  fact	  provide	  substantial	  protection	  against	  superinfection,	  but	  that	  HIV+	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individuals	  are	  more	  likely	  to	  become	  superinfected	  than	  HIV-­‐	  individuals	  are	  to	  become	  
infected.	  	  	  	  	  	  
Consequently,	  any	  study	  that	  aims	  to	  identify	  correlates	  of	  protection	  by	  comparing	  the	  
immune	  responses	  in	  superinfected	  participants	  to	  singly	  infected	  controls	  needs	  to	  analyse	  a	  
large	  number	  of	  participants.	  	  Nevertheless,	  several	  studies	  have	  attempted	  to	  identify	  potential	  
correlates	  of	  protection	  in	  a	  handful	  of	  superinfected	  individuals	  by	  comparing	  specific	  
immunological	  markers	  (such	  as	  autologous	  and	  heterologous	  neutralizing	  antibodies,	  and	  non-­‐
neutralizing	  V1V2	  antibodies)	  in	  superinfected	  participants	  to	  those	  with	  similar	  risk	  factors,	  
but	  who	  did	  not	  become	  superinfected.	  	  Two	  studies	  observed	  that	  the	  superinfected	  
participants	  had	  weaker	  autologous	  and	  heterologous	  humoral	  responses	  than	  non-­‐
superinfected	  controls,	  suggesting	  a	  potential	  role	  for	  antibodies	  in	  lowering	  susceptibility	  to	  
superinfection	  (132,	  133).	  	  In	  contrast,	  however,	  Blish	  et	  al.	  (134)	  found	  that	  in	  6	  women,	  
superinfection	  occurred	  despite	  the	  presence	  of	  robust	  neutralizing	  antibody	  responses	  at	  the	  
time	  of	  superinfection.	  However,	  our	  calculations	  suggest	  that	  these	  studies	  had	  limited	  power	  
to	  detect	  correlates	  of	  protection.	  
In	  conclusion,	  we	  show	  a	  high	  frequency	  of	  dual	  infection	  and	  superinfection	  in	  women	  from	  
Kwa-­‐Zulu	  Natal,	  not	  markedly	  different	  from	  the	  incidence	  of	  primary	  infection	  in	  the	  cohort.	  	  
We	  found	  that	  superinfection	  was	  likely	  established	  by	  a	  single	  transmitted/founder	  (T/F)	  virus	  
in	  each	  case,	  and	  that	  this	  superinfecting	  virus	  had	  properties	  similar	  to	  those	  of	  a	  primary	  T/F	  
virus.	  	  	  Further,	  we	  show	  that	  recombination	  can	  occur	  rapidly	  following	  transmission,	  and	  can	  
confound	  the	  detection	  of	  dual	  infection	  if	  not	  taken	  into	  account	  appropriately.	  	  While	  
superinfection	  provides	  a	  useful	  model	  to	  address	  the	  correlates	  of	  protection,	  we	  also	  show	  
that	  only	  an	  analysis	  of	  a	  very	  large	  number	  of	  individuals	  will	  be	  sufficiently	  powered	  to	  detect	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CHAPTER	  3: The	  clinical	  causes	  and	  consequences	  of	  multiple	  HIV	  
infection	  
3.1	  Introduction	  
Identifying	  factors	  associated	  with	  mitigation	  of	  the	  genetic	  bottleneck	  and	  susceptibility	  to	  
HIV	  infection	  may	  provide	  targets	  for	  preventative	  measures	  that	  could	  slow	  the	  epidemic.	  
Observational	  studies	  have	  overwhelmingly	  suggested	  that	  sexually	  transmitted	  infections	  
(STIs)	  can	  enhance	  susceptibility	  to	  HIV	  infection	  through	  mucosal	  disruption,	  target	  cell	  
recruitment	  and	  activation,	  or	  an	  imbalance	  of	  the	  protective	  lactobacilli-­‐dominated	  flora	  
(reviewed	  in	  150,	  151).	  	  Control	  of	  STIs	  could	  therefore	  represent	  an	  effective	  strategy	  to	  reduce	  
HIV	  incidence.	  	  However,	  to	  date,	  only	  one	  of	  nine	  intervention	  trials	  has	  demonstrated	  an	  effect	  
of	  STI	  treatment	  on	  the	  incidence	  of	  HIV	  (152,	  reviewed	  in	  153).	  	  	  It	  is	  therefore	  important	  to	  
clarify	  the	  role	  of	  STIs	  in	  modulating	  the	  susceptibility	  to	  HIV	  infection.	  Several	  studies	  that	  
have	  adjusted	  for	  risk	  behavior,	  have	  suggested	  that	  non-­‐ulcerative	  STIs	  or	  bacterial	  vaginosis	  
(BV)	  can	  increase	  the	  susceptibility	  to	  HIV	  infection	  by	  2-­‐4	  fold,	  while	  genital	  ulcer	  diseases	  
(GUD)	  can	  increase	  HIV	  acquisition	  by	  2.2-­‐11.3	  fold	  (150,	  154,	  155).	  	  	  However,	  it	  is	  difficult	  to	  
fully	  delineate	  the	  role	  of	  the	  STI,	  as	  opposed	  to	  common	  risk	  factors	  (individuals	  who	  
undertake	  risky	  sexual	  activities	  are	  more	  likely	  to	  acquire	  both	  HIV	  and	  other	  STIs).	  	  	  
Individuals	  with	  a	  higher	  susceptibility	  to	  HIV	  infection	  may	  be	  expected	  to	  be	  more	  likely	  to	  
be	  infected	  with	  more	  than	  one	  virus,	  reflecting	  the	  “breakdown”	  in	  the	  transmission	  barrier.	  	  
The	  multiplicity	  of	  infection	  in	  69	  participants	  (including	  26	  from	  the	  CAPRISA	  002	  cohort)	  has	  
also	  previously	  been	  shown	  not	  to	  follow	  a	  Poisson	  distribution	  (11),	  indicating	  that	  
multivariant	  infections	  likely	  do	  not	  represent	  multiple	  independent	  transmission	  events.	  	  This	  
would	  be	  consistent	  with	  the	  presence	  of	  factors	  in	  the	  recipient	  that	  influence	  the	  risk	  of	  
acquiring	  multiple	  viruses	  (though	  this	  could	  also	  result	  from	  other	  scenarios,	  including	  
infections	  by	  cell-­‐associated	  viruses).	  	  Indeed,	  the	  use	  of	  hormonal	  contraception	  has	  been	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associated	  with	  both	  a	  higher	  risk	  of	  infection	  (156),	  and	  with	  a	  more	  diverse	  viral	  population	  
after	  infection	  in	  a	  cohort	  of	  Kenyan	  female	  sex-­‐workers	  (157)	  .	  	  Sagar	  et	  al.	  further	  found	  that	  
the	  presence	  of	  STIs	  was	  significantly	  associated	  with	  a	  heterogenous	  viral	  population	  in	  
primary	  infection	  (158).	  	  However,	  the	  heteroduplex	  mobility	  assay	  used	  to	  characterize	  the	  
diversity	  of	  the	  viral	  population	  in	  primary	  infection	  would	  be	  insensitive	  to	  detecting	  infection	  
with	  multiple	  closely	  related	  viruses.	  	  In	  a	  subsequent	  study	  that	  used	  sequencing	  methods	  to	  
characterize	  the	  multiplicity	  of	  infection,	  genital	  tract	  inflammation	  or	  ulceration	  was	  also	  
associated	  with	  the	  mitigation	  of	  the	  genetic	  bottleneck	  at	  transmission	  (159).	  	  However,	  these	  
analyses	  were	  based	  on	  only	  five	  cases	  of	  multivariant	  infection	  and	  therefore	  only	  very	  strong	  
effects	  could	  have	  been	  identified.	  	  Furthermore,	  only	  symptomatic	  criteria	  were	  identified	  in	  
these	  patients,	  and	  specific	  STIs	  were	  not	  diagnosed	  confounding	  the	  results	  (155).	  	  	  
It	  is	  also	  potentially	  important	  to	  identify	  the	  consequences	  of	  infection	  with	  multiple	  
divergent	  HIV	  variants	  or	  strains,	  which	  could	  potentially	  promote	  viral	  diversification	  and	  
consequently	  accelerate	  the	  evolution	  of	  immune	  escape,	  fitness	  enhancements,	  and	  clinical	  
progression.	  	  An	  early	  study	  of	  five	  dual	  infected	  participants	  revealed	  that	  all	  progressed	  to	  
AIDS	  or	  died	  within	  2.4	  years	  following	  initial	  infection,	  compared	  to	  monoinfected	  individuals	  
who	  typically	  take	  more	  than	  eight	  years	  to	  progress	  to	  AIDS	  (130).	  	  Similarly,	  in	  a	  cohort	  from	  
South	  Africa,	  dual	  infection	  was	  associated	  with	  higher	  viral	  loads	  (131).	  	  Elite	  controllers	  were	  
also	  reported	  to	  have	  lost	  control	  of	  viral	  load	  following	  superinfection	  (160,	  161).	  	  On	  the	  other	  
hand,	  in	  a	  cohort	  of	  Kenyan	  women,	  superinfected	  participants	  had	  significantly	  lower	  viral	  
loads	  than	  matched	  monoinfected	  controls	  (162).	  	  Superinfections	  have	  also	  been	  identified	  in	  
long-­‐term	  non-­‐progressors	  (160,	  163),	  and	  superinfection	  of	  two	  individuals	  who	  were	  
controlling	  their	  viral	  load	  did	  not	  accelerate	  disease	  progression	  (164).	  	  However,	  these	  
reports	  were	  largely	  anecdotal.	  	  	  More	  recently,	  Pacold	  et	  al.	  systematically	  screened	  an	  MSM	  
cohort	  for	  dual	  infection	  using	  deep	  sequencing,	  and	  identified	  11	  cases	  (165).	  	  While	  in	  this	  
cohort,	  neither	  coinfected	  nor	  superinfected	  individuals	  had	  a	  significantly	  faster	  CD4	  decline	  
than	  monoinfected	  controls,	  the	  superinfected	  group	  had	  a	  significantly	  faster	  viral	  load	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increase	  over	  time	  (165).	  	  However,	  while	  host	  HLA	  genotypes	  are	  strongly	  associated	  with	  
disease	  progression	  (reviewed	  in	  22),	  this	  study	  did	  not	  control	  for	  host	  HLA	  alleles.	  	  A	  recent	  
study	  of	  37,	  well	  characterized,	  subtype	  B	  infected	  men-­‐who-­‐have-­‐sex-­‐with-­‐men	  (MSM)	  from	  
Amsterdam	  (10	  dual	  infected,	  and	  27	  monoinfected)	  controlled	  for	  HLA	  B	  alleles	  known	  to	  be	  
associated	  with	  rapid	  progression	  (based	  on	  22).	  In	  this	  study,	  dual	  infection	  was	  the	  factor	  
most	  significantly	  associated	  with	  disease	  progression	  (as	  defined	  by	  rate	  of	  CD4+	  T	  cell	  decline	  
after	  the	  mean	  time	  to	  superinfection)	  (166).	  However,	  the	  time	  from	  initial	  infection	  to	  CD4	  
counts	  <350	  cells/µl	  was	  not	  significantly	  different	  in	  dual	  infected	  participants	  compared	  to	  
monoinfected	  controls.	  	  Furthermore,	  the	  analysis	  was	  confounded	  as	  although	  all	  monoinfected	  
participants	  were	  infected	  with	  subtype	  B,	  four	  of	  the	  six	  superinfections	  in	  this	  cohort	  occurred	  
with	  a	  non-­‐B	  HIV	  subtype.	  	  	  
Recently,	  the	  potential	  of	  HIV	  superinfection	  to	  accelerate	  disease	  progression	  is	  of	  renewed	  
interest	  as	  organ	  transplants	  from	  HIV-­‐positive	  donors	  to	  HIV-­‐positive	  recipients	  are	  being	  
considered.	  	  HIV	  associated	  nephropathy	  is	  common	  and	  consequently	  many	  HIV	  positive	  
patients	  require	  renal	  transplantation.	  	  In	  resource-­‐limited	  settings,	  access	  to	  dialysis	  is	  
severely	  restricted	  and	  HIV	  positive	  patients	  (like	  others	  with	  co-­‐morbidity)	  are	  frequently	  
denied	  treatment	  (167).	  There	  is	  frequently	  a	  shortage	  of	  donor	  organs	  and	  consequently	  many	  
patients	  die	  while	  waiting	  for	  transplantation.	  	  In	  developing	  countries	  with	  a	  high	  incidence	  of	  
HIV,	  such	  as	  in	  South	  Africa,	  transplants	  from	  HIV	  positive	  donors	  to	  HIV	  positive	  recipients	  
have	  the	  potential	  to	  alleviate	  the	  situation	  for	  both	  HIV-­‐positive	  and	  –negative	  patients.	  	  
Several	  such	  renal	  transplants	  have	  been	  performed	  successfully	  in	  South	  Africa	  (167)	  ,	  and	  
recently	  there	  has	  been	  a	  petition	  by	  American	  doctors	  and	  scientists	  to	  repeal	  a	  federal	  ban	  on	  
the	  transplantation	  of	  organs	  from	  HIV+	  patients	  in	  the	  USA	  (168).	  	  However,	  organ	  donations	  
from	  HIV-­‐positive	  patients	  have	  the	  inherent	  risk	  of	  superinfecting	  the	  recipient	  and	  
accordingly,	  the	  clinical	  consequences	  of	  HIV	  dual	  infection	  need	  to	  be	  established.	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To	  better	  assess	  the	  impact	  of	  dual	  infection	  on	  disease	  progression,	  we	  utilized	  a	  well-­‐
characterized	  cohort	  of	  62	  individuals	  from	  South	  Africa	  (CAPRISA	  002).	  	  The	  cohort	  is	  
comprised	  only	  of	  women,	  and	  is	  located	  in	  an	  area	  where	  subtype	  C	  is	  almost	  exclusively	  
circulating,	  allowing	  us	  to	  control	  for	  both	  gender	  and	  infecting	  subtype.	  	  Participants	  were	  
screened	  prospectively	  for	  HIV	  infection,	  and	  consequently	  the	  timing	  of	  initial	  infection	  in	  each	  
case	  is	  known.	  	  Furthermore,	  HLA	  genotyping	  has	  been	  performed	  on	  all	  participants.	  	  This	  
study	  expands	  on	  previous	  work	  that	  screened	  39	  participants	  from	  the	  cohort	  using	  an	  
envelope	  C2C3	  heteroduplex	  mobility	  assay	  (HMA)	  to	  determine	  multiplicity	  of	  infection	  (145).	  	  
In	  this	  study	  Woodman	  et	  al.,	  detected	  four	  cases	  of	  dual	  infection,	  and	  found	  no	  significant	  
difference	  in	  their	  CD4+	  T	  cell	  counts	  or	  viral	  loads	  at	  12	  months	  post	  infection	  compared	  to	  30	  
singly	  infected	  participants.	  	  Woodman	  et	  al.	  did	  find	  an	  association	  between	  the	  presence	  of	  
any	  STI	  and	  the	  infection	  with	  heterogenous	  viruses,	  though	  this	  was	  not	  statistically	  significant.	  	  
Here,	  with	  more	  intensive	  sequencing	  efforts,	  we	  have	  identified	  an	  additional	  seven	  cases	  of	  
dual	  infection	  (see	  Chapter	  2),	  and	  revisit	  the	  impact	  of	  dual	  infection	  on	  disease	  progression,	  
controlling	  for	  potentially	  confounding	  variables.	  	  With	  this	  more	  sensitive	  sequencing	  
approach,	  together	  with	  more	  sophisticated	  statistical	  methods,	  we	  also	  address	  whether	  the	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3.2	  Methods:	  
3.2.1	  Viral	  load	  and	  CD4+	  T	  cell	  counts	  
Viral	  loads	  and	  CD4	  T+	  cell	  counts	  for	  the	  62	  participants	  were	  provided	  by	  the	  CAPRISA	  
002	  study	  team.	  	  Viral	  load	  at	  each	  visit	  was	  determined	  using	  the	  COBAS	  Amplicor	  HIV-­‐1	  
Monitor	  Test	  v1.5	  (Roche	  Diagnostic	  Corporation,	  Indianapolis,	  IN	  Diagnostics,	  Rotkreuz,	  
Switzerland)	  and	  CD4+	  T	  cell	  counts	  were	  determined	  using	  flow	  cytometry	  (FACScalibur,	  BD	  
Biosciences,	  Mountain	  View,	  CA).	  
As	  viral	  load	  can	  fluctuate	  significantly	  over	  time,	  even	  at	  set	  point,	  the	  area	  under	  the	  log	  
transformed	  viral	  load	  curve,	  per	  unit	  time,	  from	  three	  months	  to	  one	  year	  post	  infection	  was	  
used	  as	  an	  estimate	  of	  viral	  load	  set	  point.	  	  All	  participants	  except	  for	  one	  (CAP63)	  were	  
antiretroviral	  naïve	  over	  this	  period.	  	  For	  CAP63,	  area	  under	  the	  log	  viral	  load	  curve	  per	  unit	  
time	  was	  calculated	  from	  three	  months	  post	  infection	  to	  the	  initiation	  of	  treatment	  
(approximately	  nine	  months	  post	  infection).	  	  	  
Infection	  stage	  was	  categorized	  according	  to	  the	  criteria	  of	  Fiebig	  et	  al.	  (12).	  	  Individuals	  
who	  were	  viral	  RNA	  positive	  but	  EIA	  antibody	  negative	  were	  classified	  as	  being	  in	  stage	  I/II.	  	  A	  
positive	  EIA	  antibody	  test	  with	  a	  negative	  Western	  blot	  (GS	  HIV-­‐1	  Western	  blot	  analysis	  kit,	  Bio-­‐
Rad,	  WA)	  was	  classified	  as	  stage	  III.	  Those	  with	  an	  indeterminate	  Western	  blot	  result	  were	  
classified	  as	  in	  stage	  IV.	  	  A	  positive	  Western	  blot	  positive	  but	  without	  reactivity	  to	  the	  p31	  
Integrase	  band	  was	  classified	  as	  stage	  V,	  while	  a	  Western	  blot	  positive	  including	  a	  p31	  band	  was	  
classified	  as	  stage	  VI.	  	  	  
3.2.2	   STI	  diagnosis	  
Participants	  were	  screened	  upon	  enrollment	  by	  the	  CAPRISA	  002	  team	  for	  the	  presence	  of	  
sexually	  transmitted	  infections	  (STIs)	  in	  vulvovaginal	  swab	  samples	  as	  previously	  described	  
(155).	  	  Briefly,	  Chlamydia	  trachomatis,	  Neisseria	  gonorrhoeae,	  Trichomonas	  vaginalis,	  
Mycoplasma	  genitalium,	  Haemophilus	  ducreyi,	  and	  herpes	  simplex	  virus	  type	  2	  (HSV-­‐2)	  were	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identified	  by	  PCR.	  	  Genital	  herpes	  diagnosis	  was	  confirmed	  by	  enzyme	  immunoassay	  
(HerpeSelect-­‐1	  and	  HerpeSelect-­‐2,	  Focus	  Technologies,	  Cypress	  Hill,	  CA).	  	  Syphilis	  screening	  
was	  done	  using	  the	  Becton	  Dickinson	  Macro-­‐Vue	  RPR	  (rapid	  plasma	  reagin	  [RPR])	  card	  test,	  and	  
positive	  reactions	  were	  confirmed	  by	  the	  T.	  pallidum	  hemagglutination	  test	  (Omega	  ImmuTrep	  
TPHA	  test).	  	  Agents	  of	  bacterial	  vaginosis	  (BV)	  were	  assessed	  by	  Gram	  staining,	  using	  Nugents	  
criteria	  (169).	  
3.2.3	   HLA	  genotyping	  
HLA	  genotypes	  of	  participants	  were	  kindly	  provided	  by	  C.	  Gray	  (UCT,	  South	  Africa).	  	  Four	  
digit	  HLA	  class	  I	  genotyping	  was	  performed	  as	  described	  previously	  (170).	  	  Briefly,	  HLA-­‐A,	  -­‐B	  
and	  -­‐C	  typing	  was	  performed	  by	  sequencing	  of	  exons	  2,	  3	  and	  4	  using	  AlleleSeqr	  kits	  (Atria	  
Genetics/Abbott	  Laboratories,	  Abbott	  Park,	  IL)	  in	  DNA	  extracted	  from	  either	  PBMCs	  or	  
granulocytes	  using	  the	  Pel-­‐Freez	  DNA	  Isolation	  kit	  (Pel-­‐Freez	  Biologicals,	  Inc.,	  Rogers,	  AR).	  	  HLA	  
types	  were	  inferred	  using	  Assign-­‐SBT	  3.5	  (Conexio	  Genomics).	  Any	  ambiguities	  resulting	  from	  
either	  polymorphisms	  outside	  the	  sequenced	  exons	  or	  identical	  heterozygote	  combinations	  
were	  resolved	  using	  sequence-­‐specific	  primers.	  
3.2.4	   Statistical	  analysis	  
Times	  for	  CD4	  counts	  to	  fall	  below	  350	  cells/µl	  for	  two	  consecutive	  visits	  were	  compared	  in	  
a	  survival	  analysis	  using	  Kaplan-­‐Meir	  plots,	  implemented	  in	  Prism	  5	  (Graphpad,	  San	  Diego,	  CA,	  
USA).	  Participants	  were	  right	  censored	  when	  lost	  to	  follow	  up,	  or	  initiated	  onto	  antiretroviral	  
therapy.	  
CD4+	  T-­‐cell	  decline	  was	  compared	  using	  a	  linear	  mixed	  effects	  model,	  blocking	  by	  
participant,	  adjusting	  for	  HLA	  genotypes	  associated	  with	  slow	  (HLA-­‐B*5703,	  HLA-­‐B*5801)	  or	  
rapid	  progression	  (HLA-­‐B*18,	  HLA-­‐B*5802,	  and	  HLA	  Cw0602)	  (as	  defined	  in	  171).	  	  
For	  the	  Chow	  tests,	  data	  was	  partitioned	  into	  (i)	  prior	  to	  the	  lower	  bound	  of	  superinfection	  
and	  (ii)	  post	  the	  upper	  bound	  of	  superinfection	  for	  each	  of	  the	  three	  superinfected	  participants.	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Chow	  tests	  were	  performed	  on	  17	  singly	  infected	  participants	  using	  the	  same	  three	  partitions	  to	  
establish	  the	  specificity	  of	  the	  test.	  
Multivariate	  analyses	  of	  viral	  load	  and	  CD4	  decline,	  as	  well	  as	  Chow	  tests	  were	  implemented	  
in	  the	  R	  statistical	  computing	  environment	  (172),	  utilizing	  the	  “nlme”	  (linear	  mixed	  effects	  
models)	  and	  “gap”	  (Chow	  test)	  packages.	  	  Pre-­‐infection	  CD4+	  T	  cell	  counts	  were	  compared	  using	  
an	  unpaired	  T	  test	  in	  Prism	  5	  (Graphpad,	  San	  Diego,	  CA,	  USA).	  	  The	  association	  between	  STIs	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3.3	  Results	  
The	  CAPRISA	  002	  cohort	  enrolled	  a	  total	  of	  62	  individuals,	  of	  which	  three	  (CAP259,	  CAP260,	  
and	  CAP285)	  were	  lost	  to	  follow	  up	  prior	  to	  one	  year	  post	  infection	  and	  were	  excluded	  from	  our	  
analysis.	  	  One	  individual	  (CAP63)	  was	  referred	  to	  treatment	  at	  approximately	  nine	  months	  post	  
infection,	  according	  to	  the	  national	  guidelines	  at	  the	  time	  (CD4	  count	  <	  200	  cells/µl	  or	  AIDS-­‐
related	  illness).	  	  The	  median	  follow	  up	  time	  was	  1912	  days	  (range:	  259-­‐2934	  days).	  	  
In	  this	  chapter	  we	  investigated	  the	  factors	  that	  may	  enhance	  susceptibility	  to	  multiple	  
infection,	  and	  the	  clinical	  consequences	  of	  dual	  infection.	  	  Defining	  the	  multiplicity	  of	  infection	  is	  
described	  in	  Chapter	  2.	  	  Briefly,	  HIV-­‐1	  “monoinfection”	  is	  defined	  here	  as	  infection	  by	  a	  single	  
donor	  with	  either	  one	  variant	  (single)	  or	  multiple	  closely	  related	  variants	  (quasispecies)	  
(multivariant),	  together	  with	  at	  least	  two	  years	  of	  follow	  up	  with	  no	  evidence	  of	  superinfection.	  	  
HIV-­‐1	  dual	  infection	  here	  refers	  to	  individuals	  who	  were	  infected	  with	  highly	  diverse	  viruses	  
that	  could	  have	  originated	  from	  two	  independent	  donors.	  	  	  Dual	  infection	  was	  classified	  in	  
individuals	  who	  were	  either	  co-­‐infected	  (infected	  with	  >1	  virus	  prior	  to	  seroconversion)	  or	  
superinfected	  (second	  infection	  occurred	  after	  seroconversion	  and	  the	  onset	  of	  the	  immune	  
response)	  (Table	  2.1).	  	  Seven	  participants	  were	  identified	  with	  multiple	  variant	  infection,	  of	  
whom	  three	  had	  sufficient	  longitudinal	  follow	  up	  to	  classify	  as	  monoinfected.	  	  Six	  participants	  
were	  classified	  as	  co-­‐infected,	  three	  as	  superinfected,	  and	  one	  was	  dual	  infected	  with	  unknown	  
timing	  (Table	  2.1).	  All	  infections	  (and	  dual	  infections)	  occurred	  with	  HIV-­‐1	  subtype	  C.	  	  Viral	  
loads	  and	  CD4+	  T	  cell	  counts	  for	  all	  dual	  infected	  participants	  described	  here	  are	  shown	  in	  
Supplementary	  Figure	  S3.1.	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3.3.1	  Susceptibility	  to	  infection	  with	  multiple	  viruses	  
Understanding	  the	  role	  of	  target	  cell	  availability,	  and	  the	  integrity	  of	  the	  mucosal	  barrier	  on	  
the	  risk	  of	  HIV	  infection	  has	  important	  epidemiological	  implications.	  	  Higher	  numbers	  of	  target	  
cells	  may	  represent	  one	  factor	  correlated	  with	  a	  higher	  risk	  of	  infection	  with	  multiple	  viruses.	  	  	  
Using	  peripheral	  CD4+	  T	  cell	  count	  as	  a	  proxy	  of	  target	  cells	  at	  the	  mucosa	  we	  compared	  CD4+	  T	  
cell	  counts	  at	  the	  last	  visit	  prior	  to	  HIV	  infection	  between	  singly	  infected	  and	  multiply	  (co-­‐
infected	  and	  multivariant	  transmissions)	  infected	  participants.	  	  Of	  the	  59	  participants	  analyzed	  
here,	  pre-­‐infection	  CD4+	  T-­‐cell	  counts	  were	  measured	  for	  27	  (12	  singly	  infected,	  three	  infected	  
with	  more	  than	  one	  closely	  related	  variants	  (multivariant),	  four	  coinfected,	  one	  superinfected,	  
and	  seven	  of	  undetermined	  multiplicity	  of	  infection).	  	  We	  found	  no	  significant	  difference	  in	  the	  
pre-­‐infection	  CD4+	  T	  cell	  counts	  between	  monoinfected	  (mean=1042;	  range:	  424-­‐2231)	  and	  
multiply	  infected	  (mean=1017;	  range:	  756-­‐1395)	  participants	  (p=0.9068;	  figure	  3.1)	  suggesting	  
that	  target	  cell	  availability	  may	  not	  correlate	  with	  higher	  risk	  of	  infection	  with	  multiple	  viruses.	  	  
	  
	  




This	  analysis	  investigated	  target	  cells	  in	  the	  periphery	  and	  does	  not	  account	  for	  local	  target	  cell	  
availability	  in	  the	  genital	  mucosa,	  which	  is	  likely	  influenced	  by	  local	  factors,	  including	  the	  
presence	  of	  STIs	  and	  inflammation.	  	  Participants	  in	  the	  cohort	  were	  screened	  for	  the	  presence	  of	  
STIs	  (Trichomonis	  vaginalis,	  Neisseria	  gonorrhoea,	  Chlamydia	  trachomatis,	  Mycoplasma	  
genitalium,	  Herpes	  simplex	  virus	  type	  2	  (HSV2),	  Treponema	  pallidum	  (Syphilis)),	  or	  bacterial	  
vaginosis	  (BV)	  upon	  enrollment	  into	  the	  cohort.	  	  To	  evaluate	  whether	  BV	  or	  particular	  STIs,	  or	  a	  
combination	  thereof,	  was	  associated	  with	  infection	  by	  multiple	  HIV	  viruses,	  we	  performed	  a	  
logistic	  regression.	  	  Of	  all	  the	  participants,	  only	  four	  harboured	  no	  STIs	  upon	  enrollment.	  	  BV	  
and	  Trichomonas	  vaginalis	  were	  highly	  prevalent,	  and	  were	  diagnosed	  in	  30/40	  (75%)	  and	  

































Figure	  3.1	  |	  Comparison	  of	  the	  pre-­‐infection	  plasma	  CD4+	  T	  cell	  counts	  between	  
participants	  where	  infection	  was	  founded	  by	  a	  single	  virus	  (Single	  infection)	  and	  those	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HIV	  infection	  could	  be	  evaluated	  due	  to	  their	  low	  frequency.	  	  Of	  all	  the	  other	  STIs	  and	  BV,	  only	  N.	  
gonorrhoea	  was	  strongly	  associated	  with	  multiple	  HIV	  infection	  (Table	  3.2).	  	  	  Participants	  with	  
Gonorrhoea	  were	  ~11.2	  times	  more	  likely	  to	  be	  multiply	  infected	  with	  HIV	  (p=0.0566).	  
	  
Table	  3.1	  |	  Multivariate	  analysis	  testing	  the	  association	  between	  sexually	  transmitted	  infections	  or	  bacterial	  
vaginosis,	  and	  multiple	  HIV	  infection	  

















0.64	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1.30	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11.18	   0.0566	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   0.2236	  






0	   0.9951	  






	   NA	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3.3.2	  Dual	  infection	  was	  not	  associated	  with	  accelerated	  disease	  progression	  
HIV-­‐1	  dual	  infection	  has	  previously	  been	  associated	  with	  accelerated	  progression	  to	  AIDS	  
(130,	  131).	  	  To	  determine	  whether	  infection	  with	  two	  divergent	  viruses	  (i.e.	  dual	  infection	  
encompassing	  both	  co-­‐	  and	  superinfection)	  was	  associated	  with	  an	  accelerated	  loss	  of	  CD4+	  T	  
cells	  over	  time	  in	  the	  CAPRISA	  002	  cohort,	  we	  performed	  a	  Kaplan-­‐Meier	  survival	  analysis.	  	  We	  
found	  that	  no	  significant	  difference	  existed	  in	  the	  number	  of	  days	  for	  CD4+	  T	  cell	  counts	  to	  fall	  
below	  350	  cells/µl	  between	  dual	  infected	  (N=11;	  median	  survival	  >	  2226	  days)	  and	  singly	  
infected	  participants	  (N=18	  median	  survival	  =	  1582	  days)	  (p=0.6227;	  Figure	  3.2).	  	  	  
As	  there	  may	  be	  a	  systematic	  bias	  in	  selecting	  the	  monoinfected	  controls	  based	  on	  the	  
requirement	  for	  extensive	  sequencing	  data,	  we	  also	  compared	  the	  disease	  progression	  between	  
the	  identified	  dually	  infected	  participants,	  and	  the	  rest	  of	  the	  cohort.	  	  However,	  there	  was	  still	  
no	  significant	  difference	  in	  the	  rate	  of	  CD4+	  T	  cell	  decline	  (p=0.4030;	  Supplementary	  Figure	  
S3.2).	  	  Of	  the	  20	  rapid	  progressors	  in	  the	  cohort	  (ie	  CD4	  counts	  <350	  cells/µl	  within	  the	  first	  
year	  of	  infection),	  only	  two	  (10%)	  were	  dual	  infected	  (both	  were	  coinfected);	  lower	  than	  the	  


































































































Figure	  3.3	  |	  A.	  	  Average	  rate	  of	  CD4	  decline	  in	  singly	  and	  dual	  infected	  participants.	  	  B.	  Kaplan-­‐Meier	  
survival	  plot	  showing	  time	  for	  CD4+	  T	  cell	  counts	  to	  fall	  below	  350	  cells/μl	  in	  singly	  infected	  (N=18)	  and	  
dual	  infected	  (N=11)	  participants.	  
Figure	  3.2	  |	  Multiplicity	  of	  infection	  and	  cumulative	  viral	  load.	  	  In	  the	  monoinfected	  group.	  
single	  infections	  are	  shown	  in	  light	  blue,	  while	  multivariant	  transmissions	  are	  show	  in	  navy.	  	  
Within	  the	  dual	  infected	  group,	  superinfected	  participants	  are	  highlighted	  in	  red.	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Viral	  load	  at	  set	  point	  has	  previously	  been	  demonstrated	  to	  correlate	  strongly	  with	  the	  rate	  
of	  disease	  progression	  (16).	  	  We	  therefore	  compared	  set	  point	  viral	  loads	  between	  dual	  infected	  
participants	  and	  the	  rest	  of	  the	  cohort.	  	  Using	  the	  area	  under	  the	  log	  viral	  load	  curve	  per	  unit	  
time	  from	  three	  to	  12	  months	  post	  infection	  as	  a	  representation	  of	  set	  point	  viral	  load,	  we	  found	  
no	  significant	  association	  between	  dual	  infection	  and	  a	  higher	  set	  point	  viral	  load	  (Figure	  3.3;	  
p=0.8008).	  	  	  
As	  host	  HLA	  alleles	  have	  previously	  been	  demonstrated	  to	  be	  strongly	  associated	  with	  viral	  
load	  and	  CD4+	  T	  cell	  counts,	  we	  performed	  a	  multivariate	  analysis.	  While	  the	  number	  of	  
possible	  genotypes	  precludes	  the	  ability	  to	  control	  for	  these	  individually,	  we	  adjusted	  for	  the	  
presence	  of	  HLA	  alleles	  previously	  associated	  with	  slow	  or	  rapid	  progression	  (171),	  in	  a	  linear	  
mixed	  effects	  model.	  Even	  after	  adjusting	  for	  HLA	  alleles,	  neither	  the	  rate	  of	  CD4+	  T	  cell	  decline	  
(p=0.8642),	  nor	  the	  area	  under	  the	  viral	  load	  curve	  (p=	  0.2028)	  was	  significantly	  associated	  
with	  dual	  infection	  (Tables	  3.2	  and	  3.3).	  	  	  
As	  superinfected	  participants	  are	  essentially	  infected	  with	  a	  single	  variant	  for	  an	  initial	  
follow	  up	  period,	  we	  also	  compared	  the	  set	  point	  viral	  loads	  in	  the	  cohort	  to	  the	  seven	  co-­‐
infected	  participants	  only.	  	  However,	  the	  difference	  in	  the	  viral	  loads	  was	  still	  not	  significant	  
(p=0.447).	  	  Viral	  loads	  were	  also	  not	  significantly	  different	  between	  co-­‐infected	  participants	  and	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Table	  3.2	  |	  Results	  of	  a	  multivariate	  model	  testing	  the	  association	  between	  multiplicity	  of	  infection	  and	  viral	  
load,	  taking	  HLA	  alleles	  associated	  with	  slow	  and	  rapid	  progression	  into	  account.	  
	   N	   	   P	   P(multivariate)	  
HLA(Slow)	  a	   7	   	   0.496	   0.4662	  
HLA(rapid)b	   21	   	   0.579	   0.6278	  
Dual	  infection	   11	   	   0.344	   0.2028	  
Coinfection	   7	   	   0.447	   0.4308	  
Superinfection	   3	   	   0.828	   0.9419	  
	  
Table	  3.3	  |	  Results	  of	  a	  multivariate	  model	  testing	  the	  association	  between	  multiplicity	  of	  infection	  and	  CD4+	  
T	  cell	  counts,	  taking	  HLA	  alleles	  associated	  with	  slow	  and	  rapid	  progression	  into	  account.	  
	   N	   	   P	   P(multivariate)	  
HLA(Slow)	  a	   7	   	   0.2117	   0.6529	  
HLA(rapid)	  b	   21	   	   0.0714	   0.0761	  
Dual	  infection	   11	   	   0.8648	   0.8441	  
Coinfection	   7	   	   0.7580	   0.8397	  
Superinfection	   3	   	   0.7080	   0.7213	  
a	  HLA-­‐B*5703,	  HLA-­‐B*5801	  
b	  HLA-­‐B*18,	  HLA-­‐B*5802,	  and	  HLA	  Cw0602	  
	  
To	  determine	  whether	  superinfection	  resulted	  in	  accelerated	  disease	  progression	  within	  
participants,	  we	  used	  a	  Chow	  Test	  (173)	  to	  establish	  whether	  superinfection	  was	  associated	  
with	  a	  change	  in	  the	  viral	  load	  and	  CD4+	  T	  cell	  count	  trajectories.	  The	  Chow	  test	  partitions	  the	  
data	  prior	  to,	  and	  post	  superinfection,	  and	  tests	  whether	  the	  coefficients	  of	  the	  two	  regression	  
lines	  are	  the	  same.	  	  This	  approach	  found	  no	  significant	  change	  in	  the	  CD4+	  T	  cell	  count	  
trajectories	  following	  superinfection	  in	  CAP237	  and	  CAP256	  (p=0.311,	  0.49,	  respectively)	  but	  
did	  find	  evidence	  of	  an	  accelerated	  CD4	  decline	  in	  CAP281	  (p=9.07x10-­‐6)	  (Table	  3.4).	  	  However,	  
there	  was	  evidence	  of	  a	  structural	  change	  in	  viral	  load	  trajectory	  following	  superinfection	  in	  all	  
three	  participants	  (p	  =	  0.043,	  0.01,	  2.99x10-­‐7,	  for	  CAP237,	  CAP256	  and	  CAP28,1	  respectively)	  
(Table	  3.4).	  	  Comparing	  the	  slopes	  of	  the	  curves	  prior	  to	  and	  post	  superinfection	  revealed	  that	  in	  
two	  participants	  (CAP237	  and	  CAP281),	  there	  was	  a	  significantly	  greater	  viral	  load	  slope	  after	  
superinfection	  than	  before	  (Figure	  3.4A	  and	  C).	  	  However,	  for	  CAP256,	  the	  slope	  after	  
superinfection	  was	  significantly	  less	  (Figure	  3.4B).	  	  Furthermore,	  this	  analysis	  was	  likely	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confounded	  by	  the	  fact	  that	  superinfection	  in	  two	  participants	  occurred	  early	  (approximately	  
nine	  and	  13	  weeks	  post	  infection	  respectively),	  prior	  to	  viral	  load	  reaching	  an	  equilibrium	  set	  
point.	  	  Therefore,	  as	  a	  control,	  we	  used	  the	  Chow	  Test	  on	  all	  of	  the	  singly	  infected	  participants	  
using	  the	  same	  three	  partitions	  on	  viral	  load.	  	  There	  was	  significant	  evidence	  of	  a	  change	  in	  viral	  
load	  trajectory,	  according	  to	  the	  Chow	  test,	  for	  3/11	  (27.27%)	  and	  9/18	  (50%)	  of	  singly	  
infected	  participants	  at	  nine	  and	  13	  wpi,	  respectively	  (for	  seven	  participants,	  HIV	  infection	  was	  
likely	  only	  detected	  after	  nine	  wpi	  and	  therefore	  the	  denominator	  for	  the	  first	  partition	  is	  11).	  	  
There	  was	  also	  significant	  evidence	  for	  a	  structural	  change	  in	  viral	  load	  dynamics	  in	  18/18	  
(100%)	  participants	  at	  40	  wpi,	  in	  the	  absence	  of	  any	  evidence	  of	  superinfection.	  This	  illustrates	  
that	  the	  Chow	  test	  has	  a	  low	  specificity	  to	  detect	  alterations	  in	  disease	  progression,	  despite	  
being	  previously	  used	  for	  this	  purpose	  (165).	  
Taken	  together,	  these	  results	  suggest	  that	  dual	  infection	  did	  not	  significantly	  accelerate	  
disease	  progression	  in	  the	  11	  participants	  described	  here.	  	  However,	  the	  small	  sample	  size	  here	  
















A.	  	  	  	  CAP237	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  B.	  	  	  	  CAP256	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  C.	  	  	  	  CAP281	  
	  
	  
Table	  3.4	  |	  Results	  of	  a	  Chow	  test	  comparing	  linear	  regressions	  of	  viral	  load	  and	  CD4	  counts	  prior	  to	  and	  
following	  superinfection	  in	  three	  participants.	  
	   	   SI	  window	   P(CD4	  count)	   P(viral	  load)	  
CAP237	   	   09	  -­‐	  11	  wpi	   0.311	   0.0430	  
CAP256	   	   11	  -­‐	  15	  wpi	   0.49	   0.0138	  









































































































































Figure	  3.4	  |	  Viral	  load	  trajectories	  prior	  to-­‐	  and	  post-­‐superinfection	  in	  CAP237	  (A),	  CAP256	  (B),	  and	  CAP281	  (C)	  
are	  shown	  in	  blue.	  The	  overall	  trend	  in	  viral	  load	  for	  each	  participant	  is	  fitted	  with	  a	  dashed	  red	  line.	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3.4	  Discussion	  
The	  susceptibility	  to	  infection	  with	  multiple	  variants	  may	  be	  indicative	  of	  a	  higher	  
vulnerability	  to	  infection.	  	  Here	  we	  assessed	  the	  relationship	  of	  multiple	  HIV	  infection	  with	  the	  
presence	  of	  STIs,	  and	  showed	  that	  participants	  with	  Gonorrhoea	  were	  ~11	  times	  more	  likely	  to	  
be	  infected	  with	  multiple	  variants	  than	  singly	  infected	  controls,	  though	  this	  did	  not	  reach	  
statistical	  significance	  (p=0.0566).	  	  The	  association	  between	  Gonnorhoea	  and	  multiple	  HIV	  
transmission	  is	  consistent	  with	  previous	  observations	  identifying	  Gonnorhoea	  as	  a	  risk	  factor	  
for	  HIV	  acquisition	  (174,	  175).	  	  Indeed,	  in	  this	  cohort,	  Gonorrhoea	  was	  associated	  with	  an	  
approximately	  4.6	  times	  higher	  risk	  of	  HIV-­‐1	  infection	  (155).	  	  Interestingly,	  of	  all	  the	  STIs,	  the	  
strongest	  associations	  with	  multiple	  transmission	  were	  detected	  with	  Gonorrhoea	  and	  
Chlamydia,	  both	  of	  which	  are	  inflammatory	  and	  target	  the	  columnar	  epithelium.	  	  HSV-­‐2	  and	  
Syphilis,	  which	  are	  ulcerative	  infections,	  have	  also	  been	  identified	  as	  strong	  risk	  factors	  for	  HIV	  
acquisition	  (reviewed	  in	  150)	  even	  after	  controlling	  for	  other	  confounding	  factors	  (176).	  	  
However	  we	  could	  not	  address	  their	  role	  in	  multiple	  HIV	  transmission	  due	  to	  insufficient	  data.	  	  
Here	  we	  also	  sought	  to	  identify	  the	  clinical	  consequences	  of	  infection	  with	  more	  than	  one	  
divergent	  virus.	  Comparing	  11	  cases	  of	  HIV	  intra-­‐subtype	  C	  dual-­‐infection	  to	  48	  participants	  
from	  the	  same	  cohort	  for	  which	  we	  possessed	  no	  evidence	  of	  dual	  infection,	  we	  found	  no	  
significant	  difference	  in	  the	  rate	  of	  CD4+	  T	  cell	  decline,	  or	  in	  their	  viral	  loads,	  even	  after	  
controlling	  for	  host	  HLA	  alleles.	  	  This	  is	  seemingly	  in	  contrast	  to	  studies	  in	  several	  other	  cohorts,	  
where	  dual	  infection	  was	  associated	  with	  substantially	  accelerated	  disease	  progression	  (130),	  
higher	  viral	  loads	  (131),	  and	  shorter	  time	  to	  WHO	  disease	  events	  (177).	  	  However,	  cases	  and	  
controls	  were	  frequently	  not	  matched	  for	  gender,	  infecting	  subtype,	  or	  host	  HLA	  alleles,	  and	  the	  
dates	  of	  initial	  infection	  were	  often	  unknown	  or	  estimated.	  	  	  The	  most	  robust	  study	  to	  date	  on	  
the	  influence	  of	  dual	  infection	  on	  clinical	  progression	  analyzed	  a	  well-­‐characterized	  cohort	  of	  37	  
Caucasian	  men	  who	  have	  sex	  with	  men	  (MSMs),	  matched	  for	  age	  (166).	  	  In	  this	  cohort,	  dual	  
infection	  was	  associated	  with	  a	  modest	  but	  significantly	  higher	  rate	  of	  CD4	  decline,	  after	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controlling	  for	  HLA	  B	  alleles	  previously	  associated	  with	  rapid	  progression	  and	  for	  CCR5Δ32	  
homozygosity.	  	  However,	  while	  all	  singly	  infected	  controls	  were	  infected	  with	  subtype	  B,	  four	  of	  
the	  six	  superinfections	  occurred	  with	  a	  non-­‐B	  subtype,	  including	  subtype	  A	  and	  recombinant	  
forms	  AG	  and	  AE,	  confounding	  the	  analysis.	  
One	  approach	  to	  control	  for	  differences	  between	  hosts	  is	  to	  test	  whether	  superinfection	  
accelerates	  disease	  progression	  within	  individuals.	  	  In	  a	  cohort	  of	  MSM	  from	  San	  Diego,	  USA,	  
there	  was	  no	  significant	  difference	  in	  CD4+	  T	  cell	  decline	  between	  dual	  infected	  and	  
monoinfected	  participants	  (165)	  .	  	  To	  evaluate	  whether	  superinfection	  resulted	  in	  an	  
acceleration	  in	  disease	  progression	  within	  individuals	  following	  superinfection,	  Pacold	  et	  al.	  
used	  an	  econometric	  test	  (Chow	  test)	  to	  test	  for	  a	  “structural	  break”	  in	  viral	  load	  or	  CD4+	  T	  cell	  
dynamics	  at	  the	  time	  of	  superinfection	  (165).	  For	  four	  out	  of	  seven	  superinfected	  participants,	  a	  
significant	  shift	  in	  viral	  load	  dynamics	  at	  the	  time	  of	  superinfection	  was	  detected	  by	  the	  Chow	  
test,	  suggesting	  that	  superinfection	  can	  result	  in	  higher	  viral	  loads	  (165)	  .	  	  However,	  
superinfection	  was	  not	  associated	  with	  a	  shift	  in	  CD4+	  T	  cell	  count	  trajectory.	  	  Using	  the	  same	  
approach,	  we	  show	  here	  that	  superinfection	  was	  not	  associated	  with	  a	  shift	  in	  CD4+	  T	  cell	  count	  
trajectory	  in	  two	  out	  of	  three	  superinfected	  participants.	  	  While	  we	  found	  significant	  evidence	  of	  
structural	  breaks	  in	  viral	  load	  at	  the	  time	  of	  superinfection	  in	  all	  three	  superinfected	  
participants,	  in	  two	  of	  the	  cases,	  this	  was	  due	  to	  a	  significant	  decline	  in	  the	  slope	  of	  viral	  load.	  	  
This	  was	  perhaps	  to	  be	  expected,	  as	  in	  these	  two	  cases,	  superinfection	  occurred	  early,	  prior	  to	  
viral	  load	  reaching	  set	  point.	  	  Importantly,	  we	  also	  show	  here	  that	  the	  Chow	  test	  detects	  
significant	  structural	  breaks	  in	  the	  viral	  load	  trajectories	  at	  the	  same	  timepoints	  in	  many	  
monoinfected	  control	  participants.	  	  	  For	  the	  three	  partitions	  on	  viral	  load,	  the	  Chow	  test	  detects	  
significant	  evidence	  (p<0.05)	  of	  a	  structural	  break	  in	  viral	  load	  in	  3/11	  (27.27%),	  9/18	  (50%),	  
and	  18/18	  (100%)	  of	  monoinfected	  controls	  respectively.	  	  This	  is	  perhaps	  unsurprising	  given	  
the	  volatility	  of	  viral	  load,	  and	  the	  fact	  that	  the	  trajectory	  is	  not	  expected	  to	  be	  linear.	  	  However,	  
it	  does	  illustrate	  that	  the	  Chow	  test	  does	  not	  have	  a	  high	  specificity	  as	  a	  means	  to	  evaluate	  the	  
effect	  of	  superinfection	  on	  viral	  load,	  despite	  previously	  being	  used	  for	  this	  purpose	  (165).	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While	  dual	  infection	  was	  not	  significantly	  associated	  with	  accelerated	  disease	  progression	  in	  
this	  cohort,	  we	  acknowledge	  caveats	  in	  the	  present	  study.	  	  Cases	  of	  dual	  infection,	  particularly	  
intra-­‐subtype	  dual	  infection,	  can	  be	  difficult	  to	  identify,	  and	  consequently,	  we	  may	  have	  
misclassified	  cases	  of	  dual	  infection	  as	  singly	  infected.	  	  Further,	  we	  possessed	  limited	  (only	  
population	  level)	  sequencing	  data	  for	  several	  (N=6)	  “singly	  infected”	  participants	  in	  the	  cohort.	  	  
However,	  as	  superinfection	  is	  a	  relatively	  rare	  event,	  the	  number	  of	  misclassified	  participants	  is	  
expected	  to	  be	  low.	  	  Nevertheless,	  a	  sample	  size	  of	  only	  11	  cases	  of	  dual	  infection	  likely	  would	  
not	  be	  sufficient	  to	  detect	  a	  mild	  effect	  of	  dual	  infection	  on	  disease	  progression.	  	  Particularly	  as	  
disease	  progression	  has	  high	  variance,	  is	  complex,	  and	  can	  be	  affected	  by	  many	  factors	  both	  
host	  and	  viral.	  
Due	  to	  difficulties	  identifying	  cases	  of	  dual	  infection,	  studies	  to	  date	  have	  analyzed	  relatively	  
few	  cases,	  and	  individually,	  offer	  little	  power	  to	  establish	  the	  clinical	  consequences	  of	  dual	  
infection.	  	  Given	  significant	  heterogeneity	  in	  factors	  including	  ethnic	  makeup,	  infecting	  subtype,	  
and	  mode	  of	  transmission,	  it	  also	  may	  not	  be	  appropriate	  to	  pool	  the	  data	  from	  several	  cohorts	  
in	  a	  meta-­‐analysis.	  	  Nevertheless,	  HIV	  superinfection	  has	  the	  inherent	  risk	  that	  the	  
superinfecting	  variant	  is	  more	  virulent	  (178),	  or	  harbours	  drug	  resistance	  mutations	  (137)	  and	  
therefore	  still	  poses	  a	  public	  health	  concern.	  	  Consequently,	  serosorting	  practices	  should	  be	  
discouraged	  in	  any	  event	  and	  HIV	  concordant	  partners	  should	  still	  protect	  themselves	  from	  
superinfection.	  	  However,	  larger	  studies	  in	  well-­‐characterized	  cohorts	  will	  be	  required	  to	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CHAPTER	  4: Dual	  infection	  was	  not	  associated	  with	  greater	  breadth	  
of	  the	  neutralizing	  antibody	  response	  
4.1	  Introduction	  
Approximately	  20%	  of	  HIV	  infected	  individuals	  develop	  broadly	  cross-­‐neutralizing	  
antibodies	  during	  the	  course	  of	  infection	  (1,	  85,	  86,	  179).	  	  Identifying	  the	  factors	  that	  promote	  
their	  development	  during	  natural	  infection	  may	  provide	  valuable	  information	  for	  the	  design	  of	  
future	  vaccines.	  	  	  Given	  the	  tremendous	  diversity	  in	  circulating	  HIV	  strains,	  polyvalent	  
immunogens	  may	  be	  necessary	  to	  provide	  adequate	  vaccine	  coverage.	  	  HIV	  dual	  infection,	  the	  
infection	  with	  more	  than	  one	  HIV	  strain,	  provides	  a	  unique	  opportunity	  to	  characterize	  how	  the	  
immune	  system	  responds	  to	  exposure	  with	  multiple	  HIV	  antigens,	  and	  can	  inform	  the	  use	  of	  
polyvalent	  or	  heterologous	  prime-­‐boost	  immunizations.	  	  	  
Piantadosi	  et	  al.	  (72)	  	  previously	  examined	  the	  correlates	  of	  neutralizing	  antibody	  (nAb)	  
breadth,	  and	  found	  that	  in	  26	  women,	  greater	  env	  diversity	  early	  in	  infection	  was	  significantly	  
associated	  with	  greater	  antibody	  breadth,	  measured	  at	  five	  years	  post	  infection.	  	  As	  viral	  load	  
has	  been	  shown	  previously	  to	  correlate	  with	  both	  neutralizing	  antibody	  breadth	  and	  greater	  
sequence	  diversity,	  this	  association	  may	  have	  been	  driven	  by	  viral	  load.	  	  Indeed,	  in	  the	  study	  by	  
Piantadosi	  et	  al.	  (72)	  viral	  load	  set	  point	  was	  significantly	  correlated	  with	  breadth.	  	  However,	  
there	  was	  no	  significant	  association	  between	  Gag	  diversity	  and	  breadth,	  suggesting	  that	  
envelope	  diversity	  may	  be	  directly	  associated	  with	  breadth.	  	  	  
Two	  recent	  studies	  that	  specifically	  examined	  the	  effect	  of	  HIV	  dual	  infection	  on	  the	  breadth	  
and	  potency	  of	  the	  neutralizing	  antibody	  response	  both	  suggested	  that	  dual	  infection	  is	  
associated	  with	  the	  development	  of	  a	  broader,	  and	  potentially	  more	  potent,	  nAb	  response	  later	  
on	  in	  the	  course	  infection	  (162,	  180).	  	  	  In	  a	  cohort	  from	  Yaoundé,	  Cameroon,	  superinfection	  was	  
associated	  with	  a	  significant	  broadening	  of	  the	  neutralizing	  antibody	  (180),	  although	  individuals	  
were	  infected	  for	  an	  unknown	  duration,	  confounding	  the	  analysis.	  Cortez	  et	  al.,	  (162),	  on	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comparing	  12	  superinfected	  participants	  to	  36	  monoinfected,	  matched	  controls,	  found	  a	  
significant	  association	  between	  superinfection	  and	  neutralization	  breadth,	  even	  when	  adjusting	  
for	  contemporaneous	  CD4+	  T	  cell	  count	  and	  viral	  load.	  	  While	  the	  duration	  of	  infection	  was	  
known	  the	  timings	  of	  superinfections	  ranged	  to	  over	  5	  years	  post	  infection.	  	  As	  breadth	  typically	  
develops	  on	  average	  ~2.4	  years	  post	  infection	  (105),	  these	  results	  are	  potentially	  confounded	  
by	  broadly	  neutralizing	  antibody	  responses	  that	  developed	  prior	  to,	  and	  independent	  of	  
superinfection.	  	  Indeed,	  in	  this	  cohort,	  participants	  that	  later	  went	  on	  to	  be	  superinfected	  
already	  had	  significantly	  broader	  neutralizing	  antibody	  responses	  than	  monoinfected	  controls,	  
prior	  to	  superinfection.	  
These	  results	  stand	  somewhat	  in	  contrast	  to	  the	  immunodominant	  nature	  of	  the	  early	  nAb	  
response	  to	  HIV	  infection,	  which	  is	  largely	  focused	  on	  one	  or	  a	  few	  variable	  epitopes	  resulting	  in	  
typically	  type-­‐specific	  nAb	  responses.	  	  Should	  an	  association	  between	  dual	  infection	  and	  broadly	  
neutralizing	  responses	  in	  natural	  infection	  be	  validated,	  this	  would	  support	  the	  use	  of	  
polyvalent	  immunogens	  and	  prime-­‐boost	  regimens	  as	  a	  potential	  means	  to	  circumvent	  this	  
immunodominance.	  	  In	  this	  chapter,	  we	  explore	  the	  influence	  of	  dual	  infection	  on	  the	  
neutralizing	  antibody	  response.	  	  Of	  the	  62	  participants	  in	  the	  CAPRISA002	  cohort,	  plasma	  
samples	  from	  41	  have	  been	  screened	  for	  the	  presence	  of	  broadly	  neutralizing	  antibodies	  (1).	  	  
Taking	  advantage	  of	  these	  data,	  we	  evaluate	  whether	  infection	  and	  exposure	  to	  a	  diversity	  of	  
envelopes,	  through	  either	  co-­‐infection	  or	  sequential	  infection	  (superinfection)	  within	  the	  first	  
year	  of	  infection,	  resulted	  in	  a	  greater	  likelihood	  of	  developing	  cross-­‐neutralizing	  antibodies.	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4.2	  Methods	  
4.2.1	  Sequence	  analysis	  
Sequences	  were	  aligned	  using	  Muscle	  (181).	  All	  amino	  acid	  positions	  are	  numbered	  relative	  
to	  the	  HXB2	  reference	  sequence.	  	  DNA	  distances	  were	  calculated	  in	  MEGA	  5.2.2	  (182),	  using	  
Maximum	  Likelihood	  with	  gamma	  distributed	  rates	  among	  sites	  (gamma	  =	  1).	  	  Diversity	  was	  
estimated	  as	  the	  mean	  DNA	  distance	  between	  all	  sequences.	  
4.2.2	  Detecting	  evidence	  of	  selection	  in	  CAP256	  
To	  take	  recombination	  between	  the	  superinfecting	  virus	  (SI)	  and	  primary	  infecting	  virus	  
(PI)	  into	  account,	  sequences	  were	  partitioned	  into	  two	  alignments	  (an	  SI-­‐related,	  and	  a	  PI-­‐
related	  alignment)	  based	  on	  the	  inferred	  recombination	  breakpoints	  using	  an	  in-­‐house	  script.	  	  
Breakpoints	  were	  identified	  by	  a	  shift	  in	  identity	  from	  one	  reference	  towards	  the	  other,	  and	  
required	  at	  least	  two	  sequential	  polymorphisms	  in	  common	  with	  a	  corresponding	  PI/SI-­‐related	  
virus	  in	  order	  to	  be	  considered.	  	  Phylogenies	  for	  both	  alignments	  were	  then	  reconstructed	  using	  
FastTree	  (143)	  with	  a	  GTR+CAT	  model,	  and	  rooted	  on	  the	  PI/SI.	  Signals	  of	  selective	  pressure	  
were	  detected	  with	  MEME	  (episodic	  diverifying	  selection,	  183)	  and	  DEPS	  (directional	  selection,	  
184)	  using	  the	  FastTree-­‐generated	  trees,	  implemented	  in	  Hyphy	  (185).	  	  	  
4.2.3	  Cloning	  
Select	  envelope	  amplicons	  were	  re-­‐amplified	  from	  the	  SGA	  first-­‐round	  products	  using	  the	  
high	  fidelity,	  Phusion	  enzyme	  (Finnzymes,	  Thermo	  Fisher	  Scientific,	  Vantaa,	  Finland)	  with	  the	  
EnvN	  primer	  (5’–TTGCCAATCAGGGAAGTAGCCTTGTGT-­‐3’;	  HXB2	  nt	  9145	  -­‐	  9171)	  and	  a	  forward	  
primer	  containing	  a	  5’	  CACC	  overhang	  allowing	  directional	  cloning	  (Env1Arx:	  5’	  -­‐	  CAC	  CGG	  CTT	  
AGG	  CAT	  CTC	  CTA	  TAG	  CAG	  GAA	  GAA-­‐3’;	  HXB2	  nt	  5954	  -­‐	  5982).	  	  Amplification	  was	  performed	  
under	  the	  same	  cycling	  conditions	  as	  the	  second	  round	  SGA,	  described	  above	  (see	  2.2.2).	  	  
Amplicons	  were	  ligated	  into	  pcDNA3.1-­‐Topo	  Directional	  Cloning	  Vector	  (Invitrogen,	  Life	  
Technologies,	  Carlsbad,	  CA),	  and	  transformed	  into	  Top10	  Chemically	  Competent	  E.	  Coli	  cells	  
(Invitrogen,	  Life	  Technologies,	  Carlsbad,	  CA)	  according	  to	  the	  manufacturer’s	  instructions,	  and	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cultured	  on	  Luria-­‐Bertani	  agar	  supplemented	  with	  100	  μg/ml	  Carbenicillin	  (Sigma-­‐Aldrich,	  St	  
Louis,	  MO).	  	  Colonies	  were	  screened	  by	  PCR,	  using	  the	  following	  primers:	  T7	  (5’-­‐
TAATACGACTCACTATAGGG-­‐3’)	  and	  Rev15	  (5’-­‐CTGCCATTTAACAGCAGTTGAGTTGA-­‐3’;	  HXB2	  nt	  
6990	  -­‐	  7015).	  	  Colonies	  were	  added	  to	  12.5	  μl	  reactions	  containing	  1X	  SuperTherm	  PCR	  buffer,	  2	  
mM	  MgCl2,	  0.16	  mM	  of	  each	  dNTP,	  0.375	  units	  of	  SuperTherm	  Taq	  (Medox	  Biotech,	  India),	  and	  
0.3	  μM	  of	  each	  primer.	  	  Reactions	  were	  cycled	  under	  the	  following	  conditions:	  94°C	  for	  3	  
minutes,	  followed	  by	  35	  cycles	  of	  [94°C	  for	  15	  seconds,	  57°C	  for	  45	  seconds,	  and	  72°C	  for	  2.5	  
minutes],	  with	  a	  final	  extension	  of	  7	  minutes	  at	  72°C.	  
Large-­‐scale	  plasmid	  purification	  was	  performed	  using	  the	  QIAprep	  Spin	  Miniprep,	  or	  the	  
QIAfilter	  Plasmid	  Midi	  kits	  (Qiagen,	  Valencia,	  CA),	  as	  per	  the	  manufacturer’s	  instructions.	  	  
Plasmids	  were	  sequenced	  and	  assembled	  as	  described	  above	  (section	  2.2.2)	  in	  order	  to	  ensure	  
the	  clone	  contained	  no	  non-­‐synonymous	  mutations	  in	  envelope	  relative	  to	  the	  SGA-­‐derived	  
sequence.	  	  	  
4.2.4	  Cell	  lines	  
TZM-­‐bl	  (JC53-­‐bl)	  cells,	  engineered	  by	  J.	  Kappes	  and	  X.	  Wu,	  were	  obtained	  from	  the	  NIH	  AIDS	  
Research	  and	  Reference	  Reagent	  Program	  (cat#	  8129).	  	  TZM-­‐bl	  cells	  are	  an	  adherent,	  HeLa-­‐
derived	  cell	  line	  that	  has	  been	  modified	  to	  constitutively	  express	  CD4,	  CCR5	  and	  CXCR4.	  	  
Further,	  they	  contain	  an	  integrated	  luciferase	  gene	  under	  the	  tight	  regulatory	  control	  of	  an	  HIV	  
LTR	  (a	  Tat-­‐responsive	  promoter).	  	  HEK293T	  cells	  were	  obtained	  from	  George	  Shaw	  (University	  
of	  Alabama,	  Birmingham,	  AL).	  	  Both	  cell	  lines	  were	  maintained	  in	  Dulbecco’s	  Modified	  Eagle	  
Medium	  (Gibco,	  Life	  Technologies,	  Carlsbad,	  CA),	  containing	  4.5	  g/L	  glucose,	  L-­‐glutamine,	  
sodium	  pyruvate,	  and	  supplemented	  with	  50	  μg/ml	  Gentamicin	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO),	  
25	  mM	  HEPES	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO),	  and	  10%	  heat	  inactivated	  Fetal	  Bovine	  Serum	  
(FBS)	  (Biochrom,	  Cambridge,	  UK).	  	  Cells	  were	  cultured	  at	  37	  ºC	  in	  a	  humidified	  incubator	  with	  
5%	  CO2,	  and	  monolayers	  were	  disrupted	  at	  confluence	  by	  treatment	  with	  0.25%	  Trypsin	  in	  
1mM	  EDTA	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO).	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4.2.5	  Neutralization	  assays	  
Env-­‐pseudotyped	  viruses	  were	  generated	  by	  co-­‐transfecting	  Envelope	  plasmids	  with	  	  	  	  	  
pSG3ΔEnv	  (56)	  into	  HEK293T	  cells	  using	  Fugene	  6	  (Applied	  Science,	  Indianapolis,	  IA)	  
according	  to	  the	  manufacturer’s	  instructions.	  	  Pseudoviruses	  were	  harvested	  from	  the	  
supernatant	  48	  hours	  following	  transfection,	  filtered	  through	  a	  0.45	  μm	  filter	  (Millipore,	  Merck,	  
Billerica,	  MA),	  made	  up	  to	  20%	  FBS,	  and	  stored	  at	  -­‐80°C	  until	  use.	  Neutralization	  assays	  were	  
performed	  as	  described	  previously	  (58).	  	  Briefly,	  plasma	  was	  heat	  inactivated	  at	  56°C	  for	  60	  
minutes	  in	  order	  to	  remove	  complement	  activity,	  and	  serially	  diluted	  3-­‐fold	  in	  a	  96	  well	  plate,	  
beginning	  at	  a	  1:45	  dilution.	  	  Pseudotyped	  viruses	  were	  then	  thawed	  in	  an	  ambient	  temperature	  
water	  bath	  and	  diluted	  by	  a	  factor	  that	  would	  result	  in	  ~50,000	  relative	  light	  units	  (RLU)	  per	  
well	  upon	  infection	  of	  TZM-­‐bl	  cells	  for	  48	  hours	  in	  the	  absence	  of	  plasma	  (as	  previously	  
determined	  by	  serial	  dilutions	  of	  that	  stock),	  added	  to	  each	  well,	  and	  incubated	  at	  37°C	  for	  1	  
hour.	  	  Thereafter,	  10,000	  TZMbl	  cells,	  supplemented	  with	  20	  μg/ml	  DEAE-­‐Dextran	  (Sigma-­‐
Aldrich,	  St	  Louis,	  MO),	  were	  added	  to	  each	  well	  (final	  concentration	  of	  8	  μg/ml	  DEAE	  Dextran),	  
and	  incubated	  at	  37°C	  for	  48	  hours.	  	  Controls	  included	  cells	  unexposed	  to	  virus	  or	  plasma	  (cell	  
control),	  and	  cells	  exposed	  to	  virus	  in	  the	  absence	  of	  plasma	  (virus	  control).	  	  Cells	  were	  analysed	  
for	  Luciferase	  expression	  using	  Bright-­‐Glo	  (Promega,	  Madison,	  WI)	  as	  a	  substrate	  and	  
quantifying	  the	  luminescence	  produced,	  in	  RLUs,	  using	  a	  Luminometer	  (Promega,	  Madison,	  WI),	  
as	  per	  manufacturer’s	  instructions.	  	  Neutralization	  was	  measured	  as	  the	  reduction	  in	  
luminescence	  relative	  to	  the	  virus	  control,	  and	  titers	  were	  calculated	  as	  the	  reciprocal	  plasma	  
dilution	  required	  to	  reduce	  the	  RLUs	  by	  50%	  (ID50).	  	  	  
Neutralization	  breadth	  for	  the	  cohort	  was	  previously	  characterized,	  and	  quantified	  as	  the	  
proportion	  of	  heterologous	  viruses	  from	  a	  multi-­‐subtype	  pseudovirus	  panel	  each	  plasma	  sample	  
was	  able	  to	  neutralize	  at	  ID50	  titers	  >45	  (1).	  	  Neutralization	  breadth	  at	  three	  years	  post	  infection	  
(ypi)	  for	  nine	  dual-­‐infected	  participants	  was	  compared	  to	  that	  of	  16	  monoinfected	  participants	  
for	  whom	  data	  was	  available.	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4.2.6	  Statistical	  analysis	  
Antibody	  breadth	  was	  compared	  between	  groups	  using	  a	  Mann-­‐Whitney	  test	  (for	  two	  
groups)	  or	  a	  Kruskal-­‐Wallis	  test	  with	  Dunn’s	  multiple	  comparison	  post	  tests	  (for	  multiple	  
groups),	  implemented	  in	  Prism	  5.0b	  (Graphpad	  Software,	  Sand	  Diego,	  CA).	  	  The	  relationships	  
between	  envelope	  diversity,	  set	  point	  viral	  load,	  CD4	  counts	  and	  neutralizing	  antibody	  breadth	  
were	  assessed	  with	  a	  linear	  regression.	  	  The	  multivariate	  analysis	  of	  breadth	  at	  three	  years	  post	  
infection	  was	  modeled	  with	  a	  linear	  mixed	  effects	  model	  in	  R,	  using	  the	  nlme	  package.	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4.3	  Results	  
In	  this	  chapter,	  we	  firstly	  evaluated	  whether	  infection	  and	  exposure	  to	  a	  diversity	  of	  
envelopes,	  through	  either	  co-­‐infection	  or	  superinfection	  within	  the	  first	  year	  of	  infection,	  
resulted	  in	  a	  greater	  likelihood	  of	  developing	  cross-­‐neutralizing	  antibodies.	  	  The	  second	  
component	  of	  our	  work	  investigated	  the	  autologous	  neutralizing	  antibody	  responses	  to	  
different	  infecting	  strains	  or	  variants	  in	  individuals	  with	  dual	  infection.	  	  To	  do	  this	  analysis,	  we	  
utilized	  published	  neutralizing	  breadth	  data,	  determined	  at	  approximately	  three	  years	  post	  
infection,	  available	  for	  41	  participants	  from	  the	  CAPRISA	  002	  cohort	  (1)	  .	  In	  total,	  322	  sequences	  
were	  analyzed	  from	  17	  participants	  (two	  multivariant,	  five	  co-­‐infected,	  and	  ten	  singly	  infected)	  
(see	  Chapter	  2).	  	  The	  mutagenesis	  and	  neutralization	  assays	  for	  CAP256	  were	  performed	  by	  P.	  
Moore,	  M.	  Madiga,	  and	  M.	  Nonyane	  (NICD,	  JHB,	  South	  Africa).	  	  
4.3.1	  Dual	  infection	  was	  not	  associated	  with	  a	  broader	  neutralizing	  antibody	  response	  
To	  determine	  whether	  dual	  infection	  was	  associated	  with	  the	  development	  of	  broadly	  
neutralizing	  antibodies,	  we	  partitioned	  participants	  according	  to	  the	  multiplicity	  of	  infection.	  	  
Out	  of	  the	  41	  participants	  with	  available	  heterologous	  neutralization	  data,	  we	  possessed	  
sequencing	  data	  sufficient	  to	  estimate	  the	  multiplicity	  of	  infection	  for	  27.	  	  We	  classified	  six	  of	  
these	  participants	  as	  co-­‐infected,	  and	  three	  as	  superinfected	  (see	  Chapter	  2).	  	  One	  participant	  
was	  dual	  infected,	  although	  the	  timing	  of	  the	  secondary	  infection	  remains	  unclear	  (CAP200).	  	  
Seventeen	  of	  the	  41	  participants,	  were	  infected	  with	  a	  single	  virus,	  and	  had	  no	  evidence	  of	  
superinfection	  over	  at	  least	  two	  (N=7)	  or	  three	  (N=10)	  years	  of	  infection	  by	  SGA	  (N=11)	  or	  
population	  sequencing	  (N=6).	  	  	  
The	  extent	  of	  neutralization	  breadth	  was	  estimated	  using	  a	  pseudovirus	  panel	  consisting	  of	  
44	  heterologous	  envelopes	  encompassing	  subtypes	  A,	  B,	  and	  C	  (1).	  	  The	  median	  breadth	  against	  
heterologous	  pseudoviruses	  was	  11%	  for	  the	  17	  singly	  infected	  participants,	  compared	  to	  10%	  
and	  5%	  for	  the	  co-­‐infected	  (N=6)	  and	  superinfected	  (N=3)	  participants,	  respectively	  (Figure	  
4.1).	  	  Three	  of	  the	  17	  (17.7%)	  singly	  participants	  developed	  responses	  capable	  of	  neutralizing	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>40%	  of	  the	  heterologous	  panel	  at	  ID50	  titers	  greater	  than	  45.	  	  Of	  the	  dual	  infected	  participants	  
identified,	  one	  superinfected	  participant,	  CAP256,	  developed	  an	  extremely	  potent,	  broadly	  
cross-­‐neutralizing	  antibody	  response,	  and	  was	  able	  to	  neutralize	  32/42	  (~76%)	  of	  viruses,	  
frequently	  at	  ID50	  titers	  exceeding	  10,000	  (1,	  2).	  	  	  However,	  except	  for	  CAP256,	  none	  of	  the	  dual-­‐
infected	  participants	  were	  able	  to	  neutralize	  more	  than	  25%	  of	  the	  panel	  at	  ID50	  titers	  >45.	  
Plasma	  samples	  from	  CAP237,	  and	  CAP281	  who,	  like	  CAP256,	  were	  superinfected,	  were	  unable	  
to	  neutralize	  more	  than	  5%	  of	  heterologous	  viruses	  tested	  (1).	  	  	  	  
	  
	  
We	  found	  no	  association	  between	  dual	  infection	  (whether	  co-­‐infection,	  or	  superinfection)	  
and	  a	  broader	  neutralizing	  antibody	  response	  at	  three	  years	  post	  infection	  compared	  to	  single	  
infection	  (p=0.4489).	  	  To	  determine	  whether	  the	  timing	  of	  the	  second	  infection	  influenced	  the	  

































Figure	  4.1	  |	  No	  significant	  association	  between	  HIV	  dual	  infection	  and	  
the	  later	  development	  of	  neutralizing	  antibody	  breadth,	  estimated	  as	  
the	  percent	  of	  a	  44-­‐pseudovirus	  panel	  neutralized	  at	  ID50	  titers	  >45.	  	  
Within	  the	  dual	  infected	  group,	  superinfected	  participants	  are	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superinfections.	  	  However,	  there	  remained	  no	  significant	  difference	  between	  either	  of	  the	  dual	  
infected	  groups,	  and	  the	  monoinfected	  participants	  (p=0.8371).	  
As	  viral	  load	  and	  CD4	  count	  have	  previously	  been	  demonstrated	  to	  be	  significantly	  
associated	  with	  the	  development	  of	  breadth,	  we	  performed	  a	  multivariate	  analysis.	  In	  this	  
cohort,	  Gray	  et	  al.	  found	  that	  both	  viral	  loads	  and	  CD4	  counts	  at	  six	  months	  post	  infection	  were	  
significantly	  associated	  with	  neutralization	  breadth	  (1).	  	  However,	  we	  found	  that	  the	  area	  under	  
the	  load	  viral	  load	  curve	  from	  12	  to	  52	  weeks	  post	  infection	  was	  more	  predictive	  of	  breadth	  
than	  viral	  load	  at	  six	  months	  post	  infection	  was.	  	  We	  therefore	  used	  this	  representation	  of	  viral	  
load	  set	  point	  in	  the	  multivariate	  model.	  	  Dual	  infected	  participants	  did	  not	  possess	  more	  
breadth,	  on	  average,	  than	  participants	  with	  similar	  viral	  loads	  or	  CD4	  counts	  (Figure	  4.2).	  	  After	  
adjusting	  for	  viral	  load	  and	  CD4	  counts,	  there	  was	  still	  no	  significant	  association	  between	  dual	  
infection	  and	  the	  development	  of	  cross-­‐neutralizing	  antibodies	  in	  this	  cohort	  (p=0.2386;	  Table	  
4.1).	  	  If	  anything,	  dual	  infection,	  was	  associated	  with	  less	  neutralization	  breadth,	  on	  average,	  
taking	  viral	  load	  and	  CD4	  counts	  into	  account	  (B<0,	  p=0.1196).
	  
	  























































Figure	  4.2	  |	  The	  association	  between	  A.	  CD4	  counts	  at	  6	  months	  post	  infection	  
(mpi)	  and	  B.	  viral	  load	  setpoint	  and	  neutralizing	  antibody	  breadth.	  	  Viral	  load	  
setpoint	  was	  estimated	  as	  the	  area	  under	  the	  viral	  load	  curve	  from	  12	  to	  52	  
weeks	  post	  infection.	  	  Coinfected	  participants	  are	  highlighted	  in	  orange,	  and	  
superinfected	  participants	  are	  highlighted	  in	  red.	  
	  
	  




Table	  4.1	  |	  Results	  of	  a	  multivariate	  model	  testing	  the	  association	  between	  dual	  infection	  and	  the	  
development	  of	  neutralizing	  antibody	  breadth	  taking	  into	  account	  set	  point	  viral	  load	  and	  CD4	  count	  
	   N	   	   P	   P(multivariate)**	  
CD4	  count*	   41	   	   0.0652	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.4046	  (0.4303)	  
VL	  setpoint#	   41	   	   0.0018	   0.0086	  (0.0061)	  
Dual	  infection	   10	   	   0.4359	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (0.1196)	  
Coinfection	   6	   	   0.2819	   0.1604	  
Superinfection	   3	   	   0.5458	   0.6388	  
*CD4+T	  cell	  counts	  measured	  at	  6	  months	  post	  infection	  
#Estimated	  using	  the	  area	  under	  the	  viral	  load	  curve	  from	  12	  to	  52	  weeks	  post	  infection.	  
**	  The	  P	  values	  for	  the	  multivariate	  model	  when	  grouping	  coinfections	  and	  superinfections	  together	  
under	  “Dual	  infection”	  are	  shown	  in	  parentheses.	  
	  
In	  other	  cohorts	  greater	  envelope	  diversity	  early	  in	  infection	  was	  found	  to	  be	  significantly	  
associated	  with	  greater	  antibody	  breadth	  (72).	  	  We	  therefore	  investigated	  if	  the	  extent	  of	  early	  
envelope	  genetic	  diversity	  was	  correlated	  with	  the	  later	  development	  of	  cross-­‐neutralizing	  
antibodies.	  	  In	  total,	  322	  sequences	  were	  analyzed	  from	  17	  participants	  (two	  multivariant,	  five	  
co-­‐infected,	  and	  ten	  singly	  infected).	  	  Sequences	  were	  sampled	  a	  median	  of	  two	  weeks	  post	  
infection	  (range:	  1-­‐9	  wpi),	  and	  cases	  of	  superinfection	  were	  excluded.	  	  Analyzing	  a	  median	  of	  21	  
sequences	  per	  participant	  (range:	  7-­‐24),	  we	  estimated	  early	  envelope	  diversity	  as	  the	  mean	  DNA	  
distance.	  	  We	  found	  no	  significant	  correlation	  between	  early	  envelope	  diversity	  and	  the	  later	  









4.3.2	  Broadly	  neutralizing	  antibodies	  in	  CAP256	  target	  an	  epitope	  including	  residues	  in	  V2	  
of	  the	  superinfecting	  virus	  that	  is	  not	  fully	  conserved	  in	  the	  primary	  infecting	  virus	  
CAP256,	  a	  superinfected	  participant,	  developed	  an	  extremely	  potent,	  broadly	  cross-­‐
neutralizing	  antibody	  response,	  neutralizing	  77%	  of	  heterologous	  viruses	  tested,	  often	  at	  titers	  
exceeding	  10,000	  (1).	  Identifying	  the	  target	  of	  the	  cross-­‐reactive	  antibody	  response	  in	  CAP256	  
may	  shed	  light	  on	  whether	  superinfection	  may	  have	  promoted	  this	  broad	  and	  potent	  response.	  	  
Moreover,	  the	  identification	  of	  the	  epitope(s)	  targeted	  by	  these	  broadly	  cross-­‐neutralizing	  
antibodies	  could	  potentially	  identify	  vulnerable	  regions	  in	  the	  HIV	  Envelope	  that	  can	  be	  
targeted	  with	  vaccines.	  	  We	  therefore	  sought	  to	  map	  the	  epitope(s)	  targeted	  by	  cross-­‐
neutralizing	  antibodies	  present	  in	  CAP256	  plasma.	  	  
To	  elucidate	  responses	  to	  the	  primary	  and	  superinfecting	  virus,	  and	  to	  map	  the	  epitope(s)	  
targeted	  by	  CAP256	  plasma	  we	  generated	  a	  functional	  envelope	  clone	  of	  the	  T/F	  superinfecting	  
virus	  described	  in	  Chapter	  2.	  	  This	  clone	  was	  provided	  to	  P.	  Moore	  et	  al.	  (NICD,	  JHB,	  South	  























Figure	  4.3	  |	  The	  association	  between	  early	  diversity	  in	  envelope(env)	  and	  the	  later	  
development	  of	  neutralizing	  antibody	  breadth.	  	  Diversity	  was	  plotted	  as	  the	  mean	  DNA	  
distance	  between	  all	  single	  genome	  amplicons	  sampled	  near	  the	  time	  of	  seroconversion.	  	  
Co-­‐infected	  participants	  are	  shown	  in	  orange,	  while	  singly	  infected	  participants	  are	  
shown	  in	  light	  blue.	  	  Participants	  infected	  with	  multiple,	  closely	  related	  viruses	  
(multivariant	  transmissions)	  are	  shown	  in	  dark	  blue.	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Africa)	  for	  analysis.	  	  The	  neutralizing	  antibody	  response	  to	  the	  primary	  infecting	  virus	  in	  
CAP256	  arose	  by	  ~23	  wpi,	  reaching	  titers	  of	  approximately	  300,	  and	  persisted	  at	  approximately	  
this	  level	  over	  the	  next	  three	  years	  (2)	  (Figure	  4.6).	  	  While	  superinfection	  occurred	  at	  
approximately	  11-­‐13	  wpi,	  titers	  to	  the	  PI	  were	  not	  boosted	  after	  this	  window.	  	  Similar	  to	  the	  
response	  to	  the	  PI,	  neutralizing	  ID50	  titers	  against	  the	  SI	  first	  reached	  detectable	  levels	  by	  ~23	  
wpi,	  and	  reached	  titers	  of	  ~300	  at	  30	  wpi.	  However,	  while	  titers	  against	  the	  PI	  persisted	  at	  
approximately	  this	  level,	  the	  nAb	  response	  against	  the	  SI	  became	  considerably	  more	  potent,	  
rising	  at	  42	  wpi	  and	  reaching	  extremely	  high	  titers	  of	  >40,000	  by	  69	  weeks	  of	  infection	  (Figure	  
4.7).	  	  The	  rise	  in	  titer	  to	  the	  superinfecting	  virus	  correlated	  with	  the	  onset	  of	  a	  novel	  response	  
targeting	  an	  epitope	  within	  V1V2	  that	  arose	  by	  30	  wpi	  (Figure	  4.6)(2).	  	  A	  V1V2-­‐dependent	  
response	  was	  also	  shown	  to	  mediate	  neutralization	  of	  the	  PI	  after	  42	  wpi	  (186).	  	  	  
To	  aid	  in	  the	  effort	  to	  map	  the	  fine	  specificity	  of	  the	  cross-­‐neutralizing	  antibody	  response	  in	  
CAP256,	  we	  made	  use	  of	  the	  envelope	  sequences	  of	  the	  viruses	  used	  in	  the	  heterologous	  virus	  
panel.	  	  We	  first	  identified	  residues	  that	  were	  highly	  conserved	  in	  the	  viruses	  that	  were	  sensitive	  
to	  neutralization	  by	  CAP256	  serum,	  but	  were	  variable	  in	  the	  resistant	  viruses.	  	  While	  we	  were	  
aware	  that	  escape	  from	  neutralizing	  antibodies	  can	  occur	  by	  conformation	  shielding	  and	  
mediated	  by	  mutations	  potentially	  distal	  to	  the	  actual	  epitope,	  we	  initially	  identified	  whether	  
any	  of	  the	  sites	  that	  were	  conserved	  in	  the	  sensitive	  viruses	  were	  also	  under	  positive	  selection	  
over	  time.	  	  As	  CAP256	  was	  superinfected,	  we	  partitioned	  the	  sequences	  according	  to	  the	  
inferred	  recombination	  breakpoints,	  and	  performed	  a	  selection	  analysis	  on	  the	  two	  alignments.	  	  
Sites	  in	  V2	  were	  under	  strong	  selective	  pressure	  in	  both	  the	  primary-­‐	  and	  superinfecting	  viral	  
sequences.	  	  Of	  the	  sites	  experiencing	  strong	  positive	  selection,	  three	  (namely	  HXB2	  positions	  
165,	  166,	  and	  169)	  were	  conserved	  in	  sensitive	  viruses,	  but	  less	  so	  in	  resistant	  viruses,	  
suggesting	  that	  they	  were	  potentially	  contributing	  to	  the	  formation	  of	  the	  targeted	  epitope	  
(Figure	  4.5A).	  	  	  CAP256	  plasma	  had	  also	  been	  evaluated	  against	  a	  panel	  of	  over	  160	  
heterologous	  pseudoviruses	  as	  part	  of	  the	  Neutralization	  Serotype	  Discovery	  Project	  (D.	  
Montefiori	  et	  al.,	  unpublished	  data).	  	  Taking	  advantage	  of	  these	  data,	  we	  next	  compared	  the	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amino	  acid	  frequencies	  between	  the	  highly	  sensitive	  (ID50>	  5000)	  and	  resistant	  (ID50	  <	  50)	  
viruses.	  	  Supporting	  the	  role	  of	  residues	  165,	  166,	  and	  169	  in	  the	  neutralization	  by	  CAP256	  
serum,	  these	  sites	  were	  significantly	  more	  conserved	  in	  the	  highly	  sensitive	  viruses	  compared	  to	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                                    160       170       180         
                                |....|....|....|....|....|. 
SI             KNCSFNATTELRDKKKKEYALFYRLD  
CAP256.15wpi.B3                ..........................  
CAP256.15wpi.C7                ..........................  
CAP256.15wpi.C9                ..........................  
CAP256.15wpi.C1                ..........................  
CAP256.15wpi.A5                ..........................  
CAP256.53wpi.D7                ..............I...........  
CAP256.53wpi.D1                ..............I...........  
CAP256.59wpi.1a                .....S........I...........  
CAP256.59wpi.2a                ........S.....E...........  
CAP256.59wpi.7b                ......T.......I...........  
CAP256.94wpi.D12               ......T....K..I...........  
CAP256.94wpi.A11b              ......I...V...I...........  
CAP256.94wpi.A3                ......T....K..I...........  
CAP256.94wpi.A6                ......T....K..I...........  
CAP256.94wpi.A1                ......T....K..I...........  
CAP256.94wpi.F1                ......T....K..I...........  
CAP256.94wpi.C4                ......T....K..I...........  
CAP256.94wpi.B2                ......T....K..I...........  
CAP256 94wpi.E12               ......T....K..I...........  
CAP256.94wpi.B10               ......T....K..I...........  
CAP256.94wpi.F                 ..........VK..I...........  
CAP256.94wpi.C1                ..........VK..I...........  
CAP256.94wpi.D6                ..........VK..I...........  
CAP256.94wpi.C2                ..........VK..I...........  
CAP256.94wpi.A10               ..........VK..Q...........  
CAP256.176wpi.F1               ..........V...E...........	  
                                    160       170       180         
                                |....|....|....|....|....|. 
PI       KNCSFNTITEVRDKQKKEYALFYRLD  
SI          ......AT..L...K...........  
CAP256.06wpi.F7J                 ..........................  
CAP256.06wpi.C7J                 ..........................  
CAP256.13wpi.F1                  ..........................  
CAP256.30wpi.1                   ..........................  
CAP256.30wpi.2                   ..........................  
CAP256.30wpi.9                   ..........................  
CAP256.30wpi.3                   ..........................  
CAP256.30wpi.4                   ..........................  
CAP256.30wpi.8                   ................R.........  
CAP256.53wpi.A9                  .......T..................  
CAP256.53wpi.C1                  ...........T......H.......  
CAP256.53wpi.F1                  .....D....................  
CAP256.53wpi.C2                  .....D....................  
CAP256.59wpi.8b                  ................E.........  
CAP256.59wpi.12a                 ..........................  
CAP256.59wpi.9a                  .......T..................  
CAP256.59wpi.2b_cloned           .....D....................  
CAP256.59wpi.5b                  .......T..................  
CAP256.59wpi.6b                  .......T..................  
CAP256.59wpi.13B                 .......T..................  
CAP256.59wpi.10a                 .......T..................  
CAP256.59wpi.4a                  .......T..................  
CAP256.59wpi.6a                  .....T....................  
CAP256.59wpi.11a                 ..........................  
CAP256.59wpi.5a                  ..........................  
CAP256.59wpi.7a                  ..........................  
CAP256.59wpi.A11                  ................N.........  
CAP256.176wpi.C2                  ...........S....N......K..  
CAP256.176wpi.B1                  ...........S....N......K..  
CAP256.176wpi.E1                  ...........S....N.........  
CAP256.176wpi.H1                  ...........S....N.........  
CAP256.176wpi.F10                 ...........S....N.........  
.	  
Figure	  4.4	  |	  An	  alignment	  of	  V2	  sequences	  related	  to	  the	  primary	  virus	  (A)	  and	  the	  
superinfecting	  virus	  (B)	  in	  CAP256,	  with	  sites	  under	  positive	  selection	  highlighted	  in	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Mutations	  at	  residues	  165,	  166,	  and	  169,	  introduced	  by	  site-­‐directed	  mutagenesis,	  were	  
subsequently	  shown	  by	  P.	  Moore	  et	  al.	  (2)	  to	  reduce	  sensitivity	  to	  neutralization,	  confirming	  
their	  role	  in	  neutralization	  by	  CAP256	  serum.	  The	  introduction	  of	  an	  alanine	  into	  a	  consensus	  
subtype	  C	  clone	  (ConC)	  at	  position	  165	  (L165A)	  and	  at	  position	  166	  (R166A)	  reduced	  titers	  to	  
CAP256	  serum	  by	  14.6	  and	  102.3	  fold	  respectively.	  	  A	  lysine	  to	  glutamate	  mutation	  at	  position	  
169	  (K169E)	  reduced	  titers	  by	  78.5	  fold.	  	  Further	  mapping	  efforts	  utilizing	  scanning	  
mutagenesis	  also	  identified	  a	  number	  of	  adjacent	  residues,	  including	  sites	  159,	  160,	  165,	  167,	  
and	  171,	  though	  166	  and	  169	  were	  the	  major	  determinants	  of	  sensitivity	  in	  heterologous	  
viruses	  (2).	  Mapping	  of	  the	  potent	  V1V2	  response	  against	  the	  superinfecting	  virus	  found	  that,	  
similar	  to	  the	  broadly	  neutralizing	  response,	  it	  was	  also	  highly	  dependent	  on	  the	  residues	  at	  
162,	  166,	  169,	  and	  171	  (2),	  suggesting	  that	  this	  may	  represent	  the	  precursor	  of	  the	  broadly	  
neutralizing	  response.	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Figure	  4.5	  |	  Amino	  acid	  conservation	  at	  sites	  165,	  166,	  and	  169	  in	  highly	  sensitive	  and	  resistant	  viruses	  from	  
the	  (A)	  44	  virus	  panel	  initially	  used	  to	  assess	  breadth	  (1),	  and	  validated	  on	  the	  large	  NSDP	  pseudovirus	  panel	  
(B)	  (D.	  Montefiori	  et	  al.,	  unpublished	  data)	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To	  establish	  whether	  the	  likely	  precursor	  of	  the	  broadly	  neutralizing	  antibody	  response	  
arose	  to	  the	  PI,	  the	  SI,	  or	  an	  epitope	  conserved	  in	  both	  viruses,	  we	  analyzed	  the	  sequences	  of	  the	  
two	  infecting	  viruses	  in	  conjunction	  with	  the	  autologous	  neutralizing	  antibody	  response.	  	  The	  PI	  
differed	  from	  the	  SI	  sequence	  at	  positions	  161,	  162,	  165,	  and	  169	  (Figure	  4.7).	  	  These	  mutations	  
explain	  the	  relative	  resistance	  of	  the	  PI	  compared	  to	  the	  SI.	  	  However,	  they	  also	  reveal	  that	  the	  
nAb	  response	  in	  CAP256	  did	  not	  target	  an	  epitope	  fully	  conserved	  in	  both	  infecting	  viruses,	  but	  








	   *	   *	   	   	   	   	   *	   **	   *	   *	   **	   	   *	  
	   159	   160	   161	   162	   163	   164	   165	   166	   167	   168	   169	   170	   171	  
SI	   F	   N	   A	   T	   T	   E	   L	   R	   D	   K	   K	   K	   K	  
PI	   .	   .	   T	   I	   .	   .	   V	   .	   .	   .	   Q	   .	   .	  
	  
Figure	  4.7	  |	  Sequence	  homology	  in	  V2	  between	  the	  primary-­‐	  (PI)	  and	  superinfecting	  (SI)	  viruses	  in	  CAP256.	  
Sites	  identified	  in	  Moore	  et	  al.,	  (2011)	  as	  import	  for	  cross-­‐neutralization	  are	  highlighted	  with	  a	  *	  (mutations	  
at	  this	  site	  resulted	  in	  a	  5-­‐15	  fold	  reduction	  in	  titers)	  or	  **	  (mutations	  at	  this	  site	  resulted	  in	  >75-­‐fold	  





















Figure	  4.6	  |	  The	  autologous	  neutralizing	  antibody	  response	  in	  CAP256.	  	  The	  estimated	  window	  of	  
superinfection	  (7-­‐11	  wpi)	  is	  shaded	  in	  gray.	  	  PI,	  primary	  infecting	  virus;	  SI,	  superinfecting	  virus.	  	  In	  order	  to	  
differentiate	  a	  V2	  response	  (and	  therefore	  a	  potential	  precursor	  of	  the	  cross-­‐neutralizing	  response),	  the	  
neutralization	  of	  the	  PI	  and	  SI	  is	  overlaid	  onto	  the	  neutralization	  of	  chimeric	  envelopes	  consisting	  of	  a	  
resistant	  heterologous	  Envelope	  (CAP84)	  with	  the	  V1V2	  replaced	  with	  that	  of	  either	  the	  PI	  (84-­‐PI-­‐84)	  or	  SI	  
(84-­‐SI-­‐84).	  	  Data	  provided	  by	  P.	  Moore	  (NICD,	  JHB,	  South	  Africa)	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4.3.4	  Escape	  from	  autologous	  neutralizing	  antibodies	  and	  the	  relationship	  with	  
heterologous	  neutralization	  
Next,	  in	  order	  to	  address	  whether	  viral	  evolution,	  recombination,	  and	  escape	  may	  have	  
driven	  the	  antibody	  response	  in	  CAP256	  towards	  more	  conserved	  residues	  (and	  whether	  
superinfection	  contributed	  to	  this),	  we	  characterized	  the	  evolution	  of	  the	  viral	  quasispecies	  in	  
CAP256	  over	  time.	  An	  analysis	  of	  26	  SGA	  sequences,	  together	  with	  40	  sequences	  provided	  by	  P.	  
Moore,	  revealed	  that	  recombination	  within	  envelope	  was	  widespread	  (see	  Figure	  2.12B).	  	  By	  six	  
months	  post	  initial	  infection	  (~three	  months	  post	  superinfection)	  the	  sampled	  viral	  population	  
was	  comprised	  entirely	  of	  recombinants.	  	  Within	  gp120,	  sequences	  originating	  from	  the	  SI	  
dominated	  with	  the	  exception	  of	  V1V2,	  which	  was	  predominantly	  inherited	  from	  the	  PI,	  and	  
contained	  several	  mutations	  that	  confer	  resistance	  to	  the	  nAb	  response.	  	  By	  six	  months	  pi,	  
recombinant	  viruses	  harbouring	  the	  V1V2	  of	  the	  relatively	  neutralization	  resistant	  PI	  
dominated.	  As	  the	  V2	  region	  of	  the	  PI	  harboured	  several	  mutations	  sufficient	  for	  escape	  (Figure	  
4.7)	  and	  was	  significantly	  more	  resistant	  to	  neutralization,	  this	  suggests	  that	  recombination	  was	  
used	  as	  an	  initial	  mechanism	  to	  provide	  (at	  least	  partial)	  escape	  from	  the	  extremely	  potent	  V2	  
response.	  	  	  	  Consistent	  with	  this,	  titers	  to	  the	  recombinant	  virus	  cloned	  at	  six	  months	  pi	  were	  
shown	  by	  P.	  Moore	  to	  be	  ~20	  fold	  lower	  than	  to	  the	  SI	  (186).	  	  	  
Partitioning	  the	  alignment	  according	  to	  the	  recombination	  breakpoints,	  we	  were	  able	  to	  
identify	  mutations	  and	  signals	  of	  selective	  pressure	  within	  the	  recombinant	  sequences.	  	  An	  
analysis	  of	  the	  residues	  known	  to	  be	  important	  for	  neutralization	  revealed	  that,	  in	  addition	  to	  
mutations	  introduced	  by	  recombination,	  multiple	  point	  mutations	  were	  introduced	  (Figure	  4.4).	  	  
V2,	  and	  specifically	  residues	  165,	  166,	  and	  169,	  and	  171	  were	  under	  strong	  selection	  pressure,	  
consistent	  with	  escape	  from	  the	  potent	  V2	  antibody	  response	  (see	  Supplementary	  Figure	  S4.1).	  	  
By	  39	  months	  post	  infection,	  two	  distinct	  viral	  populations	  were	  evident.	  One	  cluster	  contained	  
the	  backbone	  V2	  of	  the	  PI	  with	  additional	  mutations	  at	  positions	  166	  and	  171.	  	  The	  other	  
contained	  the	  V2	  from	  the	  SI,	  and	  harboured	  mutations	  at	  positions	  165	  and	  169.	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Taken	  together,	  these	  results	  indicate	  that	  despite	  an	  extremely	  potent,	  and	  later	  broad,	  
neutralizing	  antibody	  response,	  multiple	  pathways	  to	  escape	  were	  possible.	  	  They	  also	  provide	  
evidence	  that	  recombination	  can	  potentially	  accelerate	  escape,	  allowing	  the	  introduction	  of	  
multiple	  escape	  mutations	  simultaneously.	  	  	  
As	  the	  broadly	  neutralizing	  response	  in	  CAP256	  was	  associated	  with	  subtle	  changes	  in	  
epitope	  specificity	  (2),	  we	  sought	  to	  identify	  whether	  the	  patterns	  of	  escape	  in	  the	  autologous	  
virus	  preceded	  changes	  in	  the	  antibody	  specificity.	  	  We	  know	  from	  prior	  neutralization	  studies	  
that	  heterologous	  neutralization	  by	  CAP256	  serum	  becomes	  less	  dependent	  on	  residues	  165,	  
171	  and	  to	  a	  lesser	  extent	  167	  over	  time	  (2).	  	  Analyzing	  the	  autologous	  sequence	  data	  from	  
CAP256	  (Figure	  4.8)	  revealed	  that	  D167	  was	  conserved	  over	  time	  in	  all	  of	  the	  autologous	  
sequences,	  indicating	  that	  escape	  at	  that	  position	  was	  not	  responsible	  for	  driving	  the	  specificity	  
of	  the	  antibody	  response	  away	  from	  this	  residue.	  	  While	  the	  SI	  possessed	  a	  leucine	  at	  165	  and	  
the	  PI	  possessed	  a	  valine,	  no	  other	  mutations	  were	  observed	  at	  position	  165	  either.	  
Interestingly,	  a	  K171N	  mutation	  arose	  by	  two	  years	  post	  infection	  and	  became	  dominant	  by	  
three	  years,	  coincident	  with	  the	  neutralizing	  response	  becoming	  less	  dependent	  on	  171	  after	  
two	  years.	  	  However,	  the	  response	  also	  remained	  critically	  dependent	  on	  residues	  166	  and	  169	  
(2),	  despite	  the	  dominance	  of	  K169I/Q/E	  and	  R166K/S	  mutants	  as	  early	  as	  30	  weeks	  and	  two	  
years	  post	  infection	  respectively	  (Figure	  4.8).	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Figure	  4.8	  |	  The	  dependence	  of	  CAP256	  plasma	  antibodies	  on	  specific	  residues	  for	  
neutralization	  of	  ConC	  over	  time	  (from	  42)	  is	  overlaid	  onto	  CAP256	  viral	  diversification.	  
Time	  proceeds	  from	  top	  to	  bottom,	  with	  a	  “.”	  indicating	  the	  residue	  is	  identical	  to	  that	  of	  
the	  highly	  sensitive	  superinfecting	  virus	  (SI).	  	  The	  proportion	  of	  the	  population	  with	  a	  
particular	  sequence	  (%)	  is	  estimated	  from	  the	  number	  of	  SGAs	  with	  that	  sequence	  at	  each	  
time	  point.	  SI,	  superinfecting	  virus;	  PI,	  primary	  infecting	  virus.	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4.4	  Discussion	  
We	  show	  here	  that	  in	  the	  CAPRISA	  002	  cohort,	  dual	  infection	  within	  the	  first	  year	  of	  
infection	  was	  not	  consistently	  associated	  with	  the	  development	  of	  a	  broader	  neutralizing	  
antibody	  response,	  even	  after	  adjusting	  for	  differences	  in	  CD4+	  T	  cell	  counts	  and	  viral	  load	  at	  set	  
point.	  	  There	  was	  also	  no	  significant	  association	  between	  early	  envelope	  diversity	  and	  the	  later	  
development	  of	  breadth.	  	  	  
In	  contrast,	  Piantadosi	  et	  al.	  (72)	  observed	  that	  envelope	  diversity	  in	  early	  infection	  was	  
associated	  with	  greater	  antibody	  breadth	  at	  five	  years	  post	  infection.	  	  More	  specifically,	  two	  
other	  studies	  have	  previously	  suggested	  that	  superinfection	  does	  broaden	  the	  neutralizing	  
antibody	  response	  (162,	  180).	  	  Cortez	  et	  al.,	  (162)	  compared	  the	  breadth	  of	  12	  superinfected	  
participants	  to	  that	  of	  36	  monoinfected,	  matched	  controls,	  and	  found	  that	  superinfection	  was	  
associated	  with	  broader	  neutralizing	  antibody	  responses.	  However,	  the	  timing	  of	  superinfection	  
ranged	  from	  approximately	  two	  months	  post	  infection	  to	  over	  five	  years	  post	  infection.	  	  More	  
importantly,	  given	  that	  breadth	  arises	  on	  average	  ~2.4	  years	  post	  infection	  (1,	  105),	  including	  
superinfections	  that	  occur	  late	  in	  infection	  is	  potentially	  confounded	  by	  cross-­‐neutralizing	  
antibodies	  that	  developed	  prior	  to	  and	  independent	  of	  any	  superinfection.	  	  Cortez	  et	  al.	  
attempted	  to	  control	  for	  this	  by	  evaluating	  the	  breadth	  prior	  to	  superinfection.	  	  While	  the	  
participants	  that	  later	  went	  on	  to	  become	  superinfected	  already	  had	  significantly	  higher	  
breadth	  than	  their	  singly	  infected	  counterparts	  prior	  to	  any	  superinfection	  (p=0.019),	  the	  
difference	  was	  no	  longer	  statistically	  significant	  (p=0.067)	  when	  Cortez	  et	  al.	  then	  controlled	  for	  
contemporaneous	  viral	  load,	  which	  they	  note	  was	  significantly	  different	  between	  groups.	  	  While	  
higher	  viral	  loads	  have	  been	  associated	  with	  greater	  neutralization	  breadth	  (here,	  and	  
previously),	  the	  superinfected	  group	  analyzed	  by	  Cortez	  et	  al	  had	  significantly	  lower	  viral	  loads	  
than	  the	  singly	  infected	  group	  at	  the	  pre-­‐superinfection	  timepoint.	  	  Nevertheless,	  it	  is	  incorrect	  
to	  suggest	  that	  a	  p	  value	  of	  0.067	  constitutes	  evidence	  that	  no	  difference	  existed	  between	  the	  
groups	  prior	  to	  superinfection.	  	  Cortez	  et	  al.	  did	  use	  a	  multivariate	  model	  (conditional	  Poisson	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regression)	  to	  evaluate	  differences	  in	  breadth,	  “controlling	  for”	  breadth	  prior	  to	  superinfection	  
(as	  well	  as	  contemporaneous	  viral	  loads	  and	  CD4	  counts).	  	  While	  the	  association	  between	  
superinfection	  and	  breadth	  remained	  statistically	  significant,	  the	  model	  accounts	  for	  a	  linear	  
correlation	  between	  the	  breadth	  before	  and	  breadth	  after	  superinfection.	  However,	  as	  
participants	  were	  not	  sampled	  at	  the	  same	  times	  post	  infection,	  and	  as	  breadth	  has	  a	  strong	  
temporal	  component,	  there	  was	  no	  significant	  correlation	  between	  breadth	  before	  and	  breadth	  
after	  superinfection.	  	  Simply	  comparing	  the	  broadening	  of	  the	  response	  (i.e.	  breadth	  at	  the	  post-­‐
superinfection	  time	  point	  that	  was	  not	  already	  accounted	  for	  at	  the	  pre-­‐superinfection	  time	  
point)	  with	  a	  T-­‐test,	  the	  difference	  between	  the	  superinfected	  and	  singly	  infected	  groups	  is	  not	  
statistically	  significant	  (p=0.6417	  using	  breadth	  scores;	  p=0.8136	  using	  percent	  of	  the	  panel	  
neutralized),	  suggesting	  the	  result	  may	  not	  be	  a	  robust	  one.	  
It	  is	  also	  important	  to	  consider	  the	  effect	  of	  dual	  infection	  on	  the	  neutralizing	  antibody	  
response	  mechanistically,	  and	  the	  magnitude	  of	  the	  effect.	  	  Antibody	  breadth	  is	  critically	  
dependent	  on	  targeting	  an	  epitope	  that	  is	  highly	  conserved	  across	  variants.	  	  We	  must	  therefore	  
differentiate	  between	  a	  dominant,	  an	  additive,	  or	  a	  synergistic	  effect	  of	  dual	  infection	  on	  the	  
antibody	  response.	  	  A	  dominant	  effect	  would	  result	  in	  the	  targeting	  of	  one	  variant	  at	  the	  expense	  
of	  responses	  to	  the	  other.	  	  An	  additive	  effect	  would	  result	  in	  two,	  typically	  type-­‐specific	  (at	  least	  
at	  first)	  responses.	  	  If	  dual	  infection	  instead	  redirected	  the	  immune	  response	  towards	  a	  more	  
conserved	  epitope,	  this	  would	  represent	  a	  synergistic	  effect.	  	  	  	  Assuming	  no	  other	  differences	  
other	  than	  the	  multiplicity	  of	  infection,	  in	  the	  case	  of	  dominance	  dual	  infected	  individuals	  would	  
be	  expected	  to	  have	  a	  similar	  likelihood	  of	  developing	  BCN	  antibodies	  to	  singly	  infected	  
individuals.	  	  If	  the	  effect	  is	  additive,	  we	  would	  expect	  dual	  infected	  participants	  to	  be	  
approximately	  two	  times	  more	  likely	  to	  develop	  breadth	  (as	  the	  response	  to	  each	  variant	  would	  
have	  a	  chance	  of	  developing	  cross	  reactivity).	  A	  synergistic	  effect	  would	  result	  in	  dual	  infected	  
individuals	  having	  odds	  of	  developing	  breadth	  much	  greater	  than	  two	  times	  that	  of	  those	  who	  
are	  monoinfected.	  	  While	  an	  additive	  effect	  is	  relevant,	  as	  eliciting	  several	  responses	  to	  several	  
epitopes	  may	  be	  necessary	  for	  adequate	  vaccine	  coverage,	  a	  synergistic	  response	  is	  no	  doubt	  the	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most	  desirable	  scenario.	  	  	  Ignoring	  any	  methodological	  limitations,	  Cortez	  et	  al.	  estimated	  that	  
superinfected	  participants	  had	  an	  odds	  ratio	  of	  developing	  breadth	  of	  1.51	  times	  that	  of	  
matched	  monoinfected	  participants;	  consistent	  with	  an	  additive	  effect	  rather	  than	  a	  synergistic	  
one.	  	  	  
In	  a	  second	  study	  that	  addressed	  the	  influence	  of	  superinfection	  on	  antibody	  breadth	  in	  a	  
cohort	  from	  Yaoundé,	  Cameroon,	  superinfection	  was	  associated	  with	  a	  significant	  broadening	  of	  
the	  neutralizing	  antibody	  response	  (180).	  	  	  Broadening	  of	  the	  neutralizing	  antibody	  response	  
was	  evident	  in	  three	  out	  of	  four	  dual-­‐infected	  participants,	  compared	  to	  none	  of	  23	  
monoinfected	  participants	  (180).	  	  Using	  an	  IC50	  titer	  >80	  as	  the	  definition	  for	  sensitivity,	  only	  
1/23	  (4.35%)	  of	  the	  monoinfected	  participants	  were	  able	  to	  neutralize	  more	  than	  one	  of	  the	  
four	  heterologous,	  primary	  viruses.	  	  This	  is	  in	  contrast	  to	  breadth	  in	  three	  out	  of	  the	  four	  
superinfected	  participants.	  	  However,	  time	  post	  infection	  was	  unknown	  for	  all	  subjects	  and	  
therefore	  duration	  of	  infection	  could	  not	  be	  controlled	  for.	  	  Furthermore,	  a	  panel	  including	  only	  
four	  heterologous	  primary	  viruses	  was	  used	  to	  assess	  breadth.	  	  Nevertheless,	  these	  results	  are	  
enticing,	  and	  would	  be	  consistent	  with	  a	  synergistic	  effect.	  	  However,	  the	  mechanism	  by	  which	  
superinfection	  may	  promote	  breadth	  still	  needs	  to	  be	  addressed.	  
Even	  if	  dual	  infection	  did	  not	  consistently	  enhance	  breadth	  in	  the	  CAPRISA	  cohort,	  it	  
remains	  possible	  that	  superinfection	  may	  have	  been	  a	  factor	  in	  the	  development	  of	  breadth	  in	  
CAP256.	  	  We	  can	  envisage	  several	  mechanisms	  by	  which	  dual	  infection	  could	  potentially	  
promote	  the	  development	  of	  broadly	  neutralizing	  responses	  (Table	  4.3).	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Given	  that	  dual	  infection	  has	  previously	  been	  associated	  with	  higher	  viral	  loads	  and	  lower	  
CD4	  counts,	  and	  these	  in	  turn	  have	  been	  associated	  with	  antibody	  breadth,	  it	  is	  possible	  that	  
effect	  may	  be	  an	  indirect	  one.	  	  However,	  viral	  loads	  and	  CD4	  counts	  in	  the	  Yaoundé	  cohort	  
(where	  dual	  infection	  was	  significantly	  correlated	  with	  breadth)	  were	  not	  significantly	  different	  
between	  superinfected	  and	  monoinfected	  participants,	  though	  participants	  could	  not	  be	  
matched	  for	  duration	  of	  infection.	  	  In	  the	  CAPRISA002	  cohort	  described	  here,	  dual	  infection	  was	  
also	  not	  associated	  with	  significantly	  higher	  viral	  loads,	  or	  lower	  CD4	  counts	  (see	  Figures	  3.2	  
and	  3.3).	  	  CAP256	  (the	  one	  superinfected	  participant	  that	  developed	  breadth)	  did	  have	  the	  
highest	  viral	  loads	  of	  the	  three	  cases	  of	  superinfection.	  However,	  even	  if	  superinfection	  does	  
promote	  breadth	  indirectly	  via	  effects	  on	  viral	  load	  and	  CD4	  count,	  this	  would	  provide	  limited	  
new	  information	  for	  future	  vaccination	  strategies.	  
Breadth	  in	  CAP256	  was	  also	  mediated	  almost	  exclusively	  by	  antibodies	  dependent	  on	  V1V2	  
(2),	  indicating	  that	  superinfection	  did	  not	  promote	  breadth	  by	  increasing	  the	  number	  of	  
antibody	  specificities.	  In	  any	  case,	  immunodominant	  epitopes	  in	  HIV	  Envelope	  can	  be	  
hypervariable,	  and	  consequently	  increasing	  the	  number	  of	  antibody	  specificities	  elicited	  may	  
Table	  4.3	  |	  Potential	  mechanisms	  by	  which	  superinfection	  could	  promote	  antibody	  
breadth	  
• Indirectly	  through	  higher	  viral	  loads,	  and	  lower	  CD4+	  T	  cell	  counts	  
• Increasing	  the	  number	  of	  antibody	  specificities	  elicited	  
• Promote	  antibody	  responses	  to	  conserved	  epitopes	  
• By	  modulating	  or	  accelerating	  antibody	  maturation	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never	  accumulate	  to	  the	  point	  of	  any	  significant	  breadth.	  	  As	  such,	  antibody	  breadth	  is	  likely	  
critically	  dependent	  on	  targeting	  an	  epitope	  that	  is	  highly	  conserved	  across	  variants.	  	  	  
Superinfection	  with	  a	  second,	  antigenically	  divergent	  virus	  could	  preferentially	  boost	  pre-­‐
existing	  responses	  to	  an	  epitope	  conserved	  in	  both	  infecting	  viruses.	  	  Such	  a	  mechanism	  would	  
be	  expected	  to	  enhance	  antibody	  responses	  to	  conserved	  epitopes,	  fostering	  breadth.	  	  With	  the	  
aid	  of	  computational	  predictions,	  cross-­‐neutralizing	  antibodies	  in	  CAP256	  were	  mapped	  to	  
residues	  in	  V2,	  overlapping	  that	  targeted	  by	  the	  mAbs	  PG9	  and	  PG16	  (specifically	  positions	  159,	  
160,	  165,	  166,	  167,	  169,	  and	  171).	  	  Similarly,	  an	  early	  autologous	  response	  to	  the	  superinfecting	  
virus	  was	  also	  highly	  dependent	  on	  residues	  162,	  166,	  169,	  and	  171.	  	  This,	  together	  with	  the	  fact	  
that	  breadth	  in	  CAP256	  developed	  gradually	  over	  time,	  and	  was	  associated	  with	  subtle	  changes	  
in	  specificity	  (2),	  suggests	  that	  this	  autologous	  V1V2	  response	  may	  represent	  the	  precursor	  of	  
the	  broadly	  neutralizing	  response	  detected	  later.	  	  However,	  the	  cross-­‐neutralizing	  response	  in	  
CAP256	  did	  not	  target	  an	  epitope	  fully	  conserved	  in	  both	  infecting	  viruses.	  	  The	  PI	  virus	  
contained	  several	  mutations	  within	  the	  targeted	  epitope	  (Figure	  4.7),	  and	  was	  ~100-­‐fold	  more	  
resistant	  to	  autologous	  neutralization	  than	  the	  SI	  virus	  (Figure	  4.6).	  	  Interestingly,	  after	  42	  wpi,	  
the	  primary	  virus	  was	  also	  neutralized	  by	  a	  predominantly	  V1V2-­‐dependent	  antibody	  response.	  	  
Evaluating	  the	  cross-­‐reactivity	  of	  the	  response	  at	  this	  time	  revealed	  that	  it	  was	  able	  to	  cross-­‐
neutralize	  6/42	  (14%)	  of	  heterologous	  viruses	  tested	  (2).	  	  This	  suggests	  that	  the	  neutralization	  
of	  the	  PI	  may	  have	  been	  the	  result	  of	  the	  cross-­‐reactivity	  of	  the	  response	  produced	  against	  the	  
SI,	  rather	  than	  the	  immune	  system	  preferentially	  targeting	  an	  epitope	  present	  in	  both	  infecting	  
variants.	  	  While	  the	  epitope	  sequence	  was	  not	  conserved,	  it	  remains	  possible	  that	  structural	  
homology	  existed	  in	  the	  epitopes	  within	  the	  PI	  and	  SI,	  and	  in	  fact	  the	  neutralizing	  was	  directed	  
towards	  a	  single,	  shared	  epitope.	  	  Alternatively,	  the	  PI	  may	  have	  been	  neutralized	  by	  a	  distinct	  
clonal	  population	  of	  B	  cells,	  also	  targeting	  an	  epitope	  in	  V1V2.	  	  However,	  the	  isolation	  of	  a	  mAb	  
from	  CAP256	  that	  neutralizes	  both	  the	  SI	  and	  the	  PI	  (Doria-­‐Rose	  et	  al.,	  in	  submission)	  suggests	  
that	  this	  neutralization	  was	  mediated	  by	  the	  same	  clonal	  population	  of	  B	  cells.	  	  Importantly,	  as	  
this	  V1V2-­‐dependent	  response	  arose	  by	  30	  wpi,	  this	  provides	  evidence	  of	  an	  HIV	  neutralizing	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antibody	  response	  that	  began	  to	  develop	  cross-­‐reactivity	  only	  12	  weeks	  after	  the	  response	  was	  
first	  detectable.	  	  	  
A	  significant	  consequence	  of	  dual	  infection	  is	  the	  potential	  for	  recombination	  and	  
accelerated	  diversification.	  We	  show	  here	  that	  dual	  infection	  and	  recombination	  can	  produce	  
substantial	  diversity	  in	  envelope.	  	  Recombination	  was	  also	  used	  as	  a	  mechanism	  to	  introduce	  
multiple	  escape	  mutations	  simultaneously	  into	  the	  targeted	  epitope.	  	  While	  it	  is	  conceivable	  that	  
this	  potential	  for	  accelerated	  diversification	  may	  promote	  or	  accelerate	  the	  maturation	  of	  
antibody	  responses	  towards	  breadth,	  no	  association	  between	  viral	  diversification	  and	  changes	  
in	  the	  antibody	  specificity	  were	  readily	  apparent	  in	  CAP256	  (Figure	  4.8).	  	  
It	  is	  also	  possible	  that	  the	  altered	  immunological	  environment	  as	  a	  result	  of	  primary	  HIV	  
infection	  can	  modulate	  the	  immune	  response	  to	  a	  superinfecting	  virus.	  	  Responses	  to	  antigens	  
as	  part	  of	  immune	  complexes	  are	  qualitatively	  and	  quantitatively	  different	  compared	  to	  
responses	  to	  antigen	  alone,	  indicating	  that	  antibodies	  can	  have	  influential	  immunomodulatory	  
effects.	  	  Immunisation	  with	  immune	  complexes	  has	  frequently	  been	  demonstrated	  to	  enhance	  
immunogenicity	  compared	  to	  antigen	  alone	  (reviewed	  in	  187).	  	  This	  is	  relevant	  here,	  as	  initial	  
exposure	  to	  the	  superinfecting	  variants	  would	  have	  occurred	  in	  the	  presence	  of	  anti-­‐HIV	  
antibodies	  generated	  by	  the	  initial	  infection.	  	  Humoral	  responses	  are	  also	  dependent	  on	  TLR	  
activation	  (188),	  and	  TLR	  ligands	  including	  LPS	  and	  ssRNA	  are	  present	  in	  abundance	  during	  
natural	  HIV	  infection,	  and	  could	  profoundly	  affect	  subsequent	  B	  cell	  responses	  (reviewed	  in	  
189).	  	  Whether	  primary	  HIV	  infection	  modulates	  the	  immune	  response	  to	  the	  superinfecting	  
virus	  warrants	  further	  study.	  	  	  
Taken	  together,	  however,	  we	  find	  no	  evidence	  here	  that	  superinfection	  promoted	  the	  
development	  of	  antibody	  breadth	  in	  CAP256,	  though	  we	  cannot	  exclude	  this	  possibility.	  	  In	  
contrast	  to	  the	  data	  presented	  by	  Powell	  et	  al.	  (180),	  we	  find	  no	  evidence	  that	  HIV	  co-­‐	  or	  
superinfection	  generally	  promotes	  the	  development	  of	  broadly	  neutralizing	  antibodies.	  	  It	  is	  
potentially	  important	  that	  the	  participants	  described	  here	  were	  dual	  infected	  with	  two	  subtype	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C	  viruses,	  as	  opposed	  to	  individuals	  described	  in	  Powell	  et	  al.	  who	  were	  infected	  with	  two	  
different	  subtypes.	  	  It	  is	  possible	  that	  dual	  infection	  with	  more	  divergent	  viruses	  can	  promote	  
cross-­‐reactivity	  better	  than	  dual	  infection	  with	  more	  similar	  viruses	  can.	  	  	  Consistent	  with	  this,	  
Cortez	  et	  al.,	  (162)	  found	  that	  inter-­‐subtype	  dual	  infections	  had	  greater	  neutralization	  breadth	  
than	  intra-­‐subtype	  dual	  infections	  (162).	  	  The	  effects	  of	  immunodominance	  are	  likely	  greater	  
the	  more	  similar	  the	  antigens	  are,	  and	  the	  more	  CD4	  helper	  epitopes	  they	  have	  in	  common.	  	  
Consequently,	  inter-­‐subtype	  dual	  infection	  can	  conceivably	  promote	  a	  strong(er)	  additive	  effect.	  	  
However,	  it	  is	  unclear	  whether	  intersubtype	  dual	  infection	  can	  promote	  neutralizing	  antibody	  
responses	  towards	  conserved	  epitopes.	  	  	  	  
Even	  if	  dual	  infection	  is	  convincingly	  demonstrated	  not	  to	  broaden	  the	  neutralizing	  antibody	  
response,	  understanding	  how	  the	  immune	  system	  responds	  to	  multiple	  HIV	  immunogens	  during	  
natural	  infection	  is	  relevant	  to	  the	  use	  of	  polyvalent	  vaccines,	  and	  could	  potentially	  identify	  
avenues	  that	  could	  be	  exploited	  with	  vaccination.	  	  
In	  conclusion,	  taken	  together,	  these	  observations	  suggest	  that	  polyvalent	  immunogens	  may	  
not	  necessarily	  be	  able	  to	  broaden	  immune	  responses	  to	  heterologous	  variants,	  although	  they	  
may	  elicit	  responses	  to	  each	  of	  the	  included	  immunogens.	  	  However,	  we	  acknowledge	  
limitations	  in	  the	  current	  study.	  	  Cases	  of	  superinfection	  are	  difficult	  to	  detect.	  	  Consequently,	  
there	  remains	  a	  possibility	  that	  dual	  infected	  participants	  could	  have	  been	  misclassified	  as	  
singly	  infected.	  	  However,	  all	  participants	  who	  developed	  broadly	  neutralizing	  antibodies	  in	  the	  
CAPRISA	  cohort	  were	  subject	  to	  extensive	  sequencing	  efforts	  as	  part	  of	  ongoing	  studies.	  If	  
anything,	  the	  bias	  in	  the	  sequencing	  would	  have	  enriched	  for	  detection	  of	  superinfection	  in	  the	  
broad	  neutralizers.	  	  Nevertheless,	  the	  relatively	  small	  number	  of	  participants	  analyzed	  here	  
potentially	  offers	  little	  statistical	  power	  to	  detect	  an	  effect.	  	  Larger	  studies	  will	  be	  required	  to	  
comprehensively	  address	  how	  co-­‐	  and	  superinfection	  modulate	  the	  immune	  response.	  	  It	  is	  also	  
necessary	  to	  note	  that	  natural	  infection	  may	  not	  accurately	  reflect	  the	  vaccine	  setting.	  	  During	  
natural	  infection,	  there	  is	  ongoing	  HIV	  replication	  and	  a	  significant	  immune	  dysfunction	  that	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would	  not	  be	  present	  in	  the	  vaccine	  setting.	  	  However,	  while	  dual	  infection	  may	  not	  perfectly	  
recapitulate	  the	  vaccine	  setting,	  apart	  from	  animal	  models	  and	  vaccine	  trials,	  dual	  infection	  
potentially	  provides	  the	  best	  model	  available.	  	  Moreover,	  these	  results	  are	  consistent	  with	  
responses	  seen	  in	  vaccinated	  macaques	  where	  polyvalent	  vaccination	  elicited,	  at	  best,	  
antibodies	  capable	  of	  neutralizing	  several	  isolates	  from	  the	  vaccine,	  but	  few	  heterologous	  
variants;	  indicative	  of	  multiple,	  type-­‐specific	  responses	  (114).	  	  Polyvalent	  vaccination	  of	  rhesus	  
macaques	  was	  able	  to	  elicit	  responses	  capable	  of	  neutralizing	  heterologous	  variants	  not	  part	  of	  
the	  vaccine,	  albeit	  at	  very	  low	  titers,	  and	  was	  not	  evaluated	  against	  tier	  two	  viruses	  (115).	  	  The	  
same	  polyvalent	  and	  mosaic	  vaccines	  that	  enhanced	  the	  breadth	  of	  CTL	  responses	  were	  not	  
effective	  at	  enhancing	  the	  breadth	  of	  the	  neutralizing	  antibody	  response,	  and	  did	  not	  elicit	  
responses	  capable	  of	  neutralizing	  any	  tier	  two	  viruses	  tested	  (113).	  	  In	  humans,	  a	  penta-­‐valent	  
HIV	  vaccine	  resulted	  in	  neutralizing	  responses	  to	  all	  five	  homologous	  variants,	  as	  well	  as	  several	  
heterologous,	  but	  easy	  to	  neutralize,	  tier	  1	  viruses.	  	  However,	  most	  vaccinated	  individuals	  were	  
unable	  to	  neutralize	  tier	  two	  viruses	  (117).	  	  	  Similarly,	  the	  quadrivalent	  HPV	  vaccine	  offers	  little	  
cross-­‐protection	  against	  serotypes	  not	  included	  in	  the	  vaccine	  (190).	  	  However,	  in	  the	  case	  of	  
influenza,	  a	  DNA	  prime,	  followed	  by	  a	  heterologous	  boost	  with	  an	  inactivated	  virus	  was	  able	  to	  
elicit	  cross-­‐reactive	  neutralizing	  antibodies	  in	  mice	  and	  ferrets	  (191).	  Perhaps	  the	  most	  
rigorous	  comparison	  between	  monovalent	  and	  polyvalent	  vaccines	  can	  be	  found	  with	  Polio	  
vaccines.	  	  The	  earliest	  Polio	  vaccines	  were	  monovalent,	  but	  by	  the	  early	  1960s,	  these	  were	  
phased	  out	  in	  favour	  of	  a	  trivalent	  formulation	  incorporating	  each	  of	  the	  three	  Polio	  serotypes.	  	  
Comparing	  the	  seroconversion	  rates	  in	  individuals	  receiving	  the	  monovalent	  vaccines	  to	  those	  
who	  received	  the	  same	  doses	  in	  a	  trivalent	  formulation	  revealed	  that	  the	  monovalent	  vaccines	  
are	  significantly	  more	  immunogenic	  (192,	  193).	  	  A	  single	  dose	  of	  the	  trivalent	  OPV	  (tOPV)	  
produces	  immunity	  to	  all	  three	  serotypes	  in	  ~50%	  of	  recipients.	  	  In	  comparison,	  the	  
monovalent	  vaccines	  (mOPV)	  elicit	  immunity	  in	  >90%	  of	  recipients	  after	  a	  single	  dose	  with	  type	  
1	  or	  2,	  and	  in	  ~85%	  of	  recipients	  after	  a	  single	  dose	  with	  type	  3.	  	  Seroconversion	  rates	  after	  a	  
single	  dose	  of	  the	  mOPV	  are	  also	  better	  than	  after	  even	  two	  doses	  of	  the	  tOPV	  (reviewed	  in	  194).	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Taken	  together,	  these	  data	  suggest	  that	  multivalent	  immunogens	  may	  “interfere”	  with	  antibody	  
responses	  to	  each	  other,	  perhaps	  due	  to	  immunodominance.	  	  Indeed,	  these	  studies	  also	  revealed	  
a	  consistent	  predominance	  of	  responses	  to	  Polio	  type	  2.	  	  Even	  the	  “balanced”	  formulation	  of	  the	  
trivalent	  OPV	  (10:1:3	  ratio	  of	  types	  1:2:3)	  produces	  preferential	  seroconversion	  to	  serotype	  2	  
(though	  this	  could	  potentially	  result	  from	  different	  growth	  characteristics	  or	  heat	  stability	  of	  the	  
three	  attenuated	  strains	  (194)).	  	  	  Understanding	  the	  factors	  influencing	  immunodominance	  in	  
the	  neutralizing	  antibody	  response	  will	  likely	  be	  critical	  to	  an	  effective	  HIV	  vaccine	  and	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Table	  S2.1	  |	  Twelve	  envelope	  sequencing	  primers	  
	   Primer	  Sequence	  (5’-­‐3’)	  
EF00	   GGGAAAGAGCAGAAGACAGTGGCAATGA	  
FOR14	   TATGGGACCAAAGCCTAAAGCCATGTG	  
FOR16	   TTTAATTGTGGAGGAGAATTTTTCTA	  
EF170	   AGCAGGAAGCACTATGGG	  
EF200	   GGGATAACATGACCTGGATGCAGTGGG	  
EF260	   TTCAGCTACCACCGATTGAGAGACT	  
EF175	   TTTAGCATCTGATGCACAGAATAG	  
REV15	   CTGCCATTTAACAGCAGTTGAGTTGA	  
EF115	   AGAAAAATTCTCCTCTACAATTAA	  
EF55	   GCCCCAGACCGTGAGTTGCAACATATG	  
EF15	   TGCTCTCCACCTTCTTCTTC	  
REV19	   ACTTTTTGACCACTTGCCACCCAT	  
	  
Supplementary	  Table	  S2.2:	  Number	  of	  envelope	  SGAs	  analyzed	  




	  	  	  	  	  2	  wpi	   20	  
	  	  	  	  	  13	  wpi	   11	  
	  	  	  	  	  21	  wpi	   30*	  
	  	  	  	  	  56	  wpi	   22*	  
CAP84	  
	  	  	  	  	  1	  wpi	   23	  
	  	  	  	  	  3	  wpi	   2	  
	  	  	  	  	  4	  wpi	   7*	  
	  	  	  	  	  10	  wpi	   9*	  
	  	  	  	  	  19	  wpi	   7*	  
	  	  	  	  	  54	  wpi	   20*	  
CAP137	  
	  	  	  	  	  7	  wpi	   4*	  
	  	  	  	  	  12	  wpi	   33*	  
	  	  	  	  	  23	  wpi	   24*	  
	  	  	  	  	  52	  wpi	   26*	  
CAP267	  
	  	  	  	  	  6	  wpi	   7*	  
	  	  	  	  	  10	  wpi	   12*	  
	  	  	  	  	  20	  wpi	   13*	  
	  	  	  	  	  52	  wpi	   17*	  
CAP256	  
	  	  	  	  	  6	  wpi	   2	  
	  	  	  	  	  15	  wpi	   6*#	  
	  	  	  	  	  30	  wpi	   6	  
	  	  	  	  	  53	  wpi	   10*	  
	  	  	  	  	  59	  wpi	   18	  
	  	  	  	  	  94	  wpi	   16	  
	  	  	  	  	  176	  wpi	   6	  
	  
	   	  
	  
	  
	   	   120	  
	  
	   	  
	   	  
	   	  
Supplementary	  Table	  S2.2	  contd.	   	  
	   	  
CAP237	  
	  	  	  	  	  2	  wpi	   22	  
	  	  	  	  	  4	  wpi	   3*	  
	  	  	  	  	  11	  wpi	   6*	  
	  	  	  	  	  24	  wpi	   1*	  
	  	  	  	  	  54	  wpi	   6*	  
	  	  	  	  	  171	  wpi	   10	  
CAP281	  
	  	  	  	  	  10	  wpi	   1*	  
	  	  	  	  	  13	  wpi	   3*	  
	  	  	  	  	  30	  wpi	   1*	  
	  	  	  	  	  42	  wpi	   2*	  
	  	  	  	  	  46	  wpi	   20*	  
	  	  	  	  	  101	  wpi	   10*	  
CAP200	  
	  	  	  	  	  2	  wpi	   22	  
	  	  	  	  	  11	  wpi	   5*	  
	  	  	  	  	  16	  wpi	   12*	  
	  	  	  	  	  21	  wpi	   10	  
	  	  	  	  	  176	  wpi	   33	  
CAP225	  
	  	  	  	  	  2	  wpi	   21	  
	  	  	  	  	  3	  wpi	   6*	  
	  	  	  	  	  5	  wpi	   8*	  
	  	  	  	  	  7	  wpi	   10*	  
	  	  	  	  	  24	  wpi	   2*	  
	  	  	  	  	  29	  wpi	   10*	  
	  	  	  	  	  171	  wpi	   8*	  
CAP266	  
	  	  	  	  	  7	  wpi	   10	  
	  	  	  	  	  58	  wpi	   11	  
CAP258	   	   	  
	  	  	  	  	  7	  wpi	   9	  
























































Supplementary	  Figure	  S2.1	  |	  Recombination	  can	  obscure	  the	  identification	  of	  superinfection.	  	  Reanalysis	  of	  
publicly	  available	  sequences	  from	  (128)	  identified	  two	  individuals	  with	  viruses	  harbouring	  evidence	  of	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Supplementary	  Figure	  3.1	  |	  Viral	  load	  and	  CD4	  count	  profiles	  for	  the	  11	  dual	  infected	  participants	  described.	  	  
Viral	  loads	  are	  shown	  in	  red	  (left	  Y-­‐axis),	  and	  CD4	  counts	  in	  blue	  (right	  Y-­‐axis).	  	  The	  window	  of	  
superinfection,	  where	  applicable,	  is	  shaded	  in	  orange.	  	  Initiation	  onto	  antiretroviral	  therapy	  is	  depicted	  by	  
the	  dotted	  line	  (ARVs).	  Two	  participants,	  CAP137	  and	  CAP258	  were	  lost	  to	  follow	  up,	  and	  these	  visits	  have	  
been	  whited	  out.	  
CAP37
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Supplementary	  Figure	  S3.2	  |	  Kaplan-­‐Meier	  survival	  plot	  showing	  time	  for	  CD4+	  T	  cell	  counts	  to	  fall	  below	  350	  
cells/μl	  in	  and	  dual	  infected	  (N=11)	  participants	  and	  the	  rest	  of	  the	  cohort	  (N=51).	  
	  
	  
Supplementary	  Table	  S3.1	  |	  A	  table	  of	  estimated	  statistical	  power	  for	  a	  survival	  analysis	  under	  a	  variety	  of	  
effect	  sizes	  
	   Median	  time	  to	  CD4<350	  (weeks)	  
Singles	  (N=18)	   225	  
Duals	  (N=11)	   180	  
Power	  to	  detect	   11%	  
	   	  
Singles	  (N=18)	   225	  
Duals	  (N=11)	   130	  
Power	  to	  detect	   22%	  
	   	  
Singles	  (N=18)	   225	  
Duals	  (N=11)	   100	  
Power	  to	  detect	   50%	  
	   	  
Singles	  (N=18)	   225	  
Duals	  (N=11)	   50	  


































	   	   124	  
	  
Table	  S4.1	  |	  Summary	  statistics	  for	  the	  evidence	  of	  positive	  selection	  in	  V2	  of	  the	  primary	  (PI)	  and	  
superinfecting	  (SI)	  virus	  populations	  in	  CAP256	  
HXB2	  position	   	  	   	  	   SU	   PI	  
160	   Directional	  (DEPS)	   Max	  BF	   ns*	   ns	  
Diversifying	  (MEME)	   P	  value	   ns#	   ns	  
161	   Directional	  (DEPS)	   Max	  BF	   ns	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
162	   Directional	  (DEPS)	   Max	  BF	   ns	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
163	   Directional	  (DEPS)	   Max	  BF	   ns	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
164	   Directional	  (DEPS)	   Max	  BF	   ns	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
165	   Directional	  (DEPS)	   Max	  BF	  (Preferred	  residues)	   191	  (V)	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
166	   Directional	  (DEPS)	   Max	  BF	  (Preferred	  residues)	   ns	   3403	  (S)	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
167	   Directional	  (DEPS)	   Max	  BF	   ns	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
168	   Directional	  (DEPS)	   Max	  BF	   ns	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
169	   Directional	  (DEPS)	   Max	  BF	  (Preferred	  residues)	   77095	  (IQ)	   ns	  
Diversifying	  (MEME)	   P	  value	   0.0001	   ns	  
170	   Directional	  (DEPS)	   Max	  BF	   ns	   ns	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
171	   Directional	  (DEPS)	   Max	  BF	  (Preferred	  residues)	   ns	   290	  (K)	  
Diversifying	  (MEME)	   P	  value	   ns	   ns	  
	  
*	  Bayes	  factor	  (BF)	  <20;	  #	  P>	  0.05	  
